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ABSTRACT 
 
The prescription opioid epidemic and the rise in suicide rates in the United States during the 




Opioid morbidity and mortality and suicide are two current and central public health problems in 
the U.S. Both have continuously increased in the last two decades, and disproportionately 
affected some groups more than others, leading to the suggestion that these epidemics are 
connected. However, there is little evidence on the potential role that the opioid epidemic had on 
the rise of suicides. The overarching goal of this dissertation was to advance our understanding 
of the effects of the opioid epidemic on the rise in suicide rates in the U.S. First, a systematic 
review of the literature was conducted to critically evaluate the evidence on the effects of 
different opioid exposures on suicidal outcomes (e.g., suicidal ideation, attempts and suicides). 
There was ample evidence of individual-level associations between opioid use and related abuse/ 
dependence on suicidal outcomes. In contrast, the gap in the literature on group-level effects was 
clear, with only two studies examining these effects and showing that opioid availability was 
associated with suicide behavior in different populations. Several limitations were also identified 
in the reviewed studies that could partially explain the observed associations, indicating the need 
for further research. Second, the individual-level effects of prescription opioids nonmedical use 
and related abuse/ dependence on persistence and onset of suicidal ideation and attempts were 
examined. Longitudinal data from a national representative sample of the adult U.S. population 
was used to examine these associations. Results showed that heavy/ frequent use of prescription 
opioids and related abuse/ dependence had an effect on persistence and onset of suicidal ideation 
and persistence of attempts. However, none of these exposures were associated with onset of 
suicide attempt. Overall, these findings suggest that by increasing the number of those using 
prescription opioids and with opioid abuse/ dependence, and in turn the number of those with 
suicidal ideation/ behavior, the prescription opioid epidemic could have led to increases in 
suicide rates in the population. Finally, the group-level (i.e., state level) effects of three state 
level exposures, i.e., increasing trends in the per capita volume of prescription opioids, in the 
nonmedical use of these drugs, and in unintentional fatal opioid overdoses, on the increase in 
suicide rates were examined. For this, pooled cross sectional time series data from the 50 states 
(1999-2016) were used in linear regression models with state and year fixed effects. Although 
the volume of prescription opioids and the rate of fatal opioid overdoses increased over the study 
period, the prevalence of nonmedical use of prescription opioids decreased in most states. 
Results showed that the rate of unintentional fatal prescription opioid overdoses was associated 
with an increase in the rate of suicides. The range of effects sizes compatible with the data also 
suggested that the increase in the per capita volume of prescription opioids was linked to 
increases in suicide rates. Overall, this dissertation increased our understanding of the possible 
role that the opioid epidemic played on the increase in suicide rates in the U.S. As public efforts 
continue to fight the opioid epidemic, these findings can help inform future research that will 
guide the development of suicide prevention strategies and approaches to reduce the burden that 
the opioid epidemic poses on communities.
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CHAPTER 1 : INTRODUCTION 
 
1.1. Background 
Suicide is a major health problem in the Unites States (1). In 2016, close to 45,000 suicides 
occurred among persons aged 10 or older; the age-adjusted suicide rate in this year was 15.6 per 
100,000 (1), the highest recorded in the last four decades (2) (Figure 1). Since 1998 the suicide 
rate has increased by 32% (1), and suicide has now become the 8th leading cause of death in the 
nation (3). In addition, since 2001 the rates of emergency department visits for nonfatal self-
harm also increased by 42% (1). Although suicide rates have increased among all race/ethnic 
groups, the sharpest increases occurred among non-Hispanic whites (42% increase) and among 
American Indian/Alaska Native populations (77% increase) (1); these two populations also had 
the highest suicide rates in 2016: 17.0 per 100,000 and 21.2 per 100,000, respectively vs. 6.3-6.7 
per 100,000 in other populations (1).  
 
Parallel to the rise in suicides, there has been a dramatic increase in the rate of fatal opioid 
overdoses (4) and in emergency room visits for opioid use (5) in the past two decades (Figure 2). 
Since 2000 more than 600,000 persons have died from drug overdoses in the country. In 2016 
alone, there were around 64,000 fatal overdoses, with more than 50,000 of these being opioid-
related, including 14,400 due primarily to prescription opioids (6). The unprecedented increase 
in opioid poisoning morbidity and mortality was labeled as “the worst drug epidemic in the U.S. 
history” (7). The lack of regulation for opioid prescribing practices and aggressive marketing of 
prescription opioids for non-cancer chronic pain starting in the mid 90s are believed to be 
contributing factors to this epidemic (7).  
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Although the opioid epidemic has affected all race/ethnic groups, non-Hispanic white and 
American Indian/AK Native populations are the two most affected. Both groups have the highest 
prevalence of opioid abuse/ dependence (8), and from 1999 to 2016 they had the sharpest 
increases in fatal opioid overdoses, from 3.1 to 17.1 per 100,000 in whites and from 3.3 to 14.4 
per 100,000 in American Indians/AK Natives (9). The fact that both opioid overdose and suicide 
rates have increased in unprecedented ways in the last decades, and both disproportionately 
affected these two groups more than others, lead to the suggestion that the opioid epidemic could 
have contributed to the rise in suicides (10).  
 
It is possible that the opioid epidemic influenced suicide rates through different mechanisms. 
First, the sharp increase in the availability of prescription opioids may have contributed to the 
rise in suicides by providing a lethal method of suicide, easy to access during a suicidal crisis, 
among those with suicidal ideation.  Second, the continuous use of opioids can lead to suicidal 
ideation and behavior through their influence on the reward system. As opioid use escalates 
individuals may become gradually insensitive to rewarding experiences and require higher doses 
of opioids to reach prior levels of pleasure and well-being (11). Negative affect, emotional pain, 
anxiety and high levels of distress during withdrawal periods (12) can increase the risk of 
suicidal ideation and behavior among opioid users. Third, the opioid epidemic could have 
impacted communities by weakening family and community networks that are essential for the 
preservation of the social bonds that give meaning to individuals (13, 14). This can lead to 
despair and negative affect that can increase the risk of suicidal ideation and behavior among 
those using prescription opioids, but also friends and relatives not using them.  
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Despite the apparent association between the increases in opioid morbidity and mortality and 
increases in suicide morbidity and mortality, it remains unclear the extent to which opioid use 
and suicidal behavior are casually related, both at the individual level (i.e. does opioid use 
increase the risk of suicidal behavior, and if so, how?) and at the group level (i.e. did the increase 
in opioid availability and opioid morbidity and mortality over time cause the increase in suicidal 
behavior over time?). Although epidemiologic studies provide evidence of the association 
between opioid use and suicidal ideation (15-17), uncertainty about the temporal order of the 
exposure and the outcome and confounding (e.g., childhood adversity or psychiatric disorders) 
are potential limitations in these studies. Studies establishing temporality and with 
comprehensive confounder control may provide more robust evidence in support or against the 
hypothesis that opioid use and related abuse/ dependence increase suicidal ideation and behavior. 
Also, while opioid availability and suicide rates are correlated at the national level, the lack of 
studies examining these effects at a more granular level (e.g., state level) limits our 
understanding of the effects and mechanisms through which the opioid epidemic could have 
influenced suicide rates. 
A better understanding on how the availability of opioids and opioid use, abuse and related 
overdoses can increase the risk of suicide may improve our understanding of the role that opioid 
epidemic played on the increase in suicide rates in the U.S., and can shed light on the operating 
mechanisms and the potential targets for future interventions.  
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1.2. Dissertation overview 
The overarching goal of this dissertation is to advance our understanding of the effects of the 
opioid epidemic on the rise in suicide rates in the U.S. in the past two decades. Specifically, I 
evaluate the available evidence on effects of opioid use and related abuse/ dependence on 
suicidal outcomes (e.g., suicidal ideation, attempts and suicides) (Aim 1); examine whether the 
nonmedical use of prescription opioids, the heavy frequent use of these drugs, and related abuse/ 
dependence are associated with subsequent suicidal ideation and attempts (Aim 2); and whether 
the availability of prescription opioids, the prevalence of nonmedical use of opioids and the rate 
of fatal opioid overdoses had an effect on suicide rates at the state level (Aim 3). 
 
This dissertation contains five chapters. Following this introduction, Chapter 2 presents a 
systematic review of the literature relevant to Aim 1. In this systematic review we search for 1) 
studies examining the association between opioid use and suicidal outcomes in populations of 
medical and nonmedical opioid users and also in users with opioid abuse/ dependence; and 2) 
studies examining the association between the availability of opioids and suicide outcomes in the 
population.  
 
Chapter 3 presents results from testing effects relevant to Aim 2. Longitudinal individual level 
data from a national representative sample of the U.S. population, the National Epidemiologic 
Survey on Alcohol and Related Conditions (NESARC), is used to examine these effects. The 
longitudinal design of this survey with two waves of data from 34,653 participants provided the 
opportunity to better assess the temporal relationship between the exposure and the outcome 
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while controlling for important confounders including childhood adversities and the presence of 
psychiatric disorders. 
 
In Chapter 4, results of the effects examined in Aim 3 are presented. State level cross sectional 
time series data for the 1999-2016 period are used to examine whether the availability of 
prescription opioids, the nonmedical use of opioids and unintentional fatal opioid overdoses had 
an effect on suicide rates at the state level, while controlling for current and lagged confounders. 
The identification of these effects would support the hypothesis that the opioid epidemic 
contributed to the rise in suicide rates potentially through the mechanisms described above. 
 
Chapter 5 presents a discussion of findings of this dissertation and future directions for research. 
The findings from this dissertation will advance our understanding of the role that the opioid 
epidemic played on the rise in the suicide rate, by critically assessing the existing literature and 
by providing new evidence about these effects at the individual and group levels. These findings 
will help build the evidence base for public health practice and the development of future 
research that can inform on mechanism and potential targets for interventions to reduce opioid 
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CHAPTER 2 : UNDERSTANDING THE POTENTIAL ROLE THAT OPIOID USE AND 
OPIOID ABUSE/ DEPENDENCE HAVE ON SUICIDAL OUTCOMES 
 
2.1. Abstract 
Background: Opioid morbidity and mortality and suicide are two current and central public 
health problems in the U.S. Both have continuously increased in the last two decades, and 
disproportionately affected some groups more than others, leading to the suggestion that these 
epidemics are connected. However, there is little evidence on the potential role that the opioid 
epidemic had on the rise of suicides. In the present study we systematically reviewed studies 
examining the effects of different opioid exposures on suicidal outcomes to determine the state 
of knowledge and available evidence in support or against the hypothesis that the opioid 
epidemic had an influence on suicide rates.   
Methods: We conducted a systematic literature review of studies examining the effects of opioid 
use and related abuse/ dependence on suicidal outcomes, and those examining the association 
between opioid availability and suicide rates in different populations. We restricted analyses to 
studies published between 1950 and 2018. 
Results: Results from 35 studies provided evidence of the link between opioid exposures and 
suicidal outcomes. Studies on patients receiving treatment for opioid dependence showed that 
patients had higher prevalences of suicidal outcomes than the general population; treatment for 
opioid dependence was associated with reductions in the prevalence of recent suicide attempts. 
Suicidal outcomes were also more common among individuals receiving higher doses of opioids 
to treat pain conditions than those receiving lower doses. National surveys showed that the 
heavy/ frequent nonmedical use of prescription opioids and related abuse/ dependence were 
associated with suicidal ideation and attempts in adolescent and adult populations. Evidence also 
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suggested associations between opioid availability and suicide behavior at the population level. 
Some limitations in the reviewed studies could partially explain some of described effects. 
Conclusions: Overall, the evidence suggests that opioid use and related abuse/ dependence have 
an effect on suicidal outcomes, and also that the increase in the availability of prescription 
opioids can lead to increases in suicide behavior. Future studies overcoming the limitations in the 
reviewed studies will provide stronger evidence of these effects, which will also improve our 





In the U.S. the suicide rate increased by 32.4% from 1999 to 2016, with more than 42,000 
suicides occurring per year in the last 2 years (1).  The age-adjusted rate in 2016 was 15.6 per 
100,000, which is the highest in the four decades (1).  Increases in suicides since 1999 have 
mostly occurred among non-Hispanic whites (42% increase from 1999 to 2015) and among 
American Indian/AK Native populations (77% increase) (1). The prevalence of suicidal ideation 
and attempts also increased in the U.S. white and American Indian/AK Native populations in the 
past decade (2, 3). In addition, these two populations have been the most affected groups by the 
opioid crisis, with higher prevalence of opioid use abuse/ dependence (4) and fatal opioid 
overdose rates (5). This has led to the believe that there is a link between opioid overdoses and 
suicides (6, 7), with two hypothesis being proposed to explain these phenomena: 1) The rise in 
suicide rates and in opioid-related mortality are the result of a growing epidemic of despair 
across communities, thus they share a common cause (7). This hypothesis is supported by 
evidence showing an association between economic factors and suicides (8, 9), and also the use 
of substances,(10-15) particularly nonmedical use of prescription opioids and related abuse/ 
dependence (16). 2) The rise in prescription opioid availability and in the prevalence of opioid 
abuse/dependence contributed to suicidal ideation and suicide behavior (6), thus, the opioid crisis 
is a cause of the rise in suicide rates. This hypothesis is supported by evidence showing that 
opioid misuse and related abuse/ dependence are associated with increased risk of suicide (17, 
18). As the number of individuals using/ abusing opioids increases, the number of individuals 
with suicidal ideation behavior would also increase, which eventually would be reflected in the 
suicide rate. Below, we discuss mechanisms through which the opioid crisis may have influenced 
suicide rates.  
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There are three potential mechanisms through which the opioid crisis is hypothesized to have an 
effect on suicidal behavior. First, the high availability of opioids may provide means of suicide 
to those with the intent to attempt suicide. Controlling for effective means of suicide has been a 
common tool to prevent suicide, including restrictions on pesticides, guns and drug accessibility 
(19). The sharp increase in the availability of prescription opioids in the U.S. in the past two 
decades (20, 21) may have contributed to the rise in suicides by providing a lethal method of 
suicide, easy to use during a suicidal crisis. Moreover, evidence indicates that in the U.S. the 
proportion of suicide by opioid poisoning from all suicides increased from 2.2 to 4.3% from 
1999 to 2014 (22).  
 
Second, the continuous use of opioids is hypothesized to increase the risk of experiencing 
suicidal ideation and behavior. As homeostasis of the reward system is altered by the continuous 
use of opioids (23), individuals become gradually insensitive to rewarding experiences, with 
higher doses of opioids being needed to obtain prior states of pleasure and well-being (24). 
Animal studies suggest that as opioid use continues, the reward-enhancing effects of opioids 
decrease while the anti-reward effects increase, establishing an overall reward deficiency state 
(25). The brain reward is also inhibited during withdrawal periods, by separate processes not 
linked to physical withdrawal states (e.g., physical or cramps) (25), which serve as a 
motivational factor contributing to craving, relapse and continuous opioid use (26, 27). Negative 
affect, emotional pain, anxiety and high levels of distress during withdrawal periods (23) can 
lead to allostatic overload with activation of the hypothalamic-pituitary-adrenal (HPA) axis and 
dysregulation of the noradrenergic system, intensifying negative mood states (28), and 
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potentially increasing the risk of suicidal ideation and behavior among some users.  Furthermore, 
particularly in patients with non-cancer pain, the continuous use of opioids has been associated 
with hyperalgesia, which it is believed to lead to depressive states and loss of control over opioid 
use (23, 29), and increased risk of suicidal ideation/behavior as pain becomes more intense. 
Further, it is possible that disinhibition effects of opioids could increase the risk of individuals 
with suicidal thoughts acting on these impulses (30). Finally, those with opioid abuse and 
dependence may experience discrimination from family and social networks as well as financial 
challenges that may trigger feelings of failure and despair that increase the risk of suicidal 
behavior.  
 
Third, increases in the frequency of opioid use and the presence of opioid use abuse/ dependence 
within communities may impact communities by weakening family and community networks 
that individuals rely on for support (31). The increase in fatal overdoses along with the distrust 
generated from drug activities (e.g., crime related to drug trafficking) may deteriorate the social 
norms and values that are essential for the preservation of the social bonds that give meaning to 
individuals (32, 33). This can result in feelings of despair, depression and emptiness that can 
increase the risk of suicidal thoughts and suicidal behavior, not only in those using opioids but 
also by their relatives and community members not using these drugs.  
 
Evidence from a previous drug epidemic shows how the availability of drugs could impact health 
outcomes in communities beyond the effects among those using the drugs. In the 80s and 90s, 
the increased availability of crack, predominately in minority and urban neighborhoods, resulted 
in rising distrust among neighbors, increased poverty, the spread of sexually transmitted 
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diseases, increased incarceration rates, and the escalation of violence (32, 33). In the context of 
the opioid epidemic, the increased availability of prescription opioids in the U.S. was associated 
with increases in prescription opioid abuse treatment admission and opioid-related fatal 
overdoses (34). These outcomes could have accelerated the erosion of social capital, already 
damaged by economic turndown and health inequalities, leading to increases in feelings of 
despair and suicidal ideation and behavior across community members. Moreover, the increased 
availability of heroin and fentanyl starting around 2007 (35, 36), which was responsible for 
increasing the rate of opioid fatal overdoses, may have accelerated some of these processes 
already fueled by the rise in the availability of prescription opioids. As the opioid epidemic 
continues and transitions into a heroin and fentanyl epidemic (35, 36), there is need to better 
understand whether the opioid epidemic-suicide rates effects can also operate beyond individual 
level mechanisms. 
 
Although reasonable arguments have been made for a causal connection between opioid related 
exposures (e.g., availability of opioids, opioid use abuse/ dependence, and opioid overdoses) and 
suicidal outcomes, there is little evidence supporting the validity of some of these arguments. 
Therefore, in this review we evaluate the evidence for this hypothesis from studies examining the 
association at the individual level between the use of opioids and suicidal ideation, attempts and 
suicides, and studies at the group level examining the effects of increases in the availability of 
opioids on increases in suicide rates. Understanding how opioid related exposures influence 
different suicide outcomes can shed light on the operating mechanisms and the potential targets 
for future interventions. Also, previous reviews on this topic have focused mainly on suicides 
and in populations of individuals with opioid use abuse/ dependence (17, 18) offering little 
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evidence to some of the mechanisms we have hypothesized. Therefore, we expanded this review 
to include other populations that may also be affected by opioid related exposures. A better 
understanding on how the availability of opioids and opioid use, abuse and related overdoses can 
increase the risk of suicides among opioid users and populations affected by the opioid epidemic 
will improve our understanding on the role that this epidemic played on the rise in suicide rates 
in the U.S. 
 
We conducted a systematic literature review of studies assessing the association between the use 
of opioids and suicide outcomes in populations of medical and nonmedical opioid users and also 
among users with opioid use abuse/ dependence. We also reviewed studies assessing the 
association between the availability of opioids and suicide outcomes in the overall population. 
We defined opioid use as the use of any natural (e.g., morphine), semi-synthetic (e.g., 
hydrocodone) or synthetic (e.g., fentanyl) opioids. Suicide outcomes included lifetime or current 
(e.g., past-year or past-month) suicidal ideation and suicide attempts, and suicides. 
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2.3. Methods 
We reviewed published studies from January 1, 1950 to May 30, 2018, examining the effects of 
opioid use on suicidal outcomes, including studies estimating the prevalence or incidence of 
suicidal outcomes among opioid users in/not in treatment for opioid use abuse/ dependence, and 
those examining the association between opioid availability and suicide rates at the population 
level. No restrictions were placed on sample size or population characteristics. We excluded 
commentaries or opinion papers without analysis of the effects of the exposure (e.g., opioid use) 
on outcomes of interest (suicidal ideation, attempts, and suicide), or studies in which suicidal 
outcomes are reported as part of a combined outcome with other problems, but without specific 
results for these suicidal outcomes. We also excluded studies without a comparison group; 
however, studies were not excluded if they compared the exposed group against the general 
population or other unexposed population. Although we excluded literature reviews, we checked 
the reference lists in these reviews to identify potential studies that could be included in our 
review.  
 
The systematic review was conducted by searching in PubMed, EMBASE and PsycINFO for 
peer-reviewed studies in English, but also covered studies in other languages (e.g., Spanish and 
French) if titles and abstracts were available in English. We used combinations of the following 
keywords/ Medical Subject Headings terms for the searches: 1) Substance related terms: 
substance use disorder, opioid analgesic, morphine derivate, opioid addiction, narcotic analgesic 
agent, narcotic dependence, opioids, drug addiction, substance use disorder; 2) Suicide related 
terms: suicide, suicidal ideation, suicidal attempted, suicidal behavior, self-injurious behavior. 
We also searched citations in primary studies and literature reviews on the topic.  
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A total of 841 studies were retrieved using the Medical Subject Headings/ keywords terms in 
Pubmed (n = 372), EMBASE (n = 390) and PsycINFO (n = 79). Two independent reviewers 
screened studies by reading the title and abstract, and then by reading the full text of studies that 
passed the first screen. The two reviewers discussed the disagreements on selected studies and 
reached a final decision without the need of third reviewer. A description of the number of 
studies that were included or excluded in each step is presented in Figure 2.1. After excluding 
duplicates (n =113) and manuscripts not meeting the inclusion/exclusion criteria after title and 
abstract screening  (n = 616) and after reading the full text (n = 83), a total of 29 studies were 
identified. Main reasons for not selecting studies included that articles were about other topics, 
did not assess the exposure or outcome of interest, or the article was a literature review, a 
commentary or opinion letter. We also included 6 additional manuscripts that were found in 
citations of selected studies or in reviews on the topic.  
 
Study design, quality of reporting and risk of bias of included studies were assessed following 
criteria from the Appraisal tool for Cross- Sectional Studies (AXIS tool) (37). Although this tool 
was developed to evaluate cross sectional studies, the criteria are also useful to evaluate other 
observational studies. The reporting and description of findings from included studies adhere to 
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement 
guidelines (38).  
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2.4. Results 
Results from studies are presented as follows based on studies assessing associations at the 
individual level and then at the group level. Studies assessing associations at the individual level 
were further categorized in to the following four subgroups: 1) studies comparing prevalences of 
suicidal ideation/ behavior and suicide among individuals in treatment for opioid abuse/ 
dependence (including two meta-analyses) with those in the general population or in control 
groups; 2) studies estimating the prevalence of suicidal ideation/ behavior among for opioid 
users not in treatment and comparing it with prevalences in the general population or control 
groups; 3) studies examining the effects of opioid use on suicidal outcomes in patients treated 
with prescription opioids for non-cancer pain; 4) studies examining the effects of opioid use and 
related abuse/dependence on suicidal outcomes from self-report survey data or administrative 
records. A description of studies, including potential limitations in their execution, is provided in 
Appendix Table 1-Appendix Table 5. Table 2.1 shows the list of the potential limitations that 
were used to evaluate studies.  
 
Of the 35 studies reviewed, nine were cross sectional, five were case-control studies, 19 studies 
were cohort studies or longitudinal studies examining secondary data, and two were meta-
analyses that included suicide standardized mortality ratios from other studies (we did not 
separately included studies that where used in these meta-analyses). Twenty studies focusing on 
groups of individuals in treatment for opioid abuse/ dependence, and two in opioid users not in 
treatment. Also, five studies were on individuals using prescription opioids to treat pain 
conditions, six studies on self-reported survey data/ administrative records (four based on 
nationwide and two based on school samples), and two studies on effects of opioid availability 
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on suicide outcomes in the population. We provide a summary of the results from these studies 
in figures 2.2, 2.3 and 2.4. 
 
2.4.1. Individual-level evidence on effects between opioid use, abuse/ dependence and 
suicide outcomes 
2.4.1.1. Studies of populations of opioid users entering treatment for opioid 
abuse/dependence (Appendix Table 1) 
Figure 2.2 shows the suicide Standardize Mortality Ratio (SMR) from 11 studies examining 
suicide rates among opioid users in treatment compared with rates in the general population. In 
three of these studies patients were treated for heroin abuse/ dependence; in all other studies 
patients were treated for opioid abuse/ dependence, but heroin was not explicitly mentioned. 
Studies from four countries (U.S., Norway, Australia and Taiwan) show that the suicide rate in 
those with opioid abuse/ dependence was higher than in the general population. Two studies in 
the U.S. show that the suicide rate was around 5 times higher compared with the general 
population (39, 40). The SMR across different studies ranged from 0.8 to 18.4 (41-46), with most 
results showing a SMR greater than 10. Suicide mortality ratios/SMR were higher in females 
than males (43, 44, 47). Results from meta-analyses (18, 48) show an overall suicide SMR for 
opioid use approximately 14 times greater than expected (Figure 2.2).  
 
Figure 2.3 presents results from nine studies from the U.S., Australia, and China estimating the 
prevalence of suicidal ideation and attempts among opioid users entering treatment for opioid 
abuse/ dependence. As seen in Figure 2.3, the lifetime prevalence of attempts was higher than the 
lifetime prevalence of suicidal ideation and both lifetime measures were higher than the 
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respective past-year measures. Regarding suicidal ideation, one study (49) found that the lifetime 
prevalence of suicidal ideation was 59%, which was higher than that in the general population 
(3.9%) (49). Another study (50) found that this prevalence was 66%, which also higher, although 
not by much, than that in controls not using opioids selected from the same geographical area as 
the opioid maintenance treatment clinics (55%) (50). In regards to suicide attempts, the lifetime 
prevalence of suicide attempts in those in treatment ranged from 17.3% to 42% (50-53) (females 
had a higher prevalence of suicide attempts than males: 43.1% versus 25.9%) (51), which was 
higher than the prevalence in the general population (range from 3.2 to 4.1%) (52, 53). This 
prevalence (31% among patients in treatment in the study by Maloney et al. (50)) was also 
higher than that in controls selected from the same geographical area as the opioid maintenance 
treatment clinics (20%) (50).  
 
A study following individuals with opioid abuse/ dependence showed that the prevalence of past-
year suicidal ideation at baseline was 23% and the prevalence of past-year suicide attempts was 
12.2% (51); over time, prevalences of past-year suicidal ideation and suicide attempts decreased 
after treatment (10.4 and 1.6%, respectively at 11-year follow-up), but suicidal ideation remained 
4.5 times higher and attempts four times higher than those reported in the overall population (51, 
53, 54). In a study at an urban U.S. Veterans Affairs (VA) medical center, 25.7% of patients in 
treatment experienced current (past two weeks) suicidal ideation (55), a prevalence higher than 
that in the overall veteran population, but similar to that of veterans with mental health disorders. 
A study of individuals ages 15-26 receiving methadone treatment showed that the prevalence of 
current suicide attempts was 22%, 18 times above the expected in this population (56). Also, 
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among injection users with and without HIV diagnoses, the prevalence of suicide attempts in the 
past two weeks were 37.1% and 43.2%, respectively; it was 8.5% among non-drug users (57).   
 
2.4.1.2. Studies of opioid users not in treatment (Appendix Table 2) 
A secondary analysis of longitudinal data from cohort of people who inject drugs showed that 
regular use of opioids compared with regular use of other substances (e.g., alcohol, sedatives/ 
hypnotics, cannabis) was not associated with suicide attempts (58). A study in a sample of non-
injecting heroin users (using heroin 4-6 times per week) not in treatment showed that the lifetime 
prevalence of suicidal ideation was higher (30%) than in the general population (10%) (59). 
 
2.4.1.3. Studies of patients receiving opioids to treat pain conditions (Appendix Table 3) 
Five studies examined effects of opioid use in populations receiving prescription opioids to treat 
pain conditions. Among individuals prescribed opioids for at least six weeks for chronic non-
cancer pain, prevalences of lifetime and past-year suicidal ideation (45.9% and 20%, 
respectively), and lifetime and past-year suicide attempt (20.3% and 2.5%) were higher than 
those in the general population (60). Also, a study on U.S. veterans showed that 9.2% and 2.4% 
of patients under long-term opioid therapy reported suicidal ideation and suicide attempts, 
respectively, in the next 12 months after discontinuation of opioid therapy (61). This is higher 
than prevalences of suicidal ideation and attempts in a community sample of veterans (3.8% and 
0.4%, respectively) (prevalences for these two studies are presented in Figure 2.3).  
 
Figure 2.4 shows the odds/ hazard ratios for those exposed to high doses of prescription opioids 
compared with those receiving lower doses. Veterans Affairs patients with chronic pain 
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receiving high doses (20-49, 50-99 and 100+ milligrams (mg) per day) of prescription opioids to 
treat pain had higher risk of suicide compared with those receiving 20 mg or less per day (AOR 
for the 100+mg/day dose=2.15, 95% CI: 1.64, 2.81) (30). Also, studies among seniors comparing 
suicide cases with controls have found that use of prescription opioids for moderate (codeine or 
hydrocodone) and severe pain (morphine, hydromorphone, or transdermal fentanyl) were 
associated with overall suicide (62, 63) and non-opioid poisoning suicide (63).  
 
2.4.1.4. Studies examining the risk of suicidal outcomes among opioids users or those with 
abuse/ dependence in surveys/ administrative records data (Appendix Table 4) 
Six studies used survey data/ administrative records to examine effects of opioid use and related 
abuse/ dependence on suicidal outcomes. Effect measures from these studies are presented in 
Figure 2.4. Regarding the use of prescription opioids in adults, data from the National Survey on 
Drug Use and Health (NSDUH) showed that suicidal ideation was associated with persistent 
nonmedical use (initiated use more than 2 years before the interview and continued to use in the 
past year) (AOR=1.52, 95% CI: 1.10, 2.10) (64) and any past-year nonmedical use of 
prescription opioids (AOR=1.56, 95% CI: 1.11, 2.19) (65) (2009 and 2012 NSDUH data was 
used in these studies, respectively). Heavy nonmedical use of prescription opioids (used weekly 
or more) was also associated with suicidal ideation and attempts in NSDUH 2014 data (66) 
(however, it was not clear whether authors took into account the complex survey design in 
analyses, which is required to obtain correct estimates and standard errors) (67). 
 
In adolescents, lifetime nonmedical use of prescription opioids was associated with past-year 
suicidal ideation and suicide attempts in both males and females (68). Also, a longitudinal study 
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in students from grades 7 and 8 followed over 3 years showed that prescription opioid misuse at 
wave 1 was associated with increased risk of suicidal ideation (AOR=2.31, 95% CI: 1.30, 4.11) 
and attempts (AOR=3.39, 95% CI: 1.33, 5.63) at wave 2 (Figure 2.4) (69). 
 
In regards to opioid use abuse/ dependence among adults, past-year prescription opioid abuse/ 
dependence was associated with suicidal ideation in NSDUH 2009 data (AOR=1.88, 95% CI: 
1.13, 3.12) (64). However, another study using NSDUH 2014 data showed that this association 
was weaker (AOR=1.21, 95% CI: 0.85, 1.73) (66) (as described above not clear if complex 
survey design measures were used in analyses). Opioid use abuse/dependence was also not 
positively associated with suicide attempts among those with suicidal ideation (64), or when 
compared with those without abuse/dependence in the full sample (66). One study examining 
U.S. Veterans administrative records found that opioid use abuse/dependence was associated 
with increase risk of dying by suicide in males [Hazard Ratio (HR)=1.31, 95% CI: 1.08, 1.58 and 
in females (HR=2.33, 95% CI: 1.05, 5.18] (70). The overall suicide rate among those with opioid 
abuse/ dependence was 86.9 per 100,000, much higher than that in the general population (70). 
 
2.4.2. Group level studies examining the association between prescription opioid 
availability and opioid related suicidal behavior or suicides (Appendix Table 5) 
In the United States, Davis et al., (2014) (71) examined the association between opioid 
prescriptions, based on the number of individuals with opioid prescriptions in three-zip code 
areas divided by total population of the area, and calls regarding suicide behavior using 
prescription opioids to the Researched Abuse, Diversion and Addiction-Related Surveillance 
(RADARS) System Poison Center Program. Increased accessibility of prescription opioids was 
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associated with increased number of suicide calls in which individuals had attempted suicide 
with opioids, with a stronger association in females vs. males (71). In England and Wales, a 
study (72) using 1998-2007 data from Office of National Statistics, found that the withdrawal of 
co-proxamol, a prescription opioid commonly prescribed in the UK, in 2005 was associated with 
reductions in co-proxamol prescription rates and co-proxamol poisoning suicides in the post-
intervention period [the mean quarterly change in co-proxamol suicide was -24 suicides per 
quarter (95% CI: -37, -12); the mean quarterly change in overall suicide was -22 suicides per 
quarter (95% CI: -89, 45)] (72). The reduction was equivalent to an overall decrease of 295 co-
proxamol poisoning suicides in the post-intervention period (2005-2007) compared with the 




In this systematic literature review we identified a range of studies comparing suicidal outcomes 
in opioid users and those with opioid abuse/ dependence with outcomes in the general population 
and individuals not using opioids. We also identified studies examining the association between 
opioid availability and suicides and also suicide attempts. Three general observations emerge 
from this analysis: 1) suicide, suicidal ideation and attempts are more common among 
individuals with opioid use, opioid abuse/dependence and those receiving higher doses of 
opioids compared with the general population; 2) the availability of opioids is associated with 
increases in suicidal behavior and suicides; 3) alternative explanations could partially explain the 
effects of opioids on suicidal outcomes found in these studies. 
 
Consistently, studies on individuals with opioid abuse/dependence and patients treated for 
chronic non-cancer pain provide evidence that the frequent use opioids and use at higher doses is 
associated with suicidal ideation/behavior suicide. These findings support the hypothesis of a 
causal effect between the frequent use of opioids and suicidal ideation/behavior. However, this 
evidence does not provide information about the mechanisms in operation. As theorized, if these 
effects are internally valid, it is possible that they operate through individual level mechanisms 
influencing the reward system, the distress and negative mood experienced in withdrawal 
periods, and also via the adverse experiences that opioid users face (e.g., social discrimination 
and financial challenges). In addition, opioids may also increase the risk of suicide among opioid 
users by providing a means of suicide; however, the fact that many suicides in these populations 
are not opioid-poisoning suicides, suggests that opioids providing a means of suicide is not the 
only operating mechanism. An important finding from some studies is that treatment for opioid 
  26
abuse and dependence greatly reduced the prevalence of past-year suicidal ideation and attempts, 
which provides additional evidence of the effects of opioids on suicidal outcomes.  
 
Survey studies in adolescents and adults also consistently show evidence that the nonmedical use 
of prescription opioids and opioid abuse/ dependence were associated with suicidal ideation (and 
attempts in adolescents); although in those with suicidal ideation, opioid use and related abuse/ 
dependence did not increase the risk of attempts (64). Altogether this evidence supports the 
hypothesis that opioid use and abuse/ dependence lead to suicidal ideation, and attempts at least 
in adolescents; although no information is presented on the mechanisms at play, they could also 
work through the individual level mechanisms described above. Studies on adolescents, 
including a longitudinal study (73) following students over time, provide important evidence on 
the risk of nonmedical use of opioid at an early age. 
 
Two studies show evidence of an association between the availability of prescription opioids and 
suicidal behavior/ suicides. The first study (71) shows that increases in opioid availability are 
linked to increases in suicidal behavior. Although opioid availability in a community is a group 
level exposure, these effects could have operated at the individual level through the mechanisms 
described above. Along with these individual level effects, increases in opioid availability and in 
rates of opioid abuse/ dependence and of fatal opioid overdoses could have also resulted in 
detriments of group level characteristics, e.g., social capital, that individuals rely on to solve 
problems and that give meaning to their lives. Through the erosion of social capital, the opioid 
crisis could have influenced feelings of the despair, depression and in turn in suicidal ideation/ 
behavior in opioid and non-opioid users. The second study (72) shows that the withdrawal of a 
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potent opioid co-proxamol was associated with reductions in co-proxamol-poisoning suicides, 
without increases in suicides by other methods; thus, showing that at least for some individuals 
having prescription opioids at hand may increase their risk of suicide. The time between a person 
determines to commit suicide and he/ she finds the means to do it can be crucial to reduce 
suicidal impulses and prevent suicidal behavior. Because prescription opioids can be readily 
accessible, they may not offer this possibility.  
 
There are also potential limitations in studies included in this review. Although the associations 
between opioid use and opioid abuse/ dependence and suicide outcomes described in studies can 
be causal, they could also arise from alternative explanations, including confounding. In studies 
examining patients receiving treatment for opioid abuse/ dependence, it is often found that these 
patients not only have higher prevalences of suicidal outcomes than the general population, but 
also higher levels of distress and harsh events in their life (74). They often report having 
experienced child maltreatment, having a rough child environment such as living in poverty, 
living with a parent with drug or alcohol addiction or attempting suicide, and also having 
psychiatric disorders, including depression, anxiety disorders, antisocial and borderline 
personality disorders (49, 52, 74-76) It is likely that these prior events are drivers of both suicidal 
ideation/ behavior (77-83) and also initiation and continuous use of substances that can serve as 
an alternative to cope with negative emotions (78-80, 84-87). Also, most studies used the general 
population as comparison group; however, using a control group that more closely resembles 
those in treatment for opioid dependence (e.g., in regards to child maltreatment, psychiatric 
disorders and family history of attempted suicide) (50) may provide better estimates of the effect 
that opioid abuse/ dependence has on suicidal outcomes. In addition, suicidal ideation/ attempts 
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may be an important factor predicting treatment seeking among opioid users. Because of this and 
given that these studies are based on populations of opioid users in treatment, associations 
between opioid abuse/ dependence and suicidal outcomes may be the result of selection bias. In 
this regard, one study on opioid users not in treatment (59) and therefore not affected by this type 
of selection bias, still shows that the prevalence of suicidal ideation was high in this group, 
suggesting that selection bias may only partially explain associations. 
 
Confounding may also be an issue in survey studies, as models are often not adjusted by other 
important confounders of these associations, such as traumatic childhood experiences or prior 
psychiatric disorders occurring prior to onset of prescription opioid use, mostly because there are 
no measures of these constructs in survey data. In addition, reverse causation could be an 
alternative explanation for these findings, as studies use cross sectional data with opioid use and 
suicidal outcomes measures occurring during the same time period. Because of this, there is less 
certainty about the directionality of these associations. Individuals with prior psychiatric 
diagnoses or having previously attempted suicide are also at greater risk of long-term opioid use 
and of nonmedical use of prescription opioids (88-90), suggesting that the directionality may be 
reciprocal. Longitudinal studies, such as the study by Guo et al., (69) provide stronger support 
for these effects as findings are less likely explained by reverse causation. 
 
In studies on patients with chronic non-cancer pain, confounding by indication may alternatively 
explain these associations (30, 60-63). Moderate/severe pain is an important factor that can lead 
to higher opioid dosage and to suicide risk, and therefore identifying the causal effect of opioid 
use on suicide outcomes would require appropriate control for degrees of pain experienced (30, 
  29
60, 62, 63). However, separating the effects of opioid use from levels of pain is challenging, 
particularly because the continuous use of opioids may also lead to hyperalgesia (91), a path 
through which opioids can cause suicidal outcomes. Hyperalgesia can lead to loss of control over 
opioid use, to depressive states (23, 29), and eventually to suicidal ideation and behavior. Despite 
the fact that pain could explain the effects of prescription opioids on suicidal outcomes in 
patients with chronic pain, the findings in these studies show the importance of screening for 
suicidal ideation/ attempts, and the need for greater monitoring and alternative treatment options 
for patients with suicidal ideation/ behavior.  
 
Finally, there are also potential limitations in studies examining effects of the availability of 
prescription opioids on suicide behavior. No adjustment for potential confounders and lack of 
information on estimates provided in results limit the conclusions that can be obtained from the 
study showing the effects of opioid prescriptions on suicide calls (71). Also the lack of a control 
group in the study on co-proxamol withdrawal (72) is problematic given that other laws, 
programs or events occurring around the same time could have explained the reductions in 
suicides.  
 
Limitations of this systematic literature review must be also noted. Although two independent 
reviewers selected studies to be included, only one researcher extracted the data and identified 
potential limitations in the included studies, which could lead to lower sensitivity to detect 
potential limitations or to wrongfully list limitations in some studies. Also, due to the substantial 
heterogeneity in study designs and effects shown in studies, we did not do a meta-analysis. 
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However we tried to summarize findings from studies in a clear a succinct way for a better 
understanding of this evidence. 
 
To conclude, we show evidence from national and international studies supporting our 
hypothesis of effects of opioid use and opioid abuse/dependence on suicidal outcomes. However, 
characteristics of populations studied and potential limitations in studies, including the use of 
inappropriate comparison groups and reverse causation in many of these studies, could partially 
explain these findings. Nevertheless studies included here show the importance of screening for 
suicidal ideation/ attempts, and the need for greater monitoring and treatment options for 
individuals using opioids, whether they use them for medical or non-medical purposes. Further 
studies with individual longitudinal data and addressing some of the limitations discussed here 
(e.g., adjusting for other potential confounders), will provide additional and stronger evidence 
supporting or refuting the hypothesis of effects of opioid use on suicidal outcomes. Also, group 
level studies using control groups and examining effects at a more granular level (e.g., state or 
counties) may also provide support for individual and also group level effects happening during 
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2.7. Figures and tables 
Figure 2.1: Process of selecting studies (January 1, 1950-May 30, 2018) examining 
association and mechanisms between the use of opioids and suicide, suicidal ideation or 








Figure 2.2: Summary of results from studies examining suicide rates among populations of opioid users in treatment 
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Figure 2.3: Summary of results from studies examining the prevalence of suicidal ideation and attempts in populations of 
opioid users.* 
 
*The prevalence for Campbell et al., is based on a population of patients taking prescription opioids to treat non-cancer pain; The prevalence for Demidenko et 
al. is based on a population of patients discontinued from long-term opioid therapy; the prevalence for Saint Onge et al. is based on a population of heroin users 
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Figure 2.4: Summary of results from studies examining the association between opioid exposures and suicide outcomes 
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Table 2.1: Potential limitations that could threaten the internal validity of studies 
Categories Specific items 
Introduction Aims/objectives of the study not clearly described 
Methods 
The study design was not appropriate for the stated aim 
Sample size was not justified 
Convenience sample 
The target/reference population was not clearly defined 
Sample frame was not taken from an appropriate population base so that it closely represented the target/reference population 
under investigation 
No clear if selection process likely to select agencies/individuals that were representative  of the target/reference population 
under investigation 
No evidence that measures were undertaken to address and categorize non-responders . No information on response rates 
The risk factor and outcome variables were not measures appropriate to the aims of the  study 
No information or problems with reliability/validity of the exposure measures 
No information or problems with reliability/validity of the outcome measures 
Confounders included and correctly measured. No adjustment for other potential confounders 
It was not clear what was used to determined statistical significance and/or precision  estimate 
Methods (including statistical methods) were not sufficiently described to enable them  to be repeated 
Results  
The basic data were not adequately described 
Response rate raises concerns about non-response bias 
Information about non-responders is not described in the article  
Results were not internally consistent 
Results for the analyses described in the methods were not presented 
Discussion  
The authors’ discussions and conclusions were not justified by the results 
No discussion on the limitations of the study 
Other  
Funding sources or conflicts of interest may affect the authors’  interpretation of the results 
Risk of bias due to loss to follow-up (cohort studies) 
No values described in detail for the general population 
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CHAPTER 3 : SUICIDAL IDEATION AND ATTEMPTS FOLLOWING NONMEDICAL 




Background: During the last two decades there as been an unprecedented increase in rate of 
fatal opioid overdoses and in suicide rates in the United States. The fact that both have affected 
some groups more than others, has led to the hypothesis that the opioid epidemic contributed to 
the increase in suicide rates. Identifying that opioid use and opioid abuse/ dependence cause 
suicidal outcomes would provide evidence of a potential mechanism through which the opioid 
epidemic could have influenced the suicide rate. Current available evidence of these effects is 
limited due to the cross sectional design of most studies and other limitations such as incomplete 
confounding control. In this study we take advantage of longitudinal data and available measures 
of potential confounders to test whether the nonmedical use of prescription opioids and other 
related exposures have an effect on subsequent suicidal ideation and attempts. 
Methods: We used longitudinal data from a national representative sample of the U.S. adult 
population, the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). 
Participants (n=34,653) were interviewed in 2001-2002 and re-interviewed approximately 3 
years after. A propensity score approach was used to estimate the effects of the nonmedical use 
of prescription opioid, and prescription opioid abuse/ dependence on persistent and onset of 
suicidal ideation and attempts. 
Results: The heavy/ frequent nonmedical use prescription opioids had an effect on persistent 
suicidal ideation [Adjusted Risk Ratio (ARR), 95% Confidence Interval (95% CI)=1.75, 95% CI: 
1.17-2.62] and persistent suicide attempts [ARR = 3.86, 95% CI: 2.03, 7.35], and the range of 
  44
effects sizes also suggested that this exposure had an effect on onset of suicidal ideation 
(ARR=1.98, 95% CI: 0.96, 4.10). Prescription opioid abuse/ dependence also had an effect on 
persistence (ARR= 2.12, 95% CI: 1.30, 3.47) and onset of suicidal ideation (ARR=3.06, 95% CI: 
1.50, 6.26), and also on persistence of suicide attempts (ARR=4.30, 95% CI: 1.80, 10.27). None 
of the exposures were associated with onset of suicide attempts. 
Conclusions: We found evidence of the effects of the heavy/ frequent prescription opioid use 
and related abuse/ dependence on persistent and onset of suicidal ideation and on persistence of 
suicide attempts. These individual-level effects may contributed to the increases in the suicide 
rate, as the prevalence of nonmedical prescription opioid use and of prescription opioid abuse/ 
dependence increased in the population. Altogether, these results provide evidence supporting 
the hypothesis that prescription opioid use and abuse/ dependence have an effect on suicidal 
outcomes, and also the hypothesis that the opioid epidemic contributed to the increase in the 




In the U.S., 649,610 individuals died by suicide since 1999, with an average of 42,700 suicides 
per year in the last 5 years (1). From 1998 to 2016 the suicide rate increased by 32% (2), 
reaching a rate of 15.6% per 100,000, the highest in the four decades (3). Suicide rates increased 
most dramatically among non-Hispanic whites (42% increase from 1999 to 2016) and American 
Indian/AK Native populations (77% increase) (1); the prevalence of suicide attempts also 
increased for whites from 2004-05 to 2012-2013 (4). Some literature suggests that the 
prescription opioid crisis contributed to this increase in suicidal behavior (5). The prescription 
opioid crisis in the U.S. started around 1997 and was characterized by a two-fold increase in the 
rate of long-term use of opioids to treat non-cancer pain from 1997 to 2005 (from 23.9 to 46.8 
per 1,000, respectively) (6). In this period there was also a four-fold increase in opioid-related 
fatal overdoses and an almost six-fold increase in prescription opioid abuse treatment admissions 
(7). Data from the National Survey on Drug use and Health (NSDUH) shows that between 2002-
2014 white and American Indian/AK Native populations had for most of the period the highest 
prevalences of non-medical use of prescription opioids (range: 3.8%, 5.5% and 4.3%, 10.6%, 
respectively) and of prescription opioid abuse and dependence (0.6%, 0.9% and 0.6%, 3.5%, 
respectively) (8). These two populations also had the highest rates of opioid overdoses during the 
1999 to 2016 period, and the sharpest increases in overdoses: from 3.1 to 17.1 per 100,000 in 
whites and from 3.3 to 14.4 per 100,000 in American Indians/AK Natives (9). The increase in 
opioid-related outcomes along with the parallel increase in suicide rates in these groups supports 
the hypothesis that the opioid crisis contributed to the rise in suicides in these populations.  
 
  46
One of the potential mechanism by which the opioid crisis could have influenced suicide rates is 
by increasing the number of individuals experiencing suicidal ideation and attempting suicide in 
a community, through the impact that the continuous use opioids has on the reward system (10). 
This mechanism has been previously described for patients with chronic physical pain (10) who 
become dependent on prescription opioids, but may also apply to nonmedical users. As the 
reward system is altered by external opioids and the reward threshold in the brain is elevated, 
individuals become gradually insensitive to rewarding experiences with need for higher doses of 
opioids to achieve the prior levels of pleasure and sense of psychological well-being (11). These 
mechanisms are believed to partially explain why those with heroin use disorder say they use 
heroin not to get “high”, but just to get “straight” (i.e., getting back to natural reward levels) (12). 
Emotional pain and distress experienced during withdrawal periods can also result in allostatic 
overload with activation of the hypothalamic-pituitary-adrenal (HPA) axis and dysregulation of 
the noradrenergic system. This results in elevated levels of corticotropin-releasing factor and 
dynorphins, neuropeptides that are involved in maintaining negative mood states in animal 
addiction models (13). This cascade of events ultimately can increase the risk of suicidal ideation 
and behavior among opioid users. Finally, those with opioid abuse and dependence may face 
social discrimination, financial challenges and other adversities, which may trigger feelings of 
failure and despair that eventually can lead to suicidal ideation and behavior. 
 
The presence of opioid use and related abuse/ dependence effects on suicidal ideation/ behavior 
in non-clinical settings is supported by evidence from epidemiologic surveys (14-16) based on 
measures of nonmedical use of prescription opioids. Cross-sectional studies indicate that the 
nonmedical use of prescription opioids is associated with a two-fold increased risk of suicidal 
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thoughts among adolescents (14), and 1.4-to two-fold risk of suicidal thoughts in adults (15, 16). 
However, although estimates reported by these studies accounted for potential confounders such 
as socio-demographics and other substance use, the lack of adjustment for other important 
factors, such as psychiatric disorders occurring before the exposure period of interest or growing 
up in a harsh environment (e.g., parents with drug abuse/ dependence), could partially explain 
their positive findings. In addition, because both measures of opioid use and suicide 
ideation/behavior are usually obtained for the same period (e.g., past year), it is difficult to assess 
the temporal relationship between the exposure and the outcome in these studies. Research with 
good temporality and good confounder control would provide more robust evidence testing the 
hypothesis that the use of prescription opioids and related abuse/ dependence has an effect on 
suicidal ideation and suicide behavior. 
 
In this study, we test whether at the individual level the nonmedical use of prescription opioids, 
the heavy/ frequent use of these drugs, and related abuse/ dependence are associated with 
subsequent suicidal ideation and attempts. We test these effects in a national representative 
sample of the U.S. population, the National Epidemiologic Survey on Alcohol and Related 
Conditions (NESARC). We take advantage of the two waves of data available in NESARC to 
better assess the temporal relationship between the exposure and the outcome while adjusting, 
using a propensity score analysis, for potential confounders of this association including 







We used data from the National Epidemiologic Survey on Alcohol and Related Conditions 
(NESARC), a nationally representative sample of US adults ages 18 years and older, residing in 
households and non-institutional group quarters (e.g., college quarters, group homes, boarding 
houses, and non-transient hotels). The NESARC oversamples black and Hispanic individuals and 
young adults (ages 18-24 years). In wave 1 (2001-2002), interviews were conducted with 43,093 
participants by experienced lay interviewers with extensive training and supervision (17, 18). 
The response rate in wave 1 was 81%. Wave 2 was conducted approximately 3 years after wave 
1 (mean interval, 36.6 months). After exclusion of wave 1 respondents who were 
institutionalized, deported or who died, a total of 34,653 participants were re-interviewed 
(response rate = 86.7%) (19). Interview quality assurance methods were used both in wave 1 and 




Nonmedical use of prescription opioids in past year measured at Wave 1 
Participants were coded as “having used prescription opioids nonmedically in the past year” (1) 
if they endorsed having used these drugs in the last 12 months prior to interview, and coded as 
“not having used these drugs in past year” (0) if otherwise. This measure is based on questions 
on drug use from the Alcohol Use Disorder and Associated Disabilities Schedule (AUDADIS-
IV) module (21, 22). The following statement was read to participants: “I’d like to ask you about 
your experiences with medicines and other kinds of drugs that you may have used on your own - 
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that is, either without a doctor’s prescription; in greater amounts, more often, or longer than 
prescribed; or for a reason other than a doctor said you should use them. People use these 
medicines and drugs on their own to feel more alert, to relax or quiet their nerves, to feel better, 
to enjoy themselves, or to get high or just to see how they would work”. Then participants were 
asked: “have you ever used any of these medicines or drugs: Painkillers, for example, Codeine, 
Darvon, Percodan, Dilaudid, or Demerol?”. Participants were also asked their age when they first 
used these drugs, whether they used these drugs in the last 12 months only, before the last 12 
months only, or during both time periods. The test-retest reliability of the opioid use measure in 
AUDADIS has shown to be good (Kappa = 0.66) (21).  
 
Because the effects of nonmedical use of prescription opioids on suicidal ideation/behavior may 
follow a dose-response pattern, we used two additional exposure measures: 1) past-year 
heavy/frequent nonmedical use of prescription opioids and 2) prescription opioid abuse/ 
dependence in past year. 
 
Past-year heavy/ frequent nonmedical use of prescription opioids (Wave 1) 
Respondents reported the number of days they used opioids non-medically in the past year, 
which was then categorized as: 1) heavy/ frequent users (2-3 times a month or more); and 2) 




Prescription opioid abuse/ dependence in past year (Wave 1) 
The AUDADIS-IV module (21, 22) was used to obtain measures of abuse and dependence based 
on criteria from the DSM-IV (endorsing 1 of the 4 abuse items and/or 3 of the 7 dependence 
items). A participant was considered as having prescription opioid abuse/ dependence, or both, if 
he/she met DSM-IV criteria for at least one of the two. The test-retest reliabilities of AUDADIS-
IV drug abuse and dependence measures have been shown to be excellent (Kappa coefficients 
above 0.79) (23). 
 
Figure 3.1 describes the wave of measure assessments and the period they cover.  
 
Outcomes  
We examined two related but distinct outcome measures: prevalence of suicidal ideation and 
attempt, and incidence of suicidal ideation and attempt. Prevalence captures information about 
the number of current cases, new and preexisting, at a specified point in time. Incidence, on the 
other hand, captures information about the number of new cases during specified time interval. 
Each provides different information. Based on prevalence, we can conclude that the exposure to 
nonmedical use of prescription opioids at wave 1 had an effect on persistence of suicidal 
ideation/ attempts (i.e., developing or continue having these suicidal outcomes) at wave 2. Based 
on incidence we can conclude that the exposure to nonmedical use of prescription opioids at 
wave 1 had an effect on onset of suicidal ideation/ attempts (i.e., developing these outcomes) at 
wave 2. Results based on incidence would more strongly support the hypothesis of prescription 
opioid exposures having an effect on suicidal outcomes, given that these are less affected by 
reverse causation (i.e., people with suicidal ideation before wave 1 being more likely to use 
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prescription opioids at wave 1 but also more likely to continue having suicidal ideation at wave 
2). 
 
Prevalence of suicidal ideation ad suicide attempts  
In wave 2 of NESARC, respondents were asked about suicidal ideation and suicide attempts 
since the last interview; however, this was restricted to those screened into the depression 
module in the NESARC by answering “yes” to any of the following two questions: 1) “Since 
your last interview in (MO/YR), have you ever had a time when you felt sad, blue, depressed, or 
down most of the time for at least 2 weeks?”; and 2) “Since your last interview, have you ever 
had a time, lasting at least 2 weeks, when you didn’t care about the things that you usually cared 
about, or when you didn’t enjoy the things you usually enjoyed?”. For those screened into the 
depression module the following questions were asked: “During that time since your last 
interview when (your mood was at its lowest/you enjoyed or cared the least about things), did 
you think about committing suicide? Did you attempt suicide?”. Respondents were coded as 
having suicidal ideation if they responded “yes” to the first question, and were coded as making 
a suicide attempt if they responded “yes” to the second question.   
 
Incidence of suicidal ideation and suicide attempts 
Because the incidence measure is based on participants who did not experience suicidal ideation 
before wave 1, but who developed suicidal outcomes after wave 1. We used measures of lifetime 
suicidal ideation and suicide attempts from wave 1 to restrict additional analyses to those without 
history of suicidal ideation (91.08%) and of suicide attempts (97.35%) in wave 1. Suicidal 
ideation and suicide attempts items from wave 1 were similar to those of wave 2, but instead of 
  52
referring to “since last interview” questions they were based on the occurrence of suicidal 
ideation and attempts in the past year and lifetime. 
 
Evidence shows that the use of single items to assess suicidal ideation and attempts in self-report 
surveys can misclassify a percentage of individuals (24, 25) (around 10% of those self-reporting 
having suicidal ideation or attempts can be misclassified (25)). However, the fact that in 
NESARC these questions are part of the depression module of a fully structured interview 
administered by trained lay interviewers is likely to improve the validity of these measures. 
Single items measuring these constructs have been extensively used to study suicidal ideation 
and behavior (26-29). 
Because suicidal questions were only asked to those screened into the depression module, 
individuals who are not screened do not have a chance to answer these questions. To examine 
how this limitation would bias results, we used information from additional questions on “ever 
attempt suicide” and also the “age at the most recent attempt” that were asked to all participants 
at wave 2. We identified the number of individuals who were not screened into the depression 
but who had attempted suicide since last interview at wave 2. Then, we used this information in a 
sensitivity analysis to explore the change in the magnitude of associations when these individuals 
were recoded as having attempted suicide since the last interview. 
 
Potential confounders 
Confounders are described below were selected based on literature indicating that they are 
common causes of both substance use, including prescription opioids, and suicidal ideation/ 
attempts (details on these measures and studies describing their effects on substance use and/ or 
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suicidal outcomes are presented in Appendix Table 6). All measures, except when noted, are 
from NESARC wave 1. All confounders correspond to events or problems experienced 12 
months prior to interview at wave 1. 
 
Psychiatric disorders 
Mental health problems are associated with both substance use and with suicidal 
ideation/behavior. In NESARC, the AUDADIS-IV module (21, 22) was used to classify 
participants on whether or not they meet DSM-IV criteria for psychiatric disorders. The test-
retest reliability of the AUDADIS-IV is fair to good for the psychiatric disorders included here 
(21, 22). 
 
Mood disorders: We used measures of mood disorders experienced before age 18. The following 
mood disorders were included: major depressive disorder, dysthymia, bipolar disorder, panic 
disorder, social anxiety disorder, specific phobia, and generalized anxiety disorder. A measure 
for each mood disorder was generated and coded “1” if the person met criteria for the disorder 
and “0” otherwise.  
 
Personality disorders: Personality disorders measured in wave 1 included: conduct, antisocial, 
avoidant, dependent, obsessive-compulsive, paranoid, schizoid, and histrionic personality 
disorders. To obtain lifetime measures of disorders the following was read to participants: “The 
questions I’m going to ask you now are about how you have felt or acted most of the time 
throughout your life regardless of the situation or whom you were with. Do not include times 
when you weren’t yourself or when you acted differently than usual because you were depressed 
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or hyper, anxious or nervous or drinking heavily, using medicines or drugs or experiencing their 
bad aftereffects, or times when you were physically ill”. We created a variable for each 
personality disorder coded “1” if the person meet criteria for the disorder and “0” otherwise. 
Then we created a single combined measure for personality disorders with the following 
categories: 1) not experiencing any personality disorder; 2) experiencing one personality 
disorder; 3) experiencing two personality disorders; and 4) experiencing three or more 
personality disorders. 
 
Number of symptoms of conduct/ antisocial personality disorder: we created two variables one 
measuring the number of symptoms (e.g., cut class, not go to class or go to school and leave 
without permission; stay out late at night even though parents told you to stay home; ever have 
time when bullied or pushed people around or tried to make them afraid of you) before age 15 
years and another for symptoms after age 15. Each variable was categorized as follows: 1) no 
social deviance experiences; 2) experiencing one social deviance item; 3) experiencing two; 4) 
experiencing three; 5) experiencing four; and 6) experiencing five or more social deviance items. 
 
Substance abuse/ dependence prior to the last 12 months: We created variables for meeting 
DSM-IV abuse or dependence criteria prior to the last 12 months for each substance including 
marijuana, cocaine/crack, heroin, inhalants, hallucinogens, stimulants, tranquilizers and 
sedatives. For each substance we created a single variable coded “1” if the person met criteria for 
a specific substance prior to the last 12 months, and “0” otherwise. Then we created a single 
combined measure for abuse/ dependence with the following categories: 1) no abuse/dependence 
to any substance prior to the past 12 months; 2) abuse/dependence to a substance; 3) 
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abuse/dependence to two substances; 4) abuse/dependence to 3 or more substances. AUDADIS-
IV drug abuse and dependence measures have been shown to be excellent test-retest reliabilities 
(Kappa above 0.79) (23). 
 
Other substance use prior to the last 12 months: We created variables for other substances, 
including marijuana, cocaine/crack, heroin, inhalants, hallucinogens, amphetamines, stimulants, 
tranquilizers and sedatives to indicate whether a participant had used a particular substance prior 
to the last 12 months. For each substance we created a single variable coded “1” if the person 
used the substance prior to the last 12 months, and “0” otherwise. Then we created a single 
combined measure for substance use with the following categories: 1) no use of substances prior 
to the past 12 months; 2) used one substance; 3) used two or more substances. The test-retest 
reliability of the use of different substance measures in AUDADIS has shown to be fair to 
excellent (Kappa = 0.50-0.86) (21). 
 
Low self-esteem 
As part of the avoidant personality disorder items participants were asked if they felt that they 
were not as good, smart, or attractive as most other people most of the time throughout their life. 
To better account for this variable linked to both substance use and suicidal ideation (30, 31), we 
used a separate measure of “low self-esteem” in analyses. This variable was coded as “1” if a 




Childhood adversity measures 
Prior difficult experiences have been associated with substance use and suicidal ideation (32). 
We use measures of family history that could be related to hardship during 
childhood/adolescence, including the following: lifetime history of: 1) depressive events among 
blood/natural parents; 2) drug abuse/ dependence in blood/natural parents; 3) drug abuse/ 
dependence in any full brothers/sisters; 4) behavior problems in blood/natural parents (e.g., being 
cruel to people or animals, fighting or destroying property, trouble keeping a job or paying bills, 
being impulsive); and 5) parents divorce/separation or death of at least one parent before the 
participant was 18 years old. We also included a measure from wave 2 on history of suicide 
attempts among parents or other adults living in home before the participant was 18 years old. 
 
Socio-demographic variables 
Age was used as a continuous variable; sex was categorized as male or female; race/ethnic group 
was classified as non-Hispanic white, non-Hispanic American Indian/AK Native, non-Hispanic 
black, Asian/Native Hawaiian/Pacific Islander, and Hispanic; history of end of marriage was 
classified “1” if the participant ever experienced a first marriage separation, divorce, or death of 
partner; and “0” if the participant never experienced a separation, divorce, or death of partner, 
even if never married.   
 
Other confounders 
We also used the following three variables based on characteristics of participants at the moment 
of interview (wave 1): 
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Total family income: Total family income was categorized as income lower than 20,000, 
between 20,000 and 49,999, between 50,000 and 74,999, and 75,000 or more.  
 
Health insurance coverage: Health insurance coverage can influence access to treatment and to 
disease prevention programs, therefore it can be a factor associated with both substance use and 
suicidal ideation/behavior. The insurance variable was categorized as follows: 1) No insurance, 
2) Medicare, 3) Medicaid, 4) the VA or other military health care, or 5) obtained privately or 
through a current or former employer or union.  
 
Marital status: Current marital status at wave 1 was classified as: 1) Married living with 
someone, 2) Widowed/divorced/separated, 3) Never married. 
 
We defined confounders as common causes of the exposure and outcome, and therefore 
conceptualized confounders as occurring temporally prior to the exposure of interest. However, 
NESARC measures of socio-economic status, health insurance coverage and marital status, 
represent the current situation of participants at interview. Adjusting for these variables could 
result in removing some of the effect that past-year use of prescription opioids has on the 
outcome via these variables: e.g., income and past-year nonmedical use of prescription opioids 
are both measured at wave 1, and nonmedical use of prescription opioids could lead to low 
income, which could be a path through which this exposure results in suicidal ideation. We 
included these variables in an attempt to control for confounding arising from them, but we 
acknowledge that mediation effects may be removed by doing so. We present results from 




The effect of each of the exposures (separate model for each) on suicidal ideation/ attempts was 
estimated using generalized linear models with a logarithm link function and a Poisson 
distribution. First, we calculated the crude and then the adjusted estimates of these associations. 
We calculated the population Average Treatment Effect on the Treated (ATT) (33, 34) for each 
exposure. The ATT was estimated by including the log-transformed propensity score centered at 
the mean of the exposed, plus adding an interaction term between the exposure and the log-
transformed propensity score (33): 
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For each exposure of interest, we calculated a propensity score predicting probability of exposure 
in logit models with each exposure as the dependent variable and a set of potential confounders 
(variables found in the literature to be associated with both the prescription opioid use and 
suicidal ideation/ attempts) as independent variables (33, 35-37). For the propensity score 
prediction we included only variables that were associated, in univariate analyses, with the 
exposures and the outcomes at a p-value cut-off point of 0.2 (38). Because the distribution of the 
propensity score was skewed to the right we log transformed the propensity score (39) (this 
transformation did not change the results in the final models with suicidal ideation/ attempts as 
the outcome). The balance of confounders among exposed and unexposed individuals was 
checked in separate logit regression models with the exposure as the independent variable, each 
confounder and the log transformed propensity score as independent variables. There was no 
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significant association (p<0.05) between any of the confounders used to calculate the propensity 
score and the exposures of interest (Appendix Table 7). 
 
To handle missing data, all analyses were conducted using 5 sets of imputed data. Imputation 
was conducted using switching regression, an iterative multivariable regression technique, in 
STATA 14 (40). Percent missing were 0.5% for any nonmedical use of prescription opioids, 
0.04% for frequency of use of prescription opioids, and 0.5% for both suicidal ideation and for 
suicidal attempt since last interview measures. Most variables had less than 1% missing data; the 
variables with maximum missing were those used to create measures of history of family drug 
use, family history of depression and of antisocial personality disorder [ranging from 2.7% 
(history of drug use among sisters) to 15.0% (father history of depression)], and for the specific 
phobia before age 18 measure (4.2%). All analyses were conducted in STATA 14 (40) 
accounting for the complex survey design features of the NESARC survey and combining results 




The prevalence of past-year nonmedical use of prescription opioids was 1.78% (n=549); 1.1% 
(n=322) of participants were heavy/frequent opioid users, and 0.33% (n=104) had a prescription 
opioid abuse/ dependence problem in the past year at wave 1. Also, 8.5% (n=3,069) had a history 
of suicidal ideation at wave 1, 2.38% (n=917) a history of suicide attempts at wave 1; 3.56% 
(n=1,293) of participants endorsed having suicidal thoughts at wave 2, and 0.64% (n=243) 
endorsed having attempted suicide since last interview at wave 2.  
 
Distribution of confounders in the sample: Table 3.1 describes the distribution of confounders 
across exposure groups. Those using prescription opioids nonmedically, compared with non-
users, were on average younger, male, white or American Indian/ Alaska Natives, did not have 
medical insurance, and had a higher prevalence of use of other drugs, mood, anxiety and 
personality disorders, a higher mean of symptoms of conduct/ antisocial personality disorder, had 
parents divorced before age 18, had a history of a parent and/ or siblings with a drug abuse/ 
dependence, parental history of depressive events and parental antisocial behavior problems 
(Table 3.1). Similarly, those with heavy/frequent use of prescription opioids and with abuse/ 
dependence were on average younger, male, had a higher prevalence of use of other drugs, 
higher prevalence of psychiatric disorders, had a history of a parent with a drug abuse/ 
dependence, depressive events and of antisocial behavior problems (Table 3.1). 
 
Suicidal outcomes among exposure groups: Individuals with past-year nonmedical use of 
prescription opioids, compared with those not using prescription opioids, had a higher prevalence 
of having suicidal thoughts (25.62% vs. 8.21%) and suicide attempts at wave 1 (10.64% vs. 
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2.23%) and also at wave 2 [suicidal ideation (10.66% vs. 3.43%) and suicide attempts (3.91% vs. 
0.58%) since last interview] (Table 3.1). Prevalence of suicidal outcomes at wave 1 and wave 2 
among those with heavy/frequent use of opioids and opioid abuse/ dependence were higher than 
those among those with any opioid use in the past year (Table 3.1).  
 
Results from unadjusted models: Unadjusted models showed strong associations between each of 
the exposures and persistence and onset of suicidal ideation, and persistence of suicide attempt 
(Table 3.2.a). We observed a dose response pattern with stronger risk ratios observed for those 
with opioid abuse/ dependence followed by those with past year heavy/ frequent nonmedical use 
of opioids and finally by those with any past-year nonmedical use of opioids. For the outcomes 
persistence and onset of suicidal ideation the risk ratios were of similar magnitude. The strongest 
associations were observed between each of the exposures and the outcome persistence of 
suicide attempts [e.g., the risk ratio (RR) and 95% Confidence Interval (CI) of persistence of 
suicide attempts among those with and without opioid abuse/ dependence was RR=11.71, 95% 
CI: 4.98, 27.49]. The 95% confidence intervals were wider for the associations between opioid 
abuse/ dependence and each of the outcomes, with the widest confidence interval observed for 
the association between opioid abuse/ dependence and onset of suicide attempts. In all 
associations between each exposure and the outcome onset of suicide attempts the 95% 
confidence intervals were wide and included the null value (e.g., association between opioid 
abuse/ dependence and onset of suicide attempts: RR=5.04, 95% CI: 0.77, 33.19). 
 
Results from adjusted models: We found a reduction in the magnitude of crude risk ratios after 
adjusting for the propensity score (Table 3.2.b). Overall reductions in the magnitude of estimates 
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were larger for the outcome prevalence of suicide attempt, for which the risk ratio estimates we 
reduced by more than half. The largest reduction was for the association between heavy/ frequent 
use of opioids and persistence of suicide attempts, with the change in the magnitude of RR from 
10.68 to 3.86. Despite this reduction, strong associations remained between the exposures and 
prevalence of suicide attempts, with the strongest magnitude between prescription opioid abuse/ 
dependence and persistence of suicide attempt [Adjusted Risk Ratio (ARR) = 4.3, 95% CI: 1.80, 
10.27]. The reduction in the magnitude of associations between each of the exposures and the 
suicidal ideation outcomes (persistence and onset) were similar overall.  
 
Results showed that prescription opioid abuse/ dependence had an effect on persistence and 
onset of suicidal ideation. Heavy/ frequent use of prescription opioids had an effect on 
persistence of suicidal ideation (ARR=1.75, 95% CI: 1.17, 2.62); also, the range of effects sizes 
compatible with the data suggested that heavy/ frequent use of opioids had an effect on onset of 
suicidal ideation (ARR=1.98, 95% CI: 0.96, 4.10). In the associations between past-year 
nonmedical use of prescription opioids with the persistence of suicidal ideation (ARR=1.29, 95% 
CI: 0.95, 1.75) and with onset of suicidal ideation (ARR=1.3, 95% CI: 0.80, 2.12) the 95% 
confidence intervals included the null value. The 95% confidence intervals for all associations 
between each exposure and the incidence of suicide attempts were wide and included the null 
value. 
 
Sensitivity analyses: Results restricting the sample to those for whom there was overlap in the 
propensity score distributions in the exposed and unexposed did not differ drastically from the 
results presented above. Similarly, our results were robust after additional adjustment for 
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covariates measured at time of interview at wave 1 (i.e., family income, marital status and 
medical insurance) (Table 3.3). Finally, no major changes in findings were observed in 
sensitivity analyses after recoding individuals who were not screened into the depression but 
who had endorsed attempting suicide since last interview using information from additional 
questions asked to all participants (Table 3.4). We found that 57 individuals who were not 
screened into the depression module endorsed attempting suicide since last interview in these 
additional questions; of these, two were exposed to any use of prescription opioids in the past 
year, one used two to three times a month or more, and two had prescription opioid abuse/ 




In a longitudinal representative sample of the U.S. adult population, we found that the heavy/ 
frequent nonmedical use prescription opioids and prescription opioid abuse/ dependence was 
associated with persistence and onset of suicidal ideation and suicide attempts, but not with onset 
of suicide attempts. We observed that adjustment for confounding considerably reduced the 
magnitude of the crude associations. Consistent with a dose-response effect, the risk of suicidal 
ideation and attempts was greater among those with opioid abuse/ dependence. Also, we found 
that prescription opioid abuse/ dependence in wave 1 was strongly associated with onset of 
suicidal ideation in wave 2.  
 
Adjusting for the propensity score resulted in an important reduction, from 45% to 74%, in the 
magnitude of all associations. The potential confounders we controlled for, such as prior 
psychiatric disorder events and growing up in a difficult environment, have been previously 
described as drivers of initiation and continual use of substances (23, 31, 32, 41-44) and also of 
suicidal ideation/behavior (32, 41, 44-48), and therefore adjustment for them is key to remove 
confounding when examining these associations. 
 
As we hypothesized we observed a dose-response pattern in the risk of suicidal ideation and 
attempts. Those with opioid abuse/ dependence are by definition those experiencing symptoms 
(including social problems at work, or with family or friends) derived from their drug use, and 
who are more likely to use opioids at higher frequency and in higher doses than occasional users, 
partially due to tolerance (12). Therefore, we expected to see stronger associations between this 
exposure and suicidal outcomes. The risk of suicidal outcomes in heavy/frequent users was lower 
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than that of those with opioid abuse/ dependence. It is possible that many of the heavy/ frequent 
opioid users had not yet developed drug-related problems since wave 1 (in NESARC only 15% 
of those with heavy/ frequent use of opioids met criteria for opioid abuse/ dependence at wave 1) 
and therefore were less likely to experience suicidal ideation at wave 2.  
 
Our findings indicate that opioid abuse/ dependence was associated with a three-fold increase in 
the risk of onset of suicidal ideation. Because incidence measures are less likely affected by 
reverse causation (incidence is based on participants who did not experienced suicidal ideation 
before wave 1 and therefore suicidal ideation is not a cause of opioid use at wave 1), we believe 
this finding provides stronger support for the hypothesis of a causal connection between opioid 
abuse/ dependence and suicidal ideation. In addition, we found that heavy/ frequent use of 
opioids and opioid abuse/ dependence at wave 1 increased the risk of persistence of suicidal 
ideation and attempts since last interview, with estimates being stronger in magnitude for 
persistence of suicide attempts. It is possible that disinhibition effects of opioids could increase 
the risk of individuals with suicidal thoughts acting on these impulses. Also, the availability of 
prescription opioids could provide a means of suicide that would increase the risk of attempts in 
those with suicidal thoughts. Some evidence indicates that increases in the rate of individuals 
with opioid prescriptions are associated with increases in suicidal behavior.(49)  
 
In contrast, we did not find evidence of strong associations between exposures and onset of 
suicide attempt. This may arise for several reasons. The non-medical use of prescription opioids 
and abuse/ dependence could contribute more to persistence of suicidal behavior than onset. 
Alternatively, despite the large sample size in NESARC very few participants had onset of 
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suicide attempts at wave 2, therefore we had less power to detect these effects. Finally, reverse 
causation cannot be ruled out in the estimation of effects on persistence of attempts, given that 
prior suicide attempts could lead to non-medical use prescription opioid and addiction. 
 
Overall, our findings support the hypothesis that frequent/ heavy prescription opioid use and 
abuse/ dependence have an effect on suicidal ideation and on persistence of suicide attempts. 
These findings are important as it is estimated that in the U.S. in 2016 around 1.6 million of 
adults met criteria for prescription opioid abuse/ dependence (50). If the risk of suicidal ideation 
and attempts in these exposed groups remain similar to date (assuming there are similar to our 
estimates from the 2004—2005 period), we estimate that approximately 321,969 individuals 
with opioid abuse/ dependence would experience suicidal ideation and 115,592 suicide attempts.  
 
Evidence (51) on patients registered in the Veterans Affairs health care system also show that 
higher opioid doses can also be linked to suicide (the Hazard Ratio (HR) for those receiving 100 
mg/day compared with those receiving 20 mg/day or less was HR= 2.15, 95% CI: 1.64, 2.81), 
suggesting a need to better monitor and treat risk for suicide in these patients. Screening for 
suicide risk among people misusing prescription opioids and providing monitoring and treatment 
for drug use could also lower the risk of suicide in those with heavy/frequent nonmedical use of 
prescription opioid and abuse/ dependence. However, reaching this population is challenging 
given that most individuals with substance abuse/ dependence (95.5%) in the U.S. do not feel 
like they need treatment (52) and a small percent of those in need access treatment (50). 
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In the past two decades, both opioid abuse/ dependence and completed suicide have increased 
(53, 54). Given the correlation between opioid use and suicidal behavior, to what extent could the 
increase in opioid use and related abuse/ dependence explain increase in completed suicide? 
Assuming a stable correlation between opioid abuse/ dependence and suicide attempts as 
documented in this study of approximately four-fold increased risk from adjusted models, and 
assuming that approximately 3.6% of those who attempt suicide will eventually complete (55, 
56), we estimate that around 21% (95% CI: 0%, 44%) of the increase in the suicide rate from 
1992 to 2016 in the U.S. is potentially attributable to the increase (from 0.1% to 0.7% during this 
period) (54, 57) in the prevalence of prescription opioid abuse/ dependence due to nonmedical 
use. This represents an excess of 1,065 suicides in 2016 (95% CI: 0, 2,245). The extent to which 
opioid abuse/ dependence explained increases in completed suicide may also vary by age group 
and other demographic factors.  
 
In addition to the direct effects of prescription opioid use and related abuse/ dependence on 
suicidal ideation/behavior, it is possible that indirect effects of these drugs go beyond 
prescription opioid users. The opioid epidemic could have contributed to the deterioration of 
social norms and values and the weakening of networks (58) that give support to individuals and 
provide meaning to their lives (59, 60). Also, families and friends are challenged with the 
struggles and death of relatives dependent on prescription opioids, which may cause negative 
affect and depressive states that can also be accompanied by suicidal ideation and behavior. 
Thus, through these indirect effects the opioid epidemic could have additionally contributed to 
the suicide rate beyond the effects described above in prescription opioid users. 
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There are some limitations that must be noted in our study. An important limitation of NESARC 
data is that suicidal ideation/ attempts are only measured among participants screened into the 
depression module. This means that some individuals experiencing suicidal ideation during 
periods of impulsivity without experiencing depressive episodes, or not meeting criteria, were 
not queried regarding suicidal thoughts (40.0% of those with heavy/frequent use of prescription 
opioids as well as 33.7% of those with abuse/ dependence did not screen into the depression 
module). However, because experiencing depressive episodes is one of the most important risk 
factors for suicidal ideation/ attempts (61), we believe the data captured most cases of suicidal 
ideation and attempts in the sample, and the bias arising from this type of misclassification may 
be small. In addition, results from sensitivity analyses were robust after recoding participants not 
screened into the depression module but who endorsed suicide attempts in the additional 
questions asked to all participants. NESARC also uses single items to assess suicidal ideation 
and attempts, which can increase misclassification of the outcome. However, these questions are 
asked as part of the depression module of a fully structured interview, which likely improved the 
validity of these measures. In regards to the exposure measures, NESARC participants were 
asked only about nonmedical use of prescription opioids, therefore there are no data on medical 
use of prescription opioids. This is likely to have impacted our estimates with bias towards the 
null, because individuals using prescription opioids medically, who may develop the outcome 
due to their opioid use, may be misclassified as unexposed (i.e., they answered “no” to the 
question on nonmedical use of opioids), and therefore would inflate the risk among the 
unexposed. It is also possible that significant findings in our study are due to residual 
confounding. We adjusted for multiple factors including history of psychiatric disorders and 
family history of drug use, but there may be other factors, such as recent traumatic events, not 
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available in the data, that could still confound these associations. In addition, self-report of 
exposure, outcome and confounders may have led to misclassification with correlated errors, 
likely inflating the magnitude of associations. Finally, because NESARC data used in this study 
are from 2001-2002 and 2004-2005 further assessment with data reflecting the most recent 
nonmedical use of prescription opioids and related problems and suicidal ideation/behavior 
would be important to determine if these associations shift over time as the exposure and 
outcome become more prevalent. 
 
Our propensity score approach allowed us to observe distributions of the propensity score in the 
exposed and unexposed, and although there was overlap of the distributions, they both were 
skewed to the right with most individuals with raw propensity scores values close to 0. This 
indicates that the variables frequently used as potential confounders in the substance abuse 
epidemiology literature may not be optimal predictors of nonmedical use of prescription opioid 
and related abuse/ dependence (this may apply to other substances as well), which raises concern 
about the effectiveness in removing of confounding after adjustment for these variables. Future 
studies in the field can benefit from this approach providing information on the degree of overlap 
between exposed and unexposed given a set of confounders and whether it is meaningful or not 
to adjust for these variables.  
 
In this study we focused on the average treatment effect on the treated (ATT), rather than the 
average treatment effect (ATE), as we were interested in any effect that using prescription 
opioids and related abuse/ dependence had on suicidal ideation/ attempts in those exposed to 
opioids (33). In contrast, the ATE represents the difference in suicidal outcomes if everyone in 
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the population had been exposed compared with everyone had not been exposed. Given that a 
small proportion of the U.S. population is exposed to heavy/frequent use of prescription opioids 
and abuse/ dependence, we considered that it was appropriate to calculate these effects in the 
group of exposed.  
 
3.6. Conclusions 
We found evidence supporting the hypothesis of a causal effect of heavy/frequent use of opioids 
and opioid abuse/ dependence on suicidal ideation/ attempts. Consistent with a dose-response 
effect, the risk of persistence suicidal ideation and attempts was higher among those with opioid 
abuse/ dependence. Prescription opioid abuse/ dependence was strongly associated with 
subsequent onset of suicidal ideation, which provides stronger support for this hypothesis than 
associations with prevalent suicidal ideation, as other explanations (e.g., reverse causation) are 
less likely to explain this finding. The range of effect sizes also show evidence that heavy/ 
frequent nonmedical use of prescription opioids had an effect on onset of suicidal ideation. These 
findings suggest that increases in the prevalence of heavy/ frequent use of prescription opioids 
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Table 3.1: Prevalence of psychiatric disorders, events and demographic variables by past-year  nonmedical prescription opioid 
use, heavy/frequent nonmedical prescription opioid use and related abuse/ dependence, among adults aged 18 and older (n= 
34,653) 
  Past-year prescription opioid use    Past-year heavy/frequent use   Past-year abuse/ dependence  
No Yes F, p-value   No Yes F, p-value   No Yes F, p-value 
Age at wave 1 interview (years); 
mean 45.27 34.54 F=192.87, p<0.001 45.27 40.02 F=15.06, p<0.001 45.11 35.19 F= 36.12, p<0.001 
Sex 
Female 52.25 42.45 F=10.92, p<0.01 52.25 39.63 F=7.38, p=0.009 52.13 36.52 F= 7.04, p=0.01 
Male 47.75 57.55 47.75 60.37 47.87 63.48 
Race 
Non-Hispanic white 70.82 77.18 F=5.28, p<0.001 70.82 79.8 F=8.04, p<0.001 70.92 72.54 F= 2.72, p=0.04 
Non-Hispanic black 11.13 6.32 11.13 5.47 11.06 7.02 
American Indian/ Alaska Native 2.16 4.21 2.16 5.94 2.18 7.37 
Asian/Native Hawaiian/ Pacific 
Islander 4.28 3.83 4.28 0.22 4.27 4.24 
Hispanic 11.61 8.46 11.61 8.57 11.57 8.83 
Marital status 
Married living with someone 63.44 41.99 F=62.57, p<0.001 63.43 46.62 F=8.32, p<0.001 63.12 45.29 F=6.94, p=0.002 
Widowed/ divorced/ separated 16.47 16.83 16.47 25.49 16.47 17.02 
Never married 20.09 41.21 20.09 27.89 20.41 37.69 
History of divorce/ separation/ 
widowed 28.97 26.61 F=1.12, p=0.29 28.98 39.13 F=7.00, p=0.01 28.93 29.19 F= 0.003, p=0.96 
Any other drug use F=476.22, p<0.001 F=245.93, p<0.001 F= 88.66, p<0.001 
1 drug 11.8 19.79 11.80 14.49 11.93 15.62 
2 or more drugs 9.31 57.98 9.31 64.46 10.02 58.17 
Mood disorders before age 18 
Major depressive disorder 4.36 13.05 F=72.45, p<0.001 4.37 11.88 F=21.07, p<0.001 4.46 22.04 F=60.02, p<0.001 
Dysthymia 1.14 4.79 F=44.31, p<0.001 1.15 3.79 F=12.62, p<0.001 1.18 9.94 F= 53.65, p<0.001 
Bipolar disorder 2.31 8.6 F=63.58, p<0.001 2.31 8.09 F=16.32, p<0.001 2.37 16.49 F= 49.28, p<0.001 
Anxiety disorder before age 18 
General anxiety disorder 0.83 3.27 F=22.66, p<0.001 0.83 2.04 F=3.89, p=0.05 0.85 7.24 F=34.43, p<0.001 
Social phobia 9.62 20.25 F=47.86, p<0.001 9.63 21.11 F=20.63, p<0.001 9.77 22.43 F=11.36, p<0.001 
Specific phobia 31.01 44.68 F=30.48, p<0.001 31.07 46.55 F=19.30, p<0.001 31.21 43.73 F=5.31, p=0.024 
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Panic disorder 1.75 6.78 F=62.08, p<0.001 1.75 6.22 F=14.46, p<0.001 1.82 7.58 F=14.68, p<0.001 
Any personality disorder F=70.79, p<0.001 F=57.33, p<0.001 F= 37.03, p<0.001 
Experienced 1 disorder 10.09 20.7 10.10 17.32 10.22 28.25 
Experienced 2 disorders 3.13 6.62 3.14 6.21 3.17 10.01 
Experienced 3 disorders or more 2.06 11.17 2.06 16.47 2.17 18.11 
Low self-esteem 8.32 14.51 F=16.87, p<0.001 8.33 17.63 F=13.68, p<0.001 8.38 24.93 F=17.09, p<0.001 
Social deviance before 15 years 
(number items); mean 0.53 1.85 F=68.99, p<0.001 0.53 1.92 F=32.64, p<0.001 0.54 3.35 F=32.32, p<0.001 
Social deviance after 15 years 
(number items); mean 1.77 5.80 F=182.35, p<0.001 1.77 6.42 F=68.78, p<0.001 1.83 7.58 F=64.86, p<0.001 
History of depressive events among 
parents 24.4 45.12 F=82.64, p<0.001 24.40 50.23 F=42.53, p<0.001 24.67 52.53 F= 37.40, p<0.001 
History of behavior problems among 
parents 9.03 26.03 F=114.50, p<0.001 9.03 27.64 F=47.49, p<0.001 9.25 33.79 F= 48.01, p<0.001 
History of drug abuse/ dependence in 
blood/ natural parents 3.69 16.33 F=188.57, p<0.001 3.69 20.14 F=104.39, p<0.001 3.86 20.62 F= 56.43, p<0.001 
History of drug abuse/ dependence 
disorders in any full brothers/ sisters 10.94 19.57 F=34.00, p<0.001 10.93 17.11 F=6.33, p=0.01 11.07 16.44 F= 2.47, p=0.12 
History of suicide attempts among 
parents (wave 2) 3.68 7.29 F=13.39, p<0.001 3.68 8.99 F=11.47, p=0.001 3.72 9.84 F= 4.89, p=0.03 
Parents divorce/separation  15.92 26.68 F=14.00, p<0.001 15.92 27.86 F=10.18, p<0.001 16.09 22.56 F= 1.55, p=0.22 
Family income F=14.24, p<0.001 F=8.54, p<0.001 F= 2.00, p=0.12 
<20,000 8.92 16.46 8.93 17.64 9.03 15.58 
20,000 and 49,999 13.03 18.78 13.02 14.6 13.12 15.78 
50,000 and 74,999 36.51 35.31 36.51 44.35 36.47 43.16 
 75,000 or more 41.54 29.46 41.54 23.41 41.38 25.49 
No medical insurance  17.76 30.86 F=29.57, p<0.001 17.76 26.45 F=6.09, p=0.02 17.95 31.36 F= 7.44, p=0.01 
Suicidal outcomes            
Suicidal ideation (wave 1) 8.21 25.4 F=168.05, p<0.001 8.21 32.82 F=114.57, p<0.001 8.41 39.13 F=83.81 , p<0.001 
Suicide attempts (wave 1) 2.23 10.64 F=108.06, p<0.001 2.23 18.2 F=136.33, p<0.001 2.32 21.12 F=83.25, p<0.001 
Suicidal ideation (wave 2) 3.43 10.66 F=64.68, p<0.001 3.43 14.54 F=54.03, p<0.001 3.5 20.09 F=80.67, p<0.001 
Suicide attempts (wave 2)  0.58 3.91 F=58.53,  p<0.001 0.58 6.18 F=70.79,  p<0.001 0.62 7.21 F=50.22,  p<0.001 
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Table 3.2: Past-year nonmedical use of prescription opioids, heavy/frequent use of nonmedical prescription opioids and 
related abuse/ dependence at wave 1 and their association with persistent suicidal ideation and suicide attempts since last 
interview (wave 2) in adjusted and unadjusted models 
A) Unadjusted models: 
 
Prevalence of suicidal 
ideation   
Incidence of suicidal 
ideation   
Prevalence of suicide 
attempt   
Incidence of suicide 
attempt 
  RR 95% CI   RR 95% CI   RR 95% CI   RR 95% CI 
No use Reference   Reference   Reference   Reference  
Nonmedical use of prescription 
opioids in past year 
3.11 (2.33, 4.14)   2.88 (1.77, 4.68)   6.77 (3.83, 11.96)   2.90 (0.91, 9.28) 
No heavy/frequent use Reference   Reference   Reference   Reference  
Heavy/frequent nonmedical 
use of prescription opioids 
4.23 (2.83, 6.33)   3.66 (1.76, 7.61)   10.68 (5.39, 21.17)   1.42 (0.34, 5.96) 
No abuse/ dependence  Reference   Reference   Reference   Reference  
Prescription opioid use abuse/ 
dependence in past year 
5.74 (3.83, 8.59)   5.88 (2.86, 12.12)   11.71 (4.98, 27.49)   5.04 (0.77, 33.19) 
 B) Adjusted models:*                       
  
Prevalence of suicidal 
ideation   
Incidence of suicide 
ideation   
Prevalence of suicidal 
attempt   
Incidence of suicide 
attempt 
  RR 95% CI   RR 95% CI   RR 95% CI   RR 95% CI 
No use Reference   Reference   Reference   Reference  
Nonmedical use of prescription 
opioids in past year 
1.29 (0.95, 1.75)   1.30 (0.80, 2.12)   2.52 (1.38, 4.57)   1.41 (0.51, 3.95) 
No heavy/frequent use Reference   Reference   Reference   Reference  
Heavy/frequent nonmedical 
use of prescription opioids 
1.75 (1.17, 2.62)   1.98 (0.96, 4.10)   3.86 (2.03, 7.35)   0.77 (0.16, 3.86) 
No abuse/ dependence Reference   Reference   Reference   Reference  
Prescription opioid use abuse/ 
dependence in past year 
2.12 (1.30, 3.47)   3.06 (1.50, 6.26)   4.30 (1.80, 10.27)   1.33 (0.18, 9.74) 
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*Models were adjusted by the log transformed propensity score that included the following variables: Respondent’s age, sex, and race/ethnic group; history of marriage ending 
(separated/divorced/widowed); mood and personality disorders experienced before age 18; low self-esteem; other substance use prior to past year before interview; substance use 
disorder prior to past year before interview; social deviance before and after age 15; lifetime history of depressive events among blood/natural parents; lifetime history of drug use 
disorders in blood/natural parents; lifetime history of drug use disorders in any full brothers/sisters; parents divorce/separation or death of at least one parent before the participant 
was 18 years old; family history of behavior problems in blood/natural parents; history of suicide attempts among parents or other adults living in home before the participant was 




Table 3.3: Past-year nonmedical use of prescription opioids, heavy/frequent use of nonmedical prescription opioids and 
related disorder at wave 1 and their association with persistent suicidal ideation and suicide attempts since last interview 
(wave 2) in models adjusted by additional confounders (marital status, family income and type of insurance) 
  
Prevalence of suicidal 
ideation   
Incidence of suicide 
ideation   
Prevalence of suicidal 
attempt   
Incidence of suicide 
attempt 
  RR 95% CI   RR 95% CI   RR 95% CI   RR 95% CI 
No use Reference   Reference   Reference   Reference  
Nonmedical use of prescription 
opioids in past year 
1.21 (0.88, 1.66)   1.17 (0.71, 1.93)   2.30 (1.21, 4.39)   1.23 (0.45, 3.38) 
No heavy/frequent use Reference   Reference   Reference   Reference  
Heavy/frequent nonmedical 
use of prescription opioids 
1.54 (1.03, 2.31)   1.70 (0.81, 3.59)   3.17 (1.56, 6.45)   0.59 (0.11, 3.19) 
No abuse/ dependence Reference   Reference   Reference   Reference  
Prescription opioid use abuse/ 
dependence in past year 
2.06 (1.27, 3.32)   2.76 (1.36, 5.62)   4.04 (1.71, 9.58)   1.42 (0.19, 10.56) 
*Models were adjusted by the log transformed propensity score that included the following variables: Marital status, family income, type of insurance, respondent’s age, sex, and 
race/ethnic group; history of marriage ending (separated/divorced/widowed); mood and personality disorders experienced before age 18; low self-esteem; other substance use prior 
to past year before interview; substance use disorder prior to past year before interview; social deviance before and after age 15; lifetime history of depressive events among 
blood/natural parents; lifetime history of drug use disorders in blood/natural parents; lifetime history of drug use disorders in any full brothers/sisters; parents divorce/separation or 
death of at least one parent before the participant was 18 years old; family history of behavior problems in blood/natural parents; history of suicide attempts among parents or other 
adults living in home before the participant was 18 years old. 
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Table 3.4: Sensitivity analyses after recoding participants who were not screened into the depression module but endorsed 
having attempting suicide in additional questions asked to all participants. 
  
  
Prevalence of suicidal 
attempt   
Incidence of suicide 
attempt 
    RR 95% CI   RR 95% CI 
No use  Reference   Reference  
Nonmedical use of prescription 
opioids in past year 
  2.01 (1.12, 3.62)   0.82 (0.30, 2.24) 
No heavy/frequent use  Reference   Reference  
Heavy/frequent nonmedical 
use of prescription opioids 
  2.52 (1.31, 4.82)   0.39 (0.08, 1.94) 
No abuse/ dependence  Reference   Reference  
Prescription opioid use abuse/ 
dependence in past year 
  4.01 (1.92, 8.36)   0.92 (0.12, 6.83) 
*Models were adjusted by the log transformed propensity score that included the following variables: Marital status, family income, type of insurance, respondent’s age, sex, and 
race/ethnic group; history of marriage ending (separated/divorced/widowed); mood and personality disorders experienced before age 18; low self-esteem; other substance use prior 
to past year before interview; substance use disorder prior to past year before interview; social deviance before and after age 15; lifetime history of depressive events among 
blood/natural parents; lifetime history of drug use disorders in blood/natural parents; lifetime history of drug use disorders in any full brothers/sisters; parents divorce/separation or 
death of at least one parent before the participant was 18 years old; family history of behavior problems in blood/natural parents; history of suicide attempts among parents or other 
adults living in home before the participant was 18 years old. 
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CHAPTER 4 : THE PRESCRIPTION OPIOID CRISIS AND INCREASED SUICIDE 




Background: In the past two decades in the U.S. there has been a sharp increase in the rate of 
opioid overdoses and in the rate of suicides. The increases in these rates have disproportionally 
affected whites and American Indian/Alaska native populations, suggesting that a potential 
causal link between the two may . However, although at the national level prescription opioid 
sales and the rate of fatal opioid overdoses are correlated with suicide rates, is not clear whether 
these associations are present at the state level. This study investigates the effects of increases in 
prescription opioid exposures at the state level on increases in suicide rates. 
Methods: Pooled cross sectional data from the 50 states (1999-2016) and linear regression 
models were used to examine whether increases in the volume of prescription opioid, in the 
prevalence of nonmedical use of prescription opioids, and in the rate of unintentional fatal 
prescription opioid overdoses had an effect on increases in suicide rates. Models were adjusted 
for different lagged and current state-level confounders of these associations.  
Results: Contrary to the observed increases in the volume of prescription opioid and fatal opioid 
overdoses, the prevalence of nonmedical use of prescription opioids decreased during the study 
period. Results showed that for every 1% increase in the per capita volume of prescription 
opioids there was an increase of 0.028% (95% Confidence interval (CI) = -0.0009; 0.056) in the 
rate of suicides. Also, for every 1% increase in the rate of unintentional fatal prescription opioid 
overdoses there was a 0.033% (95% CI = 0.022; 0.044) increase in the rate of suicides; the 1-
year lag of this exposure was also associated with increases in the suicide rate (0.020, 95%CI = 
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0.0008; 0.038). These estimates suggest that the increase in the volume of prescription opioids 
and in the rate of fatal prescription opioid overdoses contributed approximately to 8.6% and 
39%, respectively, of the total change in suicide rates from 1999 to 2016.  
Conclusions: The current findings provide evidence on the effects of the increase in the 
availability of prescription opioids and in the rate of unintentional fatal opioid overdoses on 
suicide rates. These findings support the hypothesis of a causal link between the opioid epidemic 





In the U.S. the suicide rate has increased by 32% from 1998 to 2016, with more than 42,000 
suicides occurring per year in the last 2 years (1). The increase in suicide rates is higher for non-
Hispanic whites and American Indian/AK Native populations than non-Hispanic blacks and 
Hispanics (2). The fact that whites and American Indian/AK Natives are also the two race/ethnic 
groups with the largest increases in the rate of opioid related abuse/ dependence (3) and opioid 
fatal overdoses in the last decades (4), suggests that there might be a link between the opioid 
crisis and the rise in suicide rates. Although the increase in suicides and opioid related problems 
could be both caused by the economic downturn (5-7) (e.g., the deceleration of productivity in 
the 70s (8), the loss of manufacturing and natural resource jobs in the 80s and 90s, and the 2007-
08 economic crisis (7)) and the resulting stress and despair generated by it (9), it is also possible 
that the availability of prescription opioids and the long-term use of these drugs contributed to 
suicidal behavior. The fact that suicide rates begin to increase around 1999, long-before the 
2007-08 economic crisis, but three years after the strong push to introduce prescription opioids 
for non-cancer pain treatment, supports this hypothesis.  
 
One possible mechanism through which increases in the availability of prescription opioids could 
influence suicide rates is by providing an effective means of suicide to individuals less likely to 
use other methods. Having access to prescription opioids, which is in turn influenced by the 
overall increased availability of opioids, may have an effect on suicidal behavior and suicides. 
Consistent with this, a study in the UK showed that restricting the sales and use of a prescription 
opioid that was a common method of suicide in the population, resulted in a reduction in the 
overall suicide rate (10). In the U.S., Oxycontin production quotas increased from 3,520 kg in 
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1993 to 108,510kg in 2007 (11, 12); the production quotas of other prescription opioids also 
increased dramatically during this period. The increased availability of opioids in the country 
could have immediate effects on suicidal behavior among those struggling with suicidal thoughts 
by providing an effective means of suicide. While evidence shows that suicide by opioid 
poisoning increased during the 1999-2014 period, it remain a small proportion of overall suicides 
(e.g. 4.3% of suicides in 2014) (13), suggesting that alternative mechanisms may be operative.   
 
Second, it is possible that the use of opioids may increase the risk of suicidal ideation and 
behavior. Because of their influence on the reward system (14), the continuous use of opioids 
may cause individuals to gradually become less sensitive to naturally rewarding experiences 
(15), and to experience negative affect, anxiety and high levels of distress during withdrawal 
periods (14), possibly with emerging suicidal thoughts and behavior. This process may escalate, 
as higher doses of the drug are needed in order to achieve prior well-being states and to avoid 
intensified depressive and stressful periods during withdrawal (15). In addition, the continuous 
use of opioids in patients with non-cancer pain has been associated with hyperalgesia, which can 
lead to increased risk of depressive states and suicidal ideation/behavior (14, 16). Moreover, 
behavioral disinhibition can result from continuous opioid consumption, which may increase the 
risk of suicide among individual with suicidal thoughts (17). Also, along with changes in the 
reward system, those with opioid abuse/dependence may also face social rejection from family 
and peers, experience isolation and financial challenges that can trigger feelings of failure and 
despair increasing the risk of suicidal ideation and behavior. These individual level mechanisms 
would be reflected in the suicide rate as the number of individuals misusing prescription opioids 
increase, which is a function of the increase availability of prescription opioids. 
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Third, the increased availability of prescription opioids and in opioid overdoses may have 
indirectly contributed to the rise in the rate of suicides by deteriorating the social capital (18) that 
individuals rely on for support and that provide meaning to their lives (19, 20). For example, 
prescription opioid abuse and opioid overdoses of friends or family members can result in 
feelings of despair and emptiness, not only in those using opioids but also in their relatives not 
using these drugs who must face the death and struggles of those abusing opioids. Feelings of 
despair may involve negative affect and depressive states that can also be accompanied by 
suicidal thoughts and behavior that could eventually contribute to increase the suicide rate.  
 
In addition, along with opioid overdoses, the distrust generated from drug activities, e.g., crime 
related to drug trafficking or burglary to steal opioid medication, could influence the 
deterioration of the social fabric, contributing to the rupture of social connections and increasing 
the risk of experiencing despair, depression and suicidal thoughts. The effects of the increased 
availability of crack during the 80s and 90s on health outcomes provide an example on how a 
drug crisis may deteriorate social capital. Minority communities hit by the crack epidemic 
experienced increases in the prevalence of sexually transmitted diseases and homicide rates as 
well as increases in incarceration rates (19, 20). In addition, illegal activity and violence spread 
fear, suspicion and mistrust among residents (19), reducing the mobility of residents, the 
frequency of social exchanges and informal social ties that are essential for survival in poor 
communities (19). While plausible mechanisms exist for an effect of the opioid epidemic on 
suicide rates, to date no one has examined which mechanisms could be the main ones. Findings 
from our study described in Chapter 3 of this dissertation indicated that heavy/ frequent 
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nonmedical use of prescription opioids and related abuse/ dependence had an effect on 
subsequent suicidal ideation and attempts. By increasing the number of individuals using 
prescription opioids, of those with opioid abuse/ dependence, and indirectly increasing the 
number of those with suicidal outcomes, the opioid epidemic could have contributed to increases 
in suicide rates. 
 
Although there is an evident correlation among the sales of prescription opioids, the rate of 
opioid overdoses and the suicide rate at the national level, it is not clear whether these 
associations also remain at a more granular level, e.g., state level. This is important, as 
identifying these effects at the state level would suggest that associations are not the result of 
aggregated estimates at the national level. In this study, we used pooled cross sectional time 
series data to examine the effects of prescription opioid exposures on suicide rates in the U.S. 
We first tested whether the state level per capita volume of prescription opioids was associated 
with increases in suicide rates between 1999 and 2016. Second, because prescription opioid 
overdoses and the prevalence of nonmedical use of prescription opioids may represent the 
burden of the opioid crisis in a state, we test whether the state rate of unintentional fatal 
prescription opioid overdoses and the prevalence of nonmedical use of prescription opioids were 







Per capita volume of prescription opioid shipments 
To obtain a measure of the volume of prescription opioids being shipped to each state each year, 
we used 1999-2016 data from the Automation of Reports and Consolidated Orders Systems 
(ARCOS), a surveillance system of controlled substance shipments available from Drug 
Enforcement Administration (DEA) Office of Diversion (21-23). ARCOS is the system that 
monitors and records the flows of transactions and deliveries, from all manufacturers and 
distributors, of all Scheduled II-V substances as specified by Controlled Substance Act of 1970. 
ARCOS data provide the volume in grams of different prescription opioids per 100,000 
individuals for each state by quarter, year and drug type. ARCOS does not include prescription 
opioids illegally entering the country (e.g., illegal internet purchase of opioids) (24). We 
calculated the morphine equivalents (in grams) per capita for four prescription opioids 
commonly used to treat chronic pain that were also commonly used for nonmedical purposes: 
hydrocodone, hydromorphone, oxycodone and codeine. Morphine equivalents were calculated 
by multiplying the gram weight of each opioid and the following multipliers: hydrocodone, 1; 
hydromorphone, 4; oxycodone, 1; and codeine, 0.15 (25, 26). 
 
Unintentional fatal prescription opioid overdose rate 
We used the rate of unintentional fatal prescription opioid overdoses as a proxy for the burden of 
the opioid epidemic in a state. We used the multiple causes of death, detailed mortality data from 
Wide-ranging ONline Data for Epidemiologic Research (WONDER), from the Centers for 
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Disease Control and Prevention (CDC), to obtain rates of unintentional fatal prescription opioid 
overdoses by state and year. The National Center for Health Statistics (NCHS) collects official 
vital statistics through the National Vital Statistics System (NVSS), as part of the 
intergovernmental sharing of vital records data between NCHS and state vital registration offices 
(57 jurisdictions send birth and death data to NCHS) (27). Data are processed and datasets are 
created through coding, validation, and other standardization processes (27). Rates of 
unintentional fatal overdoses were calculated specifying the code T40.2 for “Other opioids” that 
includes natural and semisynthetic opioids (e.g., oxycontin, hydromorphone) but excludes 
heroin, methadone and synthetic opioids such as fentanyl. As we were interested in the effect of 
prescription opioids on suicidal outcomes, we excluded overdoses from opioids such as fentanyl, 
which along with heroin is also illegally imported from overseas (28). When data was not 
available for a state in a specific year because the number of cases was below 10 (CDC 
suppresses this information to protect personal privacy), we calculated rates as if 5 deaths (the 
mean number of deaths for the range 1-9) had occurred in suppressed cells divided by the 
population provided by CDC WONDER for the state in that year. One hundred seventeen cells 
out of 918 (12.75%) state/year cells were suppressed because of low numbers in CDC 
WONDER data. We present results from analyses using the imputed data using the methods 
describe above, but we also present findings from analyses using the data with missing values for 
suppressed cells. Also, because circumstances in New Jersey in 2009 resulted in unusually low 
death counts for unintentional poisonings (29), we used the averaged number of fatal overdoses 
in 2008 and 2010 in New Jersey to recalculate the rate for the state in 2009. 
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State-year prevalence of past year nonmedical use of prescription opioids (NMPO) 
We used The National Survey on Drug Use and Health (NSDUH) restricted data to obtain 
prevalence of nonmedical use of prescription opioids by state and year based on self-report 
measures. NSDUH is a nationally and state representative sample of residents of households, 
non-institutional group quarters, and civilians living on military bases age 12 or older. NSDUH 
data includes information on prior use of substances, abuse/dependence and mental health 
problems. Every year NSDUH collects data on more than 17,500 youth (12-17 years-old), 
17,500 young adults (18-25 years-old) and 18,800 adults older than 26 years old. The sampling 
strategy oversamples younger age groups (youths aged 12-17 and young adults aged 18-25) to 
reach a balanced number of participants from each age group. Using a multi-stage probability 
sampling design, NSDUH provides yearly cross sectional data from 2004 through 2014 (30-33). 
As part of the survey strategies, NSDUH includes an audio computer-assisted self-interviewing 
method that has built-in skip, logic, and consistency checks, providing respondents with a private 
space and confidential means of responding to sensitive questions, such as drug use and related 
problems; this method increases the level of honest reporting. For the period 2004-2014, survey 
screening response and interview response rates in NSDUH varied from 84%-91% and 72%-
77%, respectively. 
 
In the NSDUH, all participants are asked: “Now we have some questions about drugs that people 
are supposed to take only if they have a prescription from a doctor. These questions are about the 
use of pain relievers. We are not interested in your use of "over-the-counter" pain relievers such 
as aspirin, Tylenol, or Advil that can be bought in drug stores or grocery stores without a doctor's 
prescription.” Then participants are asked: “Have you ever, even once, used any type of 
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prescription pain reliever that was not prescribed for you or that you took only for the experience 
or feeling it caused?.” The NSDUH provides a dichotomous variable indicating whether a 
participant used prescription opioids nonmedically in the past 12 months prior to interview. 
Using this variable we calculated the prevalence by state and year (years 2004 to 2014) of past-




As described above in the section for fatal prescription opioid overdose rates, the NCHS collects 
official vital statistics, including suicides, through the NVSS (27). The detailed mortality CDC 
WONDER data provides annual raw and age-adjusted suicide rates [ICD-10 codes: X60-X84; 
cutting or piercing (X78), falls (X80), firearms (X72, X73, X74), drug poisoning (X60–X64), 
nondrug poisoning (X65–X69), and suffocation (X70)] (2). Suicide rates per 100,000 (in the 
population ages five and older) were obtained for years 1999-2016 for each of the 50 states (all 
race/ethnic groups were included). All suicide means (e.g., firearm, suffocation, poisoning) were 
included in the estimation of overall rates. A positive association between the opioid exposures 
and all means of suicide would support the presence of all three mechanisms: opioids providing a 
means of suicide, opioids influencing suicidal ideation/behavior at the individual level (e.g., 
impact on the reward system), and opioids impacting the social capital of communities. We also 
separately obtained rates of firearm suicides and of “other types of suicides” (excluding firearms 
and poisonings, but including all other types: cutting or piercing, falls, and suffocation), to test 
whether our exposures had an effect on non-opioid poisoning suicides. Finding an association 
between opioid exposures and non-opioid poisoning suicides would suggest that opioids 




We adjusted for the following state-level confounders (measured yearly and by state) that based 
on the literature are common causes of prescription opioid misuse/ fatal opioid overdoses and 
suicide rates: 
 
Measures of socio-economic deprivation 
Economic downturn and poverty have been associated with substance use (34-39) and 
suicides/suicide ideation (5, 6, 40, 41). Although these measures of socio-economic deprivation 
could cause increase levels of opioid use and opioid fatal overdoses in states, is less clear if they 
have an effect on the per capita volume of opioid shipments (similar for other of the listed 
confounders below, e.g., ethanol sales per capita and other substance abuse/ dependence); we 
present the results from models adjusted and not adjusted by these confounders. We included 
measures of: a) unemployment rate obtained from the Bureau of Labor Statistics; b) median 
household income; c) the proportion of those living below the federal poverty level, both 
obtained from the US census Bureau (42); and d) the proportion of individuals with any college 
education, obtained from the American Community Survey from the US Census Bureau (43). 
 
Proportion of veterans in the state 
On average, veterans have a higher risk of substance use and suicide than the rest of the 
population (44, 45). Data on the proportion of veterans in the state was obtained from the 
Department of Veterans Affairs (46), and the American Community Survey from the Census 
Bureau.(43) We used data from 2000 to replace missing values in years 1999, 2001 and 2002 
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because data was not available for these years. We also used values from 2005 to replace missing 
values for years 2003 and 2004, as done in previous research (47, 48). 
 
Proportion of the population age 65 or older  
This age group is likely to be prescribed opioids to treat pain and is at higher risk of opioid 
overdose (49, 50); males in this age group have also a high suicide rate (2). Data of the 
proportion of individual 65 or older was obtained from the CDC WONDER data (2). 
 
State per-capita mental health expenditure 
Mental health disorders have been associated with use of substances and suicide (51, 52). Mental 
health spending may improve access to mental health treatment and in theory is expected to help 
reduced suicidal behavior (53) and also drug misuse, abuse and dependence. Also, increases in 
expenditures can also be a proxy for high levels of mental health problems, which would suggest 
higher rates of suicidal behavior and of drug related problems. Data on state per-capita 
expenditure was obtained from the National Association of State Mental Health Program 
Directors Research Institute (54). Because data was not available for years 1999-2001, we used 
values in year 2002 to replace missing values for these years. Similarly, we used data from 2013 
to replace missing data in years 2014-2016. 
 
Ethanol sales per capita 
Alcohol abuse has been associated with other substance use, including opioids, and also with 
suicide ideation and suicide (52). We used the state sales of ethanol per capita (55) as a proxy for 
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alcohol consumption at the state level. Because data for years 2015 and 2016 was not available, 
we used the same values in year 2014 for these two years. 
 
Prevalence of other substance use and abuse/ dependence 
substance use and related abuse/ dependence may contribute to the deterioration of family 
cohesion and collective supportive networks that individuals rely on to solve their problems (18), 
and in turn may contribute to increases in the use of other drugs, such as prescription opioids, 
and increases in suicidal outcomes. We used NSDUH restricted data to calculate state and annual 
(from 2004 to 2013) prevalences of: a) alcohol abuse/dependence; and b) “other substance” 
abuse/dependence including: marijuana, cocaine/crack, hallucinogens, inhalants, heroin, and 
prescription-type psychotherapeutics (includes prescription opioids, tranquilizers, sedatives, and 
stimulants). We replace missing values for years 2001-2003 with values from years 2004, and 
missing data from 2014-2016 with available data from 2013.   
 
Analyses 
To identify overall and state-specific trends in suicide rates as well as in the exposures (i.e., per 
capita prescription opioid shipments, the rate of unintentional fatal prescription opioid overdoses 
and the prevalence of nonmedical use of prescription opioids) we used linear regression models 
with each measure as the dependent variable and year as predictor. 
 
To estimate the effect of the per capita prescription opioid shipments (in morphine equivalents) 
on suicide rates we used linear regression models with state and year fixed effects. We log-
transformed the outcome and the exposure variables after checking the linearity assumption of 
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the relationship between the log-transformed variables (Appendix figure 1 and 2). Because we 
used the logged transformations of both the exposure and the outcome, results can be interpreted 
as the proportional change in the outcome per proportional change in the exposure (56). We first 
estimated coefficients in unadjusted models and then in models adjusted by the state level 
concurrent (lag zero) confounders. We then additionally adjusted models by the state level 
confounders lagged 1 and 2 years. In separate models we also lagged the exposure by 1 and 2 
years to test for lagged effects of exposures on the outcome. All models were weighted by the 
state total population. These models tested the change in suicide rates as a function of the per 
capita volume of prescription opioid shipments while adjusting for state level covariates: 
 
!"# = $ + . & ℎ("# + )"# + *# + +" + ,"# 
Where  !"# is the suicide rate as a function of $ the intercept,  the change in the per capita 
volume of prescription opioid shipments, )"# representing a vector from a set of state-level 
confounders, *# is a fixed effect for each year,  +" is a fixed effect for each state, and ,"# is a 
state-year fixed error term.  
The same modeling strategy was used to examine the effect of other exposures on suicide rates. 
The model fit was assessed with deviance (log-likelihood statistics), Bayesian Information 
Criterion and Akaike Information Criterion (57). 
 
To examine whether one state was driving the results in models, we conducted additional models 





4.4.1. Trends of exposures and the outcome 
4.4.1.1. The averaged state per capita volume of prescription opioids shipped to states increased 
on average from 16,795 grams per 100,000 in 1999 to 33,328 grams per 100,000 in 2016, 
representing a 98% increase. The top five states with the largest increase in prescription opioid 
shipments from 1999 to 2016 were North Dakota (382% increase), Wisconsin (236%), Iowa 
(235%), and Oklahoma (235%). Figure 4.1 shows trajectories of per capita prescription opioids 
shipped (dependent variable) based on predicted probabilities estimated from a linear regression 
model with time as the predictor. Also, the top five states with the highest per capita volume of 
prescription opioid shipments in 2016 were Oklahoma, Tennessee, Arizona, Alaska, and North 
Dakota (Table 4.1).  
 
4.4.1.2. Nationwide the rate of unintentional fatal prescription opioid overdoses increased from 
0.8 per 100,000 in 1999 to 3.8 per 100,000 in 2016. Using the imputed data for suppressed years 
in WONDER data, the top five states with the largest increase in overdoses during the study 
period were West Virginia (6,350% increase), Michigan (4,219%), Massachusetts (4,196%), 
Utah (3,734%), and Connecticut (3,150%). The top five states with the highest rate of fatal 
prescription opioid overdoses (per 100,000) in 2016 were West Virginia (17.8), Maine (10.0), 
Tennessee (9.3), Kentucky (8.7), and Utah (8.7) (Table 4.1). Figure 4.2 shows trajectories of the 
rate of prescription opioids overdoses based on predicted probabilities.  
 
4.4.1.3. The past-year prevalence of nonmedical use of prescription opioids (based on self-report 
nonmedical use of prescription opioid in the past year) in the U.S. decreased from 4.75 in 2004 
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to 3.89 in 2014 (difference = 0.84, 95% CI: 0.48, 1.21). Most states (78%) experienced 
reductions in this prevalence during this period; the top five states with the largest reduction 
from 2004 to 2014 were Rhode Island (54.9% reduction), Kentucky (53%), Wyoming (49.4%), 
Montana (49.4%), and North Dakota (47.8%). The top five states that in contrast experienced 
increases in this prevalence during this period included: Maryland (99.3% increase), Mississippi 
(70.7%), Hawaii (66.6%), Iowa (52%) and Nebraska (47.4%) (Table 4.1). Figure 4.3 shows 
trajectories of the prevalence of nonmedical use of prescription opioids based on predicted 
probabilities. On average there was a trend towards reduction from 2004 to 2014. Because the 
required premise of increases in this exposure to cause increases in the outcome was falsified, 
given that the prevalence of nonmedical use of prescription opioids decrease nationally and in 
most of states, we did not further examine the association between this exposure and suicide 
rates.  
 
4.4.1.4. Suicide rates increased for the entire nation from 11.2 per 100,000 in 1999 to 14.8 per 
100,000 in 2016. During this period all states experienced increases in the rate of suicides; the 
top five states with the highest increase were North Dakota (71% increase), Vermont (69%), 
Kansas (60%), West Virginia (59%) and Utah (65%). Also, the top five states with the highest 
rate of suicides (per 100,000) in 2016 were Montana (27.8), Alaska (27.7), Wyoming (27.1), 
New Mexico (24.2), and Utah (23.4) (Table 4.1). Figure 4.4 shows trajectories of suicide rates 




In summary, these results show that the per capita volume of prescription opioids, the rate of 
unintentional fatal opioid overdoses and the suicide rates increased in almost all states over the 
study period. Overall, the largest increases over the study period were for unintentional fatal 
opioid overdoses (ranging from 3% to 6,350%), followed by increases in the volume of 
prescription opioid (ranging from 13% to 382%), and then by suicide rates (ranging from 0.44% 
to 71.4%). In contrast, the prevalence of nonmedical use of prescription opioids decreased in 
most states from 2004-2014. 
 
4.4.2. Results from models testing the effects of prescription opioid-related exposures on 
suicide rates 
4.4.2.1. Effects of per capita prescription opioid shipments on suicide rates 
In unadjusted models we found that for every 1% increase in the per capita volume (in morphine 
equivalents) of the four prescription opioids of interest there was a 0.045% increase (95% CI: 
0.023, 0.069) in the rate of suicides (Table 4.2) (results can be interpreted as the proportional 
change in the outcome per proportional change in the exposure given that both the exposure and 
outcome are logged (56)). This means that if a state had a per capita volume of opioid shipments 
of 17,000 grams per 100,000 and a suicide rate of 11.2 per 100,000, a 1% increase (equal to 170 
grams per 100,000) in the volume of opioid shipments, would translate, on average, to an 
increase of 0.005 per 100,000 in the suicide rate. In models adjusted by contemporaneous 
confounders the estimate was robust (0.043, 95% CI: 0.018, 0.069). The estimate was attenuated 
to 0.028 (95% CI: -0.0009; 0.056) when we additionally adjusted for confounders lagged 1 and 2 
years, and although the range of effects sizes compatible with the data suggested a positive 
effect, the confidence interval included the null. The estimate for the exposure (lag zero) did not 
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drastically change after adding lags of the exposure (lagged 1 and 2 years) (Table 4.2). The 
estimates for the exposure lagged 1 and 2 years were smaller in magnitude (for the lagged 1 year 
exposure the estimate was negative) than the estimate at lag zero and the confidence intervals 
crossed the null value. 
 
To test that opioids providing a means of suicide was not the only mechanism through which 
opioids may increase suicide rates, we examined the effects of opioid exposures on firearm 
suicide rates and other type of suicide rates. Results for the effects of the per capita volume of 
prescription opioid shipments on firearm suicide rates were similar to the ones described above 
for models with all suicides as the outcome, although the magnitude of the association was 
stronger and the confidence intervals did not include the null value (Table 4.3). Results from 
models with other means of suicide as the outcome were smaller in magnitude compared with 
those when using all suicide rates as the outcome (Table 4.3).  
 
4.4.2.2. Effects of the rate of unintentional fatal prescription opioid overdoses on suicides 
rates 
Results from unadjusted models showed that for every 1% increase in the rate of fatal 
prescription opioid overdoses there was a 0.044% (95% CI: 0.036, 0.052) increase in the rate of 
suicides (Table 4.4). This means that if a state had a rate of opioid overdoses of 0.8 per 100,000 
and a suicide rate of 11.2 per 100,000, a 1% increase (equal to 0.008 per 100,000) in the rate of 
opioid overdoses, would translate, on average, to an increase of 0.005 per 100,000 in the suicide 
rate. In models adjusted by contemporaneous confounders the estimate was slightly attenuated to 
0.037 (95% CI: 0.027, 0.046), and then to 0.033 (95% CI: 0.022, 0.044) after additionally 
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adjusting for confounders lagged 1 and 2 years. The estimate for the exposure (lag zero) was 
slightly attenuated after adding lags of the exposure. When only the lag zero and lagged 1 year 
exposures were included in the adjusted model, the estimate for the exposure lagged 1 year was 
positive but smaller than that of the exposure lag zero (0.020, 95% CI: 0.0008, 0.038). When 
adding both exposures lagged 1 and 2 years, the estimates for these lagged exposures were 
smaller in magnitude than the estimate at lag zero and the 95% CI crossed the null value (Table 
4.4). 
 
Results for the effects of the rate of fatal prescription opioid overdoses on firearm suicide rates 
were in the same direction to the ones described for models with all suicides as the outcome, 
although the magnitude of the association was weaker (Table 4.5). The association was even 
weaker (close to zero) with the rate for other means of suicide compared with the association 
when using firearm suicide rates as the outcome; also, the 95% confidence interval included the 
null (Table 4.5).  
 
As a validation analysis, we also examined whether the per capita volume of prescription opioids 
was associated with the rate of unintentional fatal opioid overdoses. We found that 1% increase 
in the per capita volume of prescription opioid shipments was associated with a 0.34% (95% CI: 
0.15, 0.52) increase in rate of unintentional fatal prescription opioid overdoses in the unadjusted 
model. This means that for a state with a per capita volume of opioid shipments of 17,000 grams 
per 100,000 and a rate of fatal unintentional prescription opioid overdoses of 0.8 per 100,000, a 
1% increase (equal to 170 grams per 100,000) in the volume of opioid shipments, would 
translate, on average, to an increase of 0.0027 per 100,000 in the fatal overdose rate. Adjustment 
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for current and lagged confounders decreased the magnitude of the association with the 
confidence interval including the null (0.10% increase, 95% CI: -0.10, 0.30) (Table 4.6). Also, 
when adding the exposure (i.e., per capita volume of prescription opioid shipments) lagged 1 
year, the estimate for the exposure at lag zero became negative and close to zero, and the 
estimate for the exposure lagged 1 year was positive and stronger in magnitude (0.20%, 95% CI: 
-0.11, 0.51) compared with the estimate for lag zero in the models without the lagged exposure. 
Similarly, when adding the exposure lagged 2 years, the estimate for the 2 year-lagged exposure 
was positive and stronger in magnitude (0.30%, 95% CI: -0.03, 0.64). 
 
4.4.2.3. Analyses examining whether a single state drives the overall results 
In models testing the association between the per capita volume of prescription opioid shipments 
and suicide rates, adjusted by current and lagged confounders, we found that overall removing 
states (one at a time) only slighted changed estimates. Only for three states, California, North 
Carolina, and New York, the estimate changed by more than 20%, becoming smaller in 
magnitude when California and North Carolina were removed (36% and 23% decrease, 
respectively), and stronger when New York was removed (72% increase). In addition, for 15 
states, the magnitude of the association became stronger after removing them, with confidence 
intervals that did not include the null. For the association between unintentional fatal prescription 
opioid overdoses (lag zero) and suicide rates in models adjusted by current and lagged 
confounders, removing states had little effect in the estimate. 
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In addition, sensitivity analyses using the unintentional fatal prescription opioid overdoses data 
with missing values were similar in magnitude and direction to the ones presented above when 
missing data was imputed (Appendix Table 8). 
 
4.4.2.4. Model fit and tests of assumptions of the linear model 
We confirmed the linearity assumption of the relationship between the log-transformed exposure 
and outcome variables (Appendix Figures 1 and 2). When plotting the residuals against the fitted 
values, we did not observe any pattern suggestive of heteroscedasticity (Appendix Figures 3 and 
4). Comparing residuals against normal scores we observed the presence of outliers in each 
model for each of the exposures, suggestive of residuals not being normally distributed in these 
models (Appendix Figures 5 and 6). Outliers were Rhode Island (years 2005, 2009, 2010 and 
2013), Wyoming (years 2005, 2012, 2014 2015), the District of Columbia (years 2003, 2004, 
2008, 2009, 2014, 2015 and 2016), and Hawaii (years 2004-06, 2010 and 2014). However, the 
normality of residuals is a less important assumption, than the linearity assumption, when 
estimating regression coefficients as the error distribution averages out in the least-squares 
estimate (56). 
 
Based on log-likelihood statistics, Bayesian and Akaike information criterion values, the model 
with lagged (1 and 2 years) confounders fit the data better than the unadjusted model and 





Using pooled cross sectional time series data from the 50 states and the District of Columbia we 
examined whether increases in availability of prescription opioids and related use and overdoses 
had an effect on increases in suicide rates. Our findings showed that, on average, the prevalence 
of nonmedical use of prescription decreased over the 2004-2014 period. Also, we found evidence 
indicating that increases in the per capita volume of prescription opioids and also increases in the 
rate of unintentional fatal prescription opioid overdoses had an effect on the suicide rate.  
 
We believe that our findings of a decrease in the prevalence of nonmedical use of prescription 
are in part explained by the fact that we only had access to data on this measure from 2004-2014, 
during a period where the prevalence was already stable or starting to decrease in many states, 
specifically among adolescents and adults ages 18-25 (58). Because of this, we were unable to 
examine whether increases in this prevalence likely starting around 1996 (59), were linked to 
increases in suicide rates during the early stages of the prescription opioid epidemic. Tighter 
controls to prescribe opioids around 2004 may have contributed to the reduction in the 
prevalence of nonmedical use of prescription opioids, despite the observed increase in the 
volume of prescription opioids being shipped to states. This is because the volume of opioids 
may continue to increase as a function of a growing medical demand of these drugs across states. 
Tighter controls also likely contributed to slow down the rate at which the prevalence of 
prescription opioids abuse/ dependence increased after 2004; however, this prevalence continue 
increasing from 0.6% in 2004 to 0.8% in 2012 in the U.S. (own analyses of NSDUH public 
national data) even when the prevalence of nonmedical use of prescription opioids decreased 
over this period, indicating that the two prevalences can behave differently over time.  
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In this regard, findings described in chapter 3 showed that prescription opioid abuse/ dependence 
had stronger effects on suicidal outcomes compared to any use of prescription opioids in the past 
year, and therefore it is expected that changes in the prevalence of abuse/ dependence would 
have stronger effects on suicide rates than the prevalence of past year nonmedical use of these 
drugs. Unfortunately, we did not include a measure of state level prevalence of abuse/ 
dependence in this study, as the estimated annual state level prevalences were less stable due to 
the small number of individuals endorsing opioid abuse/ dependence per state in NSDUH. 
Instead a measure of unintentional prescription opioid overdoses was used, as a proxy for the 
impact of the prescription opioid epidemic on communities, for which results are described 
below. 
 
Our estimates of the association between the per capita volume of prescription opioid shipments 
and suicide rates are in the same direction of results from a study by Davis et al., (2014) (60), to 
our knowledge the only study examining the effects of prescription opioid availability on suicide 
behavior in the context of the opioid epidemic. Davis et al., study showed that an increase in the 
availability of prescription opioids, based on the proportion of individuals with opioid 
prescriptions in three-zip code areas, was linked to increased suicidal behavior utilizing 
prescription opioids (based on emergency calls to poison centers) (60). Our findings suggest that 
these effects are more immediate than delayed, with increases in the volume of opioids 
influencing suicide rates within the same year. However, we observed that confounding factors 
partially explained this association. Also, although with additional adjustment for confounders 
lagged by 2 years the confidence intervals became wider and included the null, the range of 
effects sizes compatible with the data suggest that increases in the volume of prescription opioids 
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led to increases in suicide rates. Putting these results in the national context, our findings suggest 
that the state averaged increase in the morphine equivalents for the four opioids examined in this 
study, from 16,795 grams per 100,000 in 1999 to 33,328 per 100,000 in 2016, would have 
resulted in a 2.8 percent increase (95% CI: -0.09, 5.5) in suicide rates, equivalent to 0.3 (95% CI: 
-0.01, 0.6) suicides per 100,000 based on the 1999 suicide rate (11.2 per 1000,000). This is 
approximately 8.6% (95% CI: -0.3%, 17.2%) of the total increase in suicide rates from 1999 to 
2016.  
 
Although it is not possible to clearly identify the mechanisms by which opioid availability 
influence suicide rates, our results suggest that other mechanisms besides prescription opioids 
providing a means of suicide were operative. We found that the per capita volume of prescription 
opioid shipments had an effect on firearm suicides, which suggests that this exposure had an 
effect on a population that was able to use firearms as means of suicide. Although suicides using 
opioids have increased greatly in the last two decades (13), these suicides still account for a 
small fraction of all suicides in the U.S. (1); the availability of prescription opioids might have 
provided the means for some individuals, but it is unlikely that it contributed to increases in the 
suicide rate through this mechanism.  
 
We also found that the rate of unintentional fatal prescription opioid overdoses had an effect on 
suicide rates. Our estimates suggests that the state averaged increase in the rate of unintentional 
fatal prescription opioid overdoses from 0.8 per 100.000 in 1999 to 3.8 per 100,000 in 2016 
would have resulted in 12.4 (95% CI: 8.3, 16.5) percent increase in suicide rates, equivalent to 
1.4 (95% CI: 0.9, 1.8) suicides per 100,000 based on the 1999 suicide rate. This is approximately 
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39% (95% CI: 26%, 51%) of the total increase in suicide rates during this period. The increase in 
the rate of fatal opioid overdoses may represent a period of high burden in a community given 
that overdoses can be seen as the tip of the iceberg of a larger problem that also includes high 
rates of non-fatal overdoses and of opioid abuse/ dependence as a result of the increased 
availability of prescription opioids. It is possible that the rate of unintentional fatal opioid 
overdoses had an effect on suicide rates through the deterioration of the social fabric that 
individuals rely on to solve their problems and that give meaning to their life. This may result in 
high levels of despair and negative affect across communities and eventually in increased rates of 
suicidal behavior. In addition, our results showed that effects were stronger for concurrent fatal 
overdoses, although delayed effects (1-year lag) were also present. Because these effects may 
work through a cumulative process that continuously deteriorates the social fabric, it is possible 
that suicide rates in a given year would be a function of recent fatal opioid overdoses and related 
events (e.g., opioid related crime) occurring in the same year, but also events happening in the 
previous year. 
 
The rate of unintentional fatal opioid overdoses may be a proxy for the number of individuals 
abusing opioids and with opioid dependence, including patients with long-term use of opioids 
who become addicted to them, who may be at high risk of overdosing and suicidal behavior (61) 
(i.e., opioid abuse/dependence as a common cause of both). If this is the case, an increase in the 
rate of fatal opioid overdoses would indicate the presence of a growing population of individuals 
with opioid abuse/dependence who could also be at high risk of suicidal ideation/behavior. 
Prescription opioid abuse/dependence among these individuals could increase the risk for 
suicidal ideation and behavior through its effects on the reward system and the distress 
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experienced during withdrawal periods, as well as through the despair and feelings of failure 
derived from social rejection and economic challenges.  
 
Although we expected to find a strong association between the volume of prescription opioid 
shipments and unintentional fatal prescription opioid overdoses, we did not find evidence of 
strong effects. We examined these effects in a way to validate our tests of the effects of 
unintentional fatal opioid overdoses on suicide rates. However, unintentional fatal opioid 
overdoses can increase in a state as a function of the legal, but also the illegal supply of 
prescription opioids, sold through the internet, or imported from other states with less rigorous 
legislation to control opioids prescribing (e.g., evidence suggests that prescription opioids were 
illegally transported to West Virginia from Florida in the 2007-2010 period) (12). It is possible 
that the illegal supply of opioids, not captured in our per capita prescription opioid shipments 
measure, could additionally explain the change in unintentional fatal opioid overdoses at the state 
level. In addition, the fact that we only had data from 1999 onwards prevented us from 
examining this association in a period when prescription opioids shipments drastically increased 
(from 1996 to 1999) and when this effect might have been stronger.  
 
Limitations must be noted. Our findings for the effects of per capita prescription opioid 
shipments and unintentional fatal prescription opioid overdoses must be taken with caution given 
that we did not adjust our models for more distal potential common causes of opioid overdose 
rates and suicide rates, such as economic downturns related to the loss of manufacturing and 
natural resource jobs during the 80s and 90s, that could further explain some of these effects. 
Second, data on some potential confounders was not available for some years and to avoid 
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dropping years from models, we imputed missing data with values from neighbor years; this 
could have resulted in inappropriate confounding control. Third, the prevalence of nonmedical 
use of prescription opioids were estimated using data from self-reports of individuals endorsing 
using the drug for nonmedical purposes. Although NSDUH uses methods to improve honest 
reporting, sensitive questions may result in lower prevalences of drug use. Also, this prevalence 
is based on “any” use of nonmedical use of prescription opioids in the past year, which may 
poorly represent the prescription opioid problem in states. Moreover, in NSDUH the following 
wording was not included as part of the definition of “nonmedical” use of prescription opioids: 
“…that you may have used in greater amounts, more often, or longer than prescribed; or for a 
reason other than a doctor said you should use them”; not including this as part of the definition 
could have resulted in lower estimates of the prevalence as well. As mentioned above, we did not 
have data on the prevalence of nonmedical use of prescription opioids before 2004 period, which 
prevented us from examining the association between this prevalence and suicide rates during a 
period in which the prevalence was increasing. Fourth, in the CDC WONDER data because of 
uncertainty on the intentionality of some fatal overdoses around 8% of these are classified as 
undetermined (although for most states the proportion of undetermined is under 10%, for 
Maryland in 2008-2010 the proportion was 85%) and therefore were not used in our analyses. 
Because the proportion of overdoses classified as undetermined is small in most states, this 
limitation is not likely to drastically impact the estimates obtained for the effects of unintentional 
overdoses on suicide rates. Fifth, there are also limitations with the “per capita volume of 
prescription opioid shipments” measure: ARCOS data includes shipments to hospitals and 
veterinarians and therefore the volume of shipments in each state could be inflated. However, the 
assumptions for working with these data are that veterinarians use other types of opioids than the 
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ones we used, and also that hospital usage is stable over time or at least will make a small 
contribution to changes in shipments (21). Also, ARCOS data do not capture the illegal 
trafficking of prescription opioids across states (as described above evidence shows that legal 
prescription opioids shipped to Florida between 2007 and 2010 were illegally transported to 
West Virginia, a period when the legal supply in West Virginia was decreasing). However, is 
likely that this biased our results towards the null, as the true availability of prescription opioids 
(e.g., legal and illegal supply in West Virginia) that could be responsible for increases in suicides 
was not fully captured in our exposure measure. To our knowledge there is no evidence 
suggesting that the states with shaper increases in suicide rates were the ones receiving larger 
amounts of prescription opioids from other states. Despite these limitations, the findings from 
this study present initial evidence of the effects of the availability of prescription opioids and the 
rate of unintentional fatal opioid overdoses on suicide rates at the state level. Further studies 
using more complete measures of confounders, including additional confounders and examining 
ways to overcome measurement problems can provide stronger evidence on these effects. A 
better understanding of the factors behind the increase in suicides in the U.S. may lead to better 
strategic interventions and adequate support and treatment to prevent suicides among individuals 
at risk. 
 
In summary, we found evidence at the state level that increases in the per capita prescription 
opioids being shipped to states and increases in the rate of fatal prescription opioid overdoses 
had an effect on suicide rates. In contrast the prevalence of the nonmedical use of prescription 
opioids decreased over time, which falsified our premise of increases in this prevalence having 
an effect on increases in suicide rates. We estimated that the increase in the per capita volume of 
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prescription opioids and the increase in the rate of fatal prescription opioid overdoses from 1999 
to 2016 contributed approximately to 8.6% and 39% of the total increase in the suicide rate 
during the study period. Changes in suicide rates given changes in these exposures remained 
strong after adjusting for current and lagged economic and demographic factors. This evidence 
suggests that prescription opioid availability and unintentional fatal prescription opioid 
overdoses could have partially contributed to increases in suicide rates. Whether mechanisms at 
the individual or/and group level were more likely responsible for changes in suicide rates needs 
to be further studied. 
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4.7. Figures and Tables 
Figure 4.1: State trajectories of per capita prescription opioid shipments rates (morphine 
equivalents in grams) (1999-2016) 
 
Note: Trajectories are based on probabilities estimated from linear regression models with the rate of prescription 
opioid shipments as the dependent variable and year as the independent variable. The red line indicates the average 
trend trajectory across all states.  TN =Tennessee; ND = North Dakota. 
 
Figure 4.2: State trajectories of unintentional fatal prescription opioid overdose rates 
(1999-2016) 
 
Note: Trajectories are based on probabilities estimated from linear regression models with the rate of prescription 
opioid overdoses as the dependent variable and year as the independent variable. The red line indicates the average 
trend trajectory across all states.  WV= West Virginia.  
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Figure 4.3: State trajectories of prevalences of nonmedical use of prescription opioids 
(2004-2014) 
 
Note: Trajectories are based on probabilities estimated from linear regression models with the prevalence of 
nonmedical use of prescription opioids as the dependent variable and year as the independent variable. The red line 
indicates the average trend trajectory across all states. 
 
Figure 4.4: State trajectories of suicide rates (1999-2016) 
 
Note: Trajectories based on probabilities estimated from linear regression models with suicide rates as the dependent 
variable and year as the independent variable. The red line indicates the average trend trajectory across all states. 






Table 4.1: Rate of prescription opioid shipments (morphine equivalents in grams per 100,000), rate of unintentional fatal 
prescription opioid overdoses and rate of suicides per 100,000 in 1999 vs. 2016 
  Presc. opioid shipments   Fatal presc. opioid overdoses   Prevalence of NMPO* use   Suicide rate 
  1999 2016   1999 2016   2004 2014   1999 2016 
Alabama 20552.1 33409.4   0.1 1.8   5.4 4.4   18 27.7 
Alaska 19629.9 50138.7   0.8 5.2   5.6 4.3   13.4 16.8 
Arizona 20719.9 52516.5   1.2 4.0   4.4 4.1   13.6 19.5 
Arkansas 15419.7 43583.0   0.2 3.1   5.0 4.7   16.7 19 
California 20722.1 27641.9   2.5 1.9   4.6 3.9   10.3 11.3 
Colorado 13476.7 28589.7   0.5 3.1   7.1 4.9   14.7 22 
Connecticut 15209.0 28709.8   0.1 4.8   4.1 4.1   8.5 10.9 
Delaware 17538.0 21644.5   0.6 3.1   5.4 4.9   5.5 5.6 
Dist. of Columbia 20491.9 42765.0   0.9 6.0   2.5 2.0   11.9 12.3 
Florida 20048.0 34847.9   0.7 4.6   4.8 3.1   13.1 15 
Georgia 14242.6 34822.9   0.2 4.0   5.5 4.2   12 14.3 
Hawaii 11948.8 24566.8   1.0 2.3   3.1 5.2   11.9 13 
Idaho 13673.1 21729.7   0.4 2.9   5.6 3.9   11.1 15.7 
Illinois 13650.3 35697.1   0.3 2.5   3.9 3.7   15.9 23 
Indiana 17495.3 19757.2   0.2 3.3   5.7 4.0   8.9 11.5 
Iowa 10786.0 36171.3   0.2 2.3   2.7 4.1   11.2 16.5 
Kansas 13081.5 35615.7   0.2 2.3   3.8 5.4   12.1 19.3 
Kentucky 24765.2 45435.0   0.7 8.7   7.4 3.5   12.5 18 
Louisiana 16609.1 39242.4   0.2 2.2   5.1 4.9   12.8 15.2 
Maine 16715.0 23006.0   0.4 10.0   4.7 2.9   7.2 9.4 
Maryland 17020.8 33005.8   0.1 2.6   2.7 5.3   8.9 10 
Massachusetts 14573.2 31794.9   0.1 3.4   3.8 3.1   14.4 17.1 
Michigan 22796.1 43209.8   0.1 4.8   5.6 3.5   10.6 14.3 
Minnesota 11427.8 19931.4   0.2 2.1   3.7 2.8   9.6 14.2 
Mississippi 13186.5 40743.8   0.2 2.9   2.9 4.9   13.5 19.7 
Missouri 17020.7 37546.7   0.2 3.1   4.4 3.2   11.8 13.6 






Nebraska 12152.3 28602.8   0.3 1.2   2.4 3.5   11.8 14 
Nevada 25761.0 38401.4   2.5 6.0   6.1 4.3   11.9 20.4 
New Hampshire 15021.7 33157.3   0.4 3.9   4.7 4.4   11.3 14 
New Jersey 12751.7 33836.7   1.0 3.6   3.5 4.1   12 18.5 
New Mexico 14921.6 25783.1   6.0 6.2   6.1 4.4   7.1 7.7 
New York 14628.1 21754.2   0.2 3.9   4.8 3.6   19.4 24.2 
North Carolina 12850.8 21074.7   0.5 5.5   3.8 3.9   22.9 23 
North Dakota 10229.1 49347.1   0.8 1.7   4.5 2.3   6.7 8.7 
Ohio 18048.1 31056.8   0.5 6.6   5.1 5.0   10.4 15.2 
Oklahoma 17035.5 57005.7   1.1 6.9   4.6 4.6   15.5 22.6 
Oregon 20040.6 37045.5   0.4 2.3   5.5 4.6   14.9 19.2 
Pennsylvania 17208.1 38740.9   0.4 4.7   4.5 3.6   11 15.8 
Rhode Island 15770.5 27017.6   0.5 7.3   6.7 3.0   9.7 12 
South Carolina 14439.5 43093.5   0.5 6.4   5.0 3.8   11.3 16.9 
South Dakota 11283.1 23319.8   0.7 2.2   2.2 2.2   14.7 21.7 
Tennessee 18068.0 56598.4   0.6 9.3   5.2 3.7   13.6 17.5 
Texas 14539.3 33537.1   0.4 1.5   4.3 3.7   11 13.5 
Utah 13329.4 39527.2   0.2 8.7   6.9 3.7   15.1 23.4 
Vermont 14314.6 27450.0   0.8 2.6   4.6 3.2   12 14.2 
Virginia 14013.8 23649.4   1.2 3.6   3.9 3.8   11 18.6 
Washington 18500.8 32940.1   1.2 3.0   7.1 4.4   15.1 16 
West Virginia 24275.4 29346.3   0.3 17.8   5.8 4.3   11.9 15.8 
Wisconsin 13616.1 45686.8   0.4 5.0   4.5 4.1   13 20.7 
Wyoming 12236.7 34158.6   1.0 3.9   5.2 2.6   21.8 27.1 







Table 4.2: Models examining the effects of the volume of prescription opioid shipments (morphine equivalents as grams per 
100 individuals) on suicide rates 
  Estimate 95% CI   
Exposure 
lagged 1 year 95% CI   
Exposure lagged 
2 years 95% CI 
Unadjusted 0.045 0.023, 0.069              
Adjusted by confounders 0.043 0.018, 0.069             
Adjusted by confounders at lag zero 
and lagged 1 year 0.036 0.009, 0.063             
Adjusted by confounders at lag zero 
and lagged 1 and 2 years 0.028 -0.0009, 0.056             
Exposure lagged 1 year* 0.029 -0.015, 0.074   -0.002 -0.046, 0.042       
Exposure lagged 2 years* 0.035 -0.001, 0.081   -0.025 -0.090, 0.040   0.023 -0.025, 0.071 
*Adjusted by confounders at lag zero, and lagged 1 and 2 years 
 
 
Table 4.3: Models examining the effects of the rate of prescription opioid shipments (morphine equivalents as grams per 100 
individuals) on firearm suicide rates and other means of suicides 
   Estimate 95% CI 
Firearm suicides 
Unadjusted 0.103 0.071, 0.135 
Adjusted by confounders* 0.070 0.030, 0.110 
Other means of suicide 
Unadjusted 0.044 0.007, 0.081 
Adjusted by confounders* 0.016 -0.032, 0.065 













Table 4.4: Models examining the effects of the rate of unintentional fatal prescription opioid overdoses on suicide rates 
  Estimate 95% CI   
Exposure 
lagged 1 year 95% CI   
Exposure lagged 
2 years 95% CI 
Unadjusted 0.044 0.036, 0.052             
Adjusted by confounders 0.037 0.027, 0.046             
Adjusted by confounders at lag zero 
and lagged 1 year 0.033 0.023, 0.043       
Adjusted by confounders at lag zero 
and lagged 1 and 2 years 0.033 0.022, 0.044             
Exposure lagged 1 year* 0.030 0.011, 0.050   0.020 0.0008, 0.038       
Exposure lagged 2 years* 0.031 0.011, 0.051   0.018 -0.004, 0.04   0.0011 -0.017, 0.019 
*Adjusted by confounders at lag zero, and lagged 1 and 2 years 
 
 
Table 4.5: Models examining the effects of the rate of unintentional fatal prescription opioid overdoses on firearm suicides and 
other means of suicide (excluding firearm and poisonings) 
   Estimate 95% CI 
Firearm suicides 
Unadjusted 0.038 0.026, 0.050 
Adjusted by confounders* 0.017 0.001, 0.033 
Other means of suicide 
Unadjusted 0.023 0.009, 0.036 
Adjusted by confounders* 0.005 -0.015, 0.024 







Table 4.6: Models examining the effects of the volume of prescription opioid shipments (morphine equivalents as grams per 
100 individuals) on the rate of unintentional fatal prescription opioid overdoses 
  Estimate 95% CI   
Exposure 
lagged 1 year 95% CI   
Exposure lagged 
2 years 95% CI 
Unadjusted 0.337 0.152, 0.522             
Adjusted by confounders 0.169 -0.018, 0.356             
Adjusted by confounders at lag zero 
and lagged 1 year 0.139 -0.059, 0.336             
Adjusted by confounders at lag zero 
and lagged 1 and 2 years 0.102 -0.099, 0.303             
Exposure lagged 1 year* -0.053 -0.366, 0.261   0.199 -0.110, 0.507       
Exposure lagged 2 years* -0.018 -0.304, 0.340   -0.103 -0.556, 0.350   0.303 -0.032, 0.637 
*Adjusted by confounders at lag zero, and lagged 1 and 2 years
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CHAPTER 5 : CONCLUSIONS 
 
Opioid morbidity and mortality and suicide are two central public health problems in the U.S. 
Both increased in unprecedented ways in the last decade, and both disproportionately affected 
some groups more than others, leading to the suggestion that these epidemics are connected (1-
3).  This dissertation addressed the possible connection between the opioid epidemic and suicide 
rates in several ways. First, I reviewed the literature to evaluate the existing evidence for this 
association at both the individual and the group level; second, I examined the individual-level 
association to determine if individuals who use opioids nonmedically and those with opioid 
abuse/ dependence are at increased risk of suicidal ideation and attempt; third, I examined the 
group-level (i.e., state level) association to determine whether trends in opioid availability and 
opioid fatal overdoses had an effect on trends in suicide rates. The results of these studies are 
summarized and discussed below. 
 
The systematic literature review (Chapter 2), provided three main findings. First, there was 
ample evidence of an individual-level association between opioid use and related abuse/ 
dependence on suicidal outcomes. Studies on patients receiving treatment for opioid dependence 
showed that these patients had higher prevalences of suicidal ideation and attempts and also 
increased risk of suicide than the general population. Also, treatment greatly reduced the risk of 
suicidal ideation and attempts over time. Studies on patients treated with prescription opioids 
showed that higher doses of these opioids were associated with increased risk of suicide than 
lower doses. In addition, studies using survey data showed that the nonmedical use of 
prescription opioids and related abuse/ dependence were associated with suicidal ideation, and in 
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adolescents with both ideation and attempts. Second, there were only two studies examining 
evidence of a group-level association between opioid availability and suicidal outcomes. One 
study showed an association between increases in opioid availability and increases in opioid-
poisoning suicide attempts, and another showed a reduction in suicides when an opioid 
commonly use as a means of suicide, was withdraw from the market. The gap in the literature on 
group-level associations between opioid availability and suicidal outcomes is clear. Third, the 
observed associations in the reviewed studies could be partially explained by methodological 
artifacts, indicating the need for further research. For example, in many studies showing higher 
risk of suicidal outcomes in individuals with opioid abuse/ dependence there was poor 
confounder control. Similarly, evidence from cross-sectional studies is limited due to challenges 
in confounding control and in assessment of temporality, with the risk that these associations can 
be partially explained by reverse causation.  
 
Although we cannot determine whether limitations fully explain the observed associations in the 
reviewed papers, future studies overcoming these limitations would generate stronger test of 
these hypotheses. 
 
In Chapter 3, we conducted a study to overcome some limitations in previous studies. We used 
longitudinal data from a national representative sample of the adult U.S. population to estimate 
the effects of the nonmedical use of prescription opioid and related abuse/ dependence on 
suicidal outcomes. This allowed us to have a better assessment of the temporal order of the 
exposure and outcome and to adjust for confounders not used in previous studies. We estimated 
effects of these exposures on the prevalence and incidence of suicidal outcomes. Prevalence 
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captures information about the number of current cases, new and preexisting; incidence, captures 
information about the number of new cases during a specified time interval. With the prevalence, 
we can conclude that exposure effects are on the development or persistence of suicidal 
outcomes at wave 2. With incidence we can conclude that exposure effects are on the 
development of suicidal outcomes at wave 2. Positive results based on incidence would more 
strongly support the hypothesis that prescription opioid exposures have a causal effect on 
suicidal outcomes, given that these are less affected by reverse causation (e.g., suicidal ideation 
leading to opioid use).  
 
Our approach also used a propensity score to address confounding. The propensity score can 
provide information on the balance of confounders among exposure groups, indicating whether 
or not it is meaningful to compare them. Also, this approach minimizes bias due to prior beliefs 
about associations as the model can be built blind to the effect. In this study, when the 
distribution of confounders across exposure groups was assessed, we found that there were 
differences between opioid users and non-users on confounding factors, yet there was enough 
overlap in the propensity score. Adjusting models for the propensity score resulted in an 
important reduction, from 45% to 74%, in the magnitude of all associations.  
 
Results showed that prescription opioid abuse/ dependence at wave 1 had an effect on 
persistence and onset of suicidal ideation at wave 2, and also on persistence of suicide attempts, 
but not with onset of suicide attempts. Likewise heavy/ frequent nonmedical use of prescription 
opioids had an effect on persistence of suicidal ideation and persistence of suicide attempts. In 
addition, although not significant at a 95% confidence, the range of effects sizes compatible with 
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the data suggested that heavy/ frequent nonmedical use of prescription opioids also had an effect 
on onset of suicidal ideation. Heavy/ frequent nonmedical use of prescription opioids was not 
associated with onset of suicide attempts. 
 
Thus, prescription opioid abuse/dependence was associated with persistence and onset of suicidal 
ideation; heavy/ frequent non-medical prescription opioid use was associated with persistence 
and onset of suicidal ideation; and opioid abuse/dependence as well as heavy/ frequent non-
medical prescription opioid use were associated with persistence of suicide attempts, but not with 
onset of suicide attempts. Taken together, these results indicate that there are more identified 
associations for prevalent suicidal behavior than incident. This may arise for several reasons. It 
could be that non-medical prescription opioid use and abuse/dependence contributes more to 
persistence of suicidal behavior than onset. Alternatively (or in addition), prevalent suicidal 
behavior includes more respondents than incident (very few participants had onset of suicide 
attempts at wave 2), so we may have more power to detect an effect. Finally, with prevalence 
estimates we cannot rule out reverse causation, so these results may arise because suicidal 
behavior could lead to non-medical prescription opioid use and addiction. 
  
There were also limitations in this study that threatens the validity of the findings. First, although 
we controlled for several confounders, other factors, such as recent traumatic events, not 
available in the data, could still confound these associations. Second, self-report of the exposure, 
outcome and confounders can lead to misclassification with correlated errors, which would 
inflate the magnitude of associations. Third, asking these questions only to participants screened 
into the depression module could have led to misclassification of these outcomes. However, 
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because experiencing depressive episodes is one of the most important risk factors for suicidal 
ideation/ attempts, it is likely that most individuals with suicidal ideation and behavior were 
classified as having these outcomes. Also, using information from additional questions in 
NESARC on suicide attempts that were asked to all participants, we observed that results were 
robust to recoding of participants who did not screen into the depression module but endorsed 
attempting suicide since last interview in these additional questions. Fourth, the use of single-
item questions to measure suicidal ideation and attempts could have also led to misclassification 
of these outcomes. It is possible that misclassification due to the use of single–items is not 
differential, with the bias introduced being small. However, future research could provide 
evidence on whether individuals exposed and unexposed to prescription opioids differ in the 
ways they recall, perceive/ define, and report suicidal outcomes, and whether the use of single-
items contributes to this. Despite these limitations, this study had multiple strengths including the 
use of longitudinal data, use of measures of onset of suicidal outcomes, and adjustment for a 
variety of confounders usually not found in other studies. Overall, this study provided additional 
evidence on the effects of heavy use of prescription opioid and abuse/ dependence on suicidal 
outcomes, supporting the hypothesis that the opioid epidemic could have contributed to suicide 
rates.  
 
Finally, in Chapter 4 we examined whether the increase in the per capita volume of prescription 
opioids, in the prevalence of nonmedical use of prescription opioids and in the rate of fatal 
prescription opioid overdoses had an effect on suicide rates. We used pooled cross sectional data 
from the 50 states (1999-2016) and conducted analyses using a linear regression models with 
state and year fixed effects adjusted for different lagged and current state-level confounders of 
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these associations (including unemployment rates, the proportion of veterans, state per-capita 
mental health expenditures, ethanol sales per capita and the prevalence of other substance use 
disorders). This allowed us to overcome limitations of previous studies examining similar effects 
but without controlling for confounders.  In addition, we used lags of the exposure to test for 
delayed exposure effects on the outcome.  
 
Results showed that the increase in the rate of unintentional fatal prescription opioid overdoses 
was associated with an increase in the rate of suicides. Also, although the 95% confidence 
interval included the null, the range of effects sizes compatible with the data suggested that the 
increase in the per capita volume of prescription opioids was also associated with suicide rates. 
In contrast with observed trends for opioid shipments and the rate of fatal overdoses, the 
prevalence of nonmedical use of prescription opioids decreased on average during the 2004-2014 
period. NSDUH restricted state-level data, which we used to estimate state prevalences of the 
nonmedical use of prescription opioids, were only available from 2004 to 2014, a period in 
which the prevalence was already stable or starting to decrease in many states. This could be 
linked to the introduction of regulations to control the access to prescription opioids. Although 
tighter controls also likely affected prevalence of prescription opioids abuse/ dependence after 
2004, this prevalence continue increasing, as did the rate of unintentional overdoses, even when 
the prevalence of nonmedical use of prescription opioids was decreasing. It is likely that these 
measures might respond more slowly to regulations, given that those abusing prescription 
opioids may find alternative ways to find these drugs, or use them in combination with other 
substances that may increase the risk of an overdose. This limitation in NSDUH data prevented 
us from examining whether increases in the prevalence starting around 1996 (4), were linked, or 
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not, to increases in suicide rates during early stages of the epidemic. Because the premise of an 
increasing trend in this exposure was falsified, further analyses were not conducted for this 
exposure. 
 
Given the results from Chapter 3 showing that prescription opioid abuse/ dependence had 
stronger effects on suicidal outcomes compared to any prescription opioid use in the past year, it 
is possible that the state level prevalence of opioid abuse/ dependence would have had a stronger 
effect on suicide rates than the prevalence of past year nonmedical use of these drugs. In this 
study we did not include a measure of prevalence of abuse/ dependence because the estimated 
annual state level prevalences from NSDUH restricted data (only available from 2004 to 2014) 
were less stable due to the small number of individuals endorsing opioid abuse/ dependence in 
each state. Instead, as described above, a measure of the annual occurrence of unintentional 
prescription opioid overdoses was used as a proxy for the burden of the opioid epidemic across 
states. 
 
Although not entirely clear, the effects of the per capita volume of opioid shipments and the rate 
of fatal overdoses on suicide rates may operate through the following mechanisms: First, the 
availability of opioids could provide a means of suicide to individuals going through a suicidal 
crisis. However, the fact that there was also a positive effect of this exposure on firearm suicide 
rates, suggests that other mechanisms were in place, as individuals had access to other means of 
suicide. Second, the increase in the rate of unintentional fatal prescription opioid overdoses could 
affect the suicide rate by deteriorating the social capital that individuals rely on for support and 
to solve their problems. Isolation and despair, which could lead to suicidal ideation and behavior, 
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might increase in a community as the rate of fatal opioid overdoses rise, and also as distrust 
generated from opioid related crime escalate. Third, the increase in fatal opioid overdoses may 
be a proxy for increases in the number of individuals with opioid dependence, including patients 
with long-term use of opioids who become addicted to them. If this is the case, these effects 
could also work through individual level mechanisms in which opioids alter the reward system 
with exacerbation of distress and anxiety levels that could lead to suicidal ideation, behavior and 
eventually suicides. Evidence from chapter 3 showing that heavy/ frequent use of opioids and 
related abuse/ dependence increases the risk of suicidal outcomes, along with evidence showing 
that the prevalence of prescription opioid abuse/ dependence in the U.S. increased from 0.1% in 
1992 to 0.7% in 2016, suggest that this mechanism could have played an important role in the 
rise of suicide rates.  
 
There are also limitations in this study that threaten the validity of these findings. First, data on 
some confounders was missing for some years and we imputed it with values from neighbor 
years; this might resulted in inappropriate confounding control. Second, the prevalence of 
nonmedical use of prescription opioids was estimated using data from self-reports, potentially 
leading to underreporting of opioid use. Also, as stated above, data on nonmedical use of 
prescription opioids is not available at the state level for years before 2004, and the available 
data indicated a decrease in this prevalence after 2004. We believe that the rate of fatal overdoses 
used in this study may be a better measure of the burden that the opioid epidemic posed on 
communities than the prevalence of any prescription opioid use in the past year. Because of this, 
our findings for fatal overdoses can provide better evidence of the effects of the opioid epidemic 
on suicide rates. Third, in CDC WONDER data some overdose deaths are classified as 
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undetermined due to uncertainty on the intentionality of the overdose, and were not used in 
analyses. However, the proportion of overdoses classified as undetermined is small (around 8%) 
in most states, and this likely did not impact the estimates obtained for the effects of 
unintentional overdoses on suicide rates. Fourth, the data on the per capita volume of 
prescription opioids do not capture the illegal trafficking of prescriptions opioids across states, 
which may result in misclassification of the exposure. To our knowledge there is no evidence 
suggesting that states with sharper increases in suicide rates were the ones receiving larger 
amounts of prescription opioids illegally transported from other states. It is possible that this 
misclassification biased our results towards the null, as the true availability of prescription 
opioids (i.e., legal and illegal supply) that could be responsible for increases in suicides, was not 
fully captured in our exposure measure. Despite these limitations, the results from this study 
present initial evidence of the effects of the availability of prescription opioids and the rate of 
fatal opioid overdoses on suicide rates at the state level. Further studies using more complete 
measures of confounders, including additional confounders and examining ways to overcome the 
problems with measures of the exposures would improve the strength of the evidence on these 
effects. 
 
In conclusion, the results from the three studies in this dissertation provide evidence supporting 
the hypothesis of a causal link between the opioid epidemic and increases in suicide rates. The 
comprehensive review provided a critical analysis of available data from studies examining the 
effects of opioid exposures on suicidal outcomes, which allowed us to identify gaps in the 
knowledge (i.e., estimates in previous studies could be the result of methodological artifacts; no 
previous studies examined the effects of the availability of opioids and measures of opioid use 
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and overdoses at the state level), as well as future directions for research. This dissertation also 
presented evidence from two analytical approaches that attempted to minimize the risk of bias 
that may arise from limitations observed in previous studies. Findings from the first analytical 
study provided evidence on heavy/ frequent use of prescription opioids and related abuse/ 
dependence having an effect on persistence and onset of suicidal ideation and on persistence of 
suicide attempts. In contrast, these exposures were not associated with onset of suicide attempt, 
possibly due the low number of participants with this outcome. The second analytical study 
provided novel evidence on the effects of the opioid epidemic on suicide rates by showing that 
the increases in the volume of prescription opioids and in the rate of fatal prescription opioid 
overdoses were on average linked to increases in suicide rates at the state level. Overall, the two 
analytical studies advanced our understanding on how the opioid epidemic could have 
contributed to the rise in suicide rates in the U.S. during the beginning of the 21st century. 
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5.1. Implications and Future Directions  
The findings from this dissertation help to build the evidence base for public health practice and 
for future research. Results from most analyses in this dissertation showed positive effects of 
opioid exposures on suicidal outcomes. Future studies aiming at assessing the effects and the 
mechanisms through which opioids influence suicidal outcomes, need to consider the important 
bias that can arise from the lack of control for known confounders of these associations. This is 
important as substance use and suicidal outcomes share many common causes including 
psychiatric disorders and traumatic experiences that may lead individuals to start using opioid to 
cope with physical or emotional pain. New studies should also consider the use of longitudinal 
data to better assess the temporal relationship between these exposures and outcomes.  
 
As described in the introduction of this dissertation, despite the fact that blacks had similar rates 
of fatal prescription opioid overdoses compared with white and Native American/Alaska native 
populations from 1999 to 2001, blacks had a much lower suicide rate during these years than 
these two groups. Also, since 2012 the suicide rate among blacks has only slightly increased 
despite the sharp increase in opioid overdoses in blacks in recent years. Is not clear which factors 
may be responsible for this difference in suicide rates even when opioid overdose rates were 
similar. However, it is possible that this is related to the double paradox in psychiatric 
epidemiology in which blacks have a lower prevalence of major depression than whites, despite 
having similar or higher levels of distress due to economic challenges, the discrimination and 
inequalities they face (5). Further research exploring the diverse effects of the prescription opioid 
epidemic on suicidal and other health outcomes in different race/ ethnic groups could improve 
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our understanding of the range of effects and the burden of the opioid epidemic across 
communities in the U.S. 
 
Also, the findings from the second analytical study indicated that effects of opioid exposures on 
suicide rates might not uniquely operate through prescription opioids providing a means of 
suicide. However, is not yet clear which are the key mechanisms through which opioids 
influence suicides. Future studies could explore whether these effects operate via impacting the 
social networks that give support and meaning to individuals, and also through the increased risk 
of suicidal ideation and attempts among opioids users in the population. A better understanding 
of the mechanisms in operation could shed light on the potential targets for future interventions. 
 
Most importantly, these results highlight the devastating consequences of opioid use and 
addiction in communities around the country, both for users and for families and communities. 
The opioid epidemic is among the greatest public health challenges of our time. Concerted 
efforts on the part of multiple stakeholders to bring evidence to bear regarding the collateral 
damage of opioid addiction is necessary to understand the full picture of the burden, and 
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Individual level studies examining the effects of opioid use and related abuse/ dependence on suicidal outcome  






















from the Central 
Population Register and 





Suicide SMR = 10.7 (95% 
CI, 4.5, 25.8) 
Reliability/validity of the 
outcome measure (suicides 











Heroin users with and 










The SMR of suicide 
mortality was 16.2 and 3.1 
in the opioid substitution 
group (OST) and non-OST 
group, respectively. 
Sample size was not justified. 
Convenience sample. 
Reliability/validity of the 
outcome measure (suicides 
vs. unintentional overdose). 
Information about non-
















patients from opioid 
treatment programs in 
United States, and from 








The SMR for suicide in the 
Taiwan group was 18.1-fold 
higher than that of the 
general population.  In the 
US group the SMR was 0.8 
-fold higher than in the 
general population 
Sample size was not justified. 
Convenience sample. 
Reliability/validity of the 
outcome measure (suicides 
vs. unintentional overdose). 
Information about non-


















e maintenance (MT), 
detoxification (DTX), 
drug free residential 
rehabilitation (RR) and 












The prevalence of lifetime 
suicide attempts was 32%. 
Females had a higher 
prevalence (43.1% vs. 
25.9%); also, the prevalence 
of current suicidal ideation 
was 23.1% and the 
No evidence that measures 
were undertaken to address 
and categorize non-
responders   











prevalence of past-year 
suicide attempt was 12.2%.  
In females there was a 
significant declined in the 
prevalence of suicide 
attempts one year from 
baseline (from 19.7 to 
9.8%); in males there was 
no significant reduction 
(8.7% vs. 8.1%) 
There was a significant 
reduction in the prevalence 
of current suicidal ideation 
over the follow up (23.1% 
vs. 6.9%). Of those who 
reported suicidal ideation at 
baseline, 22.8% made an 






















e maintenance (MT), 
detoxification (DTX), 
drug free residential 
rehabilitation (RR) and 







Suicide attempt prevalence 
decreased over time: 
Baseline (11.4%); 12 
months (7.8%); 24 months 
(5.4%); 36 months (2.3%). 
Reductions were stronger in 
females.  
Levels of suicidal ideation 
and attempts remained 
higher than in the general 
population. 
No evidence that measures 






















e maintenance (MT), 
detoxification (DTX), 
drug free residential 
rehabilitation (RR) and 









After 11 years of follow up, 
42.2% of the cohort 
reported ever having made a 
suicide attempt. 11.1% 
made a first attempt 
subsequent to baseline. 
In the year preceding 11-
year follow-up, 1.6% 
reported having made a 
suicide attempt. 
No evidence that measures 
were undertaken to address 
and categorize non-
responders  







Suicide attempts, suicidal 
ideation and having a 
suicidal plan were not 
different from the 
prevalences at 36-months of 
follow up. 
At follow up recent attempts 
were 4 times those reported 
amongst the Australian 
population, current ideation 
4.5 times higher and a 
current plan 7 times higher.  
Degenhar













Patients registered for 
opioid substitution 





The SMR (by age, sex and 
year) for suicide = 6.2 (95% 
CI: 5.6, 6.7) 
Reliability/validity of the 
outcome measure (suicides 











Heroin addicts either in 






Individuals ages 15-26 who 
were in the methadone and 
abstinent program groups 
had a yearly suicide-attempt 
prevalence (20-22%) that 
was 18 and 16 times above 
the expected in the 
population, respectively. 
Aims/objectives of the study 
not clearly described. 
Convenience sample. Sample 
size not justified. 
Target/reference population 
not clearly defined. No 










Different populations of 






The overall SMR for opioid 
use from 9 studies was = 
14.0 (95% CI: 10.79, 17.88) 
Reliability/validity of the 
outcome measure (suicides 
vs. unintentional overdose) in 
studies included in analysis 












Heroin injection drug 
users in 
treatment/Outpatient 






The prevalence of current 
suicidal ideation was 43.2% 
among injection heroin 
users without HIV positive 
test, 37.1% among injection 
heroin users with HIV 
positive test and 8.5% 
among non-drug users. 
Convenience sample. Sample 
size not justified. 
Target/reference population 
not clearly defined. No 
evidence that measures were 
undertaken to address and 
categorize non-responders  















Heroin users who 
attended the methadone 
maintenance treatment 
programs in all treatment 




Suicide mortality rate = 
0.45; SMR = 18.4 (95%CI: 
13.2, 24.8)  
Suicide SMR in males = 
13.5 (95%CI: 9.5, 18.6) 
Suicide SMR in females = 
27.0 (95%CI: 8.7, 63.0) 
Reliability/validity of the 
outcome measure (suicides 













Individuals who had 
participated in public or 
private opioid 
maintenance treatment 
clinics at any time in 
lifetime. Controls were 
required to have used 
opioids illicitly less than 
five times over their 




centers, etc., from the 









Cases had a higher 
prevalence of lifetime 
suicidal ideation (OR = 1.40 
(95% CI: 1.06, 1.85), 
lifetime suicidal plan (OR = 
1.40 (95% CI: 1.06, 1.87)) 
and of lifetime suicide 
attempt (OR = 1.65 (95% 
CI: 1.20, 2.29). 
There were no differences 
between the two groups in 
regards to past-year suicide 
attempts. 
Females were more likely to 
report a suicide attempt 
compared with males. In 
models adjusted for 
confounders, opioid 
dependence was not 
significantly associated with 
suicide attempts 
The design is based on 
selection of cases and 
controls; however, cases are 
selected based on the 
exposure (i.e., opioid 
dependence) and not the 
outcome (i.e., suicidal 
ideation). No evidence that 
measures were undertaken to 
address and categorize non-
responders . Not clear what 
was the measure of suicide 
attempts (lifetime vs. past-



















Lifetime prevalence of 
suicide attempts = 17.3%  
Females = 34.4%; Males = 
11.6% 
In the community residents 
in New Haven the 
prevalence = 4.1% 
The prevalence of suicide 
attempts in non-white 
individuals with dependence 
was not much higher than 
that in non-whites (12.9% 
Sample size not justified. 
Convenience sample. 
Information about non-
responders is not described in 
the article. No evidence that 
measures were undertaken to 
address and categorize non-
responders . Statistical 
methods not sufficiently 
described 




















The rate of suicide in males 
was 538 per 10,000. The 
suicide rate in the male 
Kentucky population in 
1960 was 170 per 10,000. 
There were no suicides 
among females 
Aims/objectives of the study 
not clearly described. Sample 
size not justified. Information 
about non-responders is not 
described in the article. 
Reliability/validity of the 
outcome measure (suicides 
vs. unintentional overdose) 
No evidence that measures 
were undertaken to address 
and categorize non-
responders . No adjustment 
for confounders or statistical 
methods to compare groups 











Patients dependent on 






mortality ratio (SMR) = 
16.2 (95% CI: 12.5–19.9) 
Females SMR = 25.0 (95% 
CI: 8.7, 41.3) 
Males SMR = 15.5 (95% 
CI: 11.7, 19.2) 
Convenience sample. 
Reliability/validity of the 
outcome measure (suicides 

















Incidence density ratio 
(MH-IDR) = 21.4; Females: 
IDR = 33.6 
The highest MH-IDR was 
for the period 1972-81 
(Males = 45.1; Females = 
70.7) 
The MH-IDR compares the 
suicides between drug 
addicts and the total 
population 
Convenience sample. 
Reliability/validity of the 
outcome measure (suicides 











treatment for opiate 
dependence at an urban 
VA medical center 





25.7% patients reported 
current suicidal ideation. 
The authors indicate that 
this prevalence is higher that 
the one in the overall 
Convenience sample. 
Aims/objectives of the study 
not clearly described. 
Target/reference population 
not clearly defined. No 








population or among 
veterans, but similar to that 
of veterans receiving mental 
health care 
evidence that measures were 
undertaken to address and 
categorize non-responders . 
Information about non-
responders is not described in 
the article. No values 
described in detail for the 
general population 
Watterson 












The Drug Abuse 
Reporting Program, 







The three-year suicide rate 
was 63 per 100,000, over 5 
times the suicide rate of the 
general population in 1971 
Convenience sample. 
Aims/objectives of the study 
not clearly described. 
Reliability/validity of the 
outcome measure (suicides 
vs. unintentional overdose) 
No clear if selection process 
likely to select agencies that 
were representative of the 
target/reference population 
under investigation. No 
discussion on the limitations 








Different populations of 






The overall SMR for opioid 
use was 13.51 (95% CI: 
10.47, 17.15). 
The SMR for females was 
3.57 (95% CI: 9, 19.90). 
The SMR for males was 
7.56 (95% CI: 4.40, 12.10).  
The fixed and random 
effects SMR for opioid use 
were approximately 14 
times greater than expected 
(SMR = 13.75; 95% CI: 
10.72, 17.63) 
Reliability/validity of the 
outcome measure (suicides 
vs. unintentional overdose) in 
studies included in analysis 


















Past-month suicidal ideation 
prevalence = 17.9%; 
Lifetime suicidal ideation 
prevalence = 58.9% 
These prevalences are much 
higher than the than the 
Convenience sample. Sample 
size not justified. No clear if 
selection process likely to 
select institutions that were 
representative of the 
target/reference population 





lifetime prevalence in the 
Chinese overall population 
(3.9%) 
under investigation. No 
evidence that measures were 
undertaken to address and 
categorize non-responders  
 




















Individuals who were 





OR= 0.86, 95% CI: 0.52, 
1.42 (Comparison group: 
those not using opioids but 
who could be using other 
drugs) 
Excluded participants (lost to 
follow-up) were more likely 
to be opioid users compared 



















Prevalence at baseline = 
30% 
Of those with no ideation at 
baseline 19.67% reported 
suicidal ideation in later 
waves. The prevalence of 
suicidal ideation in a 
nationally representative 
sample of Mexican 
Americans = 10% 
Sample size not justified. 
Information about non-
responders is not described in 
the article 
 













n = 1514 
Australia 
Patients taking 
prescription opioids to 









These prevalences of all 
forms of suicidal ideation 
and attempts in the chronic 
pain cohort were higher than 
those in the general 
population: prevalence of 
lifetime suicidal ideation 
(45.9% vs. 13.3%, 
respectively), lifetime 
suicide attempts (20.3% vs. 
Sample size not justified . 
Response rate raises concerns 
about non-response bias 





3.2%), past-year suicidal 
ideation (20.0% vs. 2.3%); 
and past year suicide 
attempt (2.5% vs. 0.4%).  
Demidenk






























9.2% of patients endorsed 
having suicidal thoughts; 
2.4% had suicidal self-
directed violence.  
Prevalences were 3.8% and 
0.4%, respectively, in a 
community sample of 
veterans.  
Sample size not justified. No 
evidence that measures were 
undertaken to address and 
categorize those who died 
(e.g., whether or not they 
died by suicide). The 
outcome variable ascertained 
based solely on medical chart 
review (risk of missing the 












Veterans Affairs health 
care system treatment 








Compared with those 
receiving 20 mg/day (mg/d), 
the hazard ratios (HR) = 
1.48 (95% CI: 1.25, 1.75) 
for thse receiving 20 to 50 
mg/d; 
HR = 1.69 (95% CI: 1.33, 
2.14) for those receiving 50 
to 99 mg/d; HR = 2.15 (95% 
CI: 1.64, 2.81) for those 
receiving 100 or more mg/d.  
Acetaminophen dose was 
not associated with suicide: 
suicide rate was 45.4 (95% 
CI: 40.4, 50.8) per 100,000 
person-years when the 
maximum dose was 0 mg 
and 63.0 (95% CI: 36.7-
96.3) when the maximum 
dose was 300+ mg/d.  
Reliability/validity of the 
outcome measure (suicides 











Cases (66 years and 
older who had died by 
suicide), from the 
records of the Office of 
the Chief Coroner for 




Use of prescription opioids 
for moderate pain (codeine 
or hydrocodone) was 
associated with suicide in 
adjusted models: AOR = 
1.24 (95% CI: 1.04, 1.47). 
Reliability/validity of the 
outcome measure (suicides 
vs. unintentional overdose). 
No adjustment for other 
potential confounders 





selected from the 
Registered Persons 
Database. Controls were 
matched by age, sex, and 
residential income. 
Prescription opioids for 
severe pain (morphine, 
hydromorphone, or 
transdermal fentanyl) were 
also associated with suicide: 
AOR = 4.07 (95% CI: 2.51, 
6.59) 
Voakland










Cases (66 years and 
older who had died by 
suicide) were from the 
British Columbia (BC) 
Vital Statistics; controls 
were randomly selected 
from the BC Health 
Insurance Registry. Data 
from: Physician Claim, 
BC Pharmacare, BC 
Health Insurance 





Use of prescription opioids 
was associated with: AOR = 
2.57 (95% CI: 1.71, 3.86). 
The use of strong opioid 
medication (e.g. fentanyl, 
morphine) was more 
strongly associated with 
overall suicide (AOR = 
6.30, 95% CI: 2.61, 15.20) 
and non-opioid poisoning 
suicide (AOR = 7.56, 95% 
CI:  2.59, 22.06). 
Reliability/validity of the 
outcome measure (suicides 
vs. unintentional overdose). 
No adjustment for other 
potential confounders 
 








Sample of source Outcome Time point Estimate Potential limitations 
Ashrafiou








National Survey on Drug 








Heavy nonmedical use of 
prescription opioids (weekly 
or more) was associated 
with:  
Suicidal ideation: AOR = 
1.62 (95% CI: 1.19, 2.21)  
Suicide planning: AOR = 
1.76 (95% CI: 1.10, 2.84) 
Suicide attempts: AOR = 
2.03 (95% CI: 1.11, 3.71) 
Past-year prescription 
opioid use 
abuse/dependence was not 
Methods were not 
sufficiently described to 
enable them  to be repeated 
(No information on whether 
authors took into account the 
complex survey design in 
analyses). No adjustment for 
other potential confounders 





















and National Death 




Opioid use disorder was 
associated with 1.31 (95% 
CI: 1.08, 1.58) increase risk 
of dying by suicide in males 
and 2.33 (95% CI: 1.05, 
5.18) risk in females. Over 
the six-year follow-up, the 
suicide rate among those 
with opioid use disorder was 
86.9 per 100,000 
Reliability/validity of the 
outcome measure (suicides 
vs. unintentional overdose). 











National Survey on Drug 




Past-year nonmedical use of 
prescription opioids was 
associated with past-year 
suicidal ideation: Adjusted 
Odds Ratio (AOR) = 1.56 
(995% CI: 1.11, 2.19) 
No adjustment for other 
potential confounders 










Students from grades 7 






Nonmedical use of 
prescription opioids was 
associated with suicidal 
ideation at follow up: 
Adjusted odds ratio (AOR) 
= 2.31 (95% CI: 1.30, 4.11) 
Nonmedical use of 
prescription opioids was 
associated with suicide 
attempt at follow up: AOR 
= 3.39 (95% CI: 1.33, 5.63) 
Sample size not justified. No 
clear if selection process 
likely to select individuals 




adolescents in schools were 
included). No adjustment for 










Adults 18 and 
older/National Survey on 




Prevalence of past-year 
suicidal ideation = 5% 
In adjusted models 
persistent nonmedical use of 
prescription opioids was 
associated with past-year 
No adjustment for other 
potential confounders 





suicidal ideation: Adjusted 
Odds Ratio (AOR) = 1.52 
(95% CI: 1.10, 2.10) 
Recent onset use of 
prescription opioids was not 
associated with suicidal 
ideation: AOR = 1.27 (95% 
CI: 0.94, 1.73) 
Abuse/dependence of 
opioids was associated with 
suicide attempts: AOR 
=1.88 (95% CI: 1.13, 3.12) 
There were no significant 
associations between any of 
the exposures and suicide 












Adolescents in grades 9–
12 enrolled in five public 







Lifetime nonmedical use of 
prescription opioids was 
associated with past-year 
suicidal ideation in males: 
AOR = 2.17 (95% CI: 1.54, 
3.06), and females: AOR 
=1.98 (95% CI: 1.51, 2.58), 
and with suicide attempts in 
males: AOR = 1.79 (95% 
CI: 1.24, 2.57), and females: 
AOR = 1.97 (95% CI: 1.48, 
2.62).  
Sample size not justified. No 
information on response 
rates. No evidence that 
measures were undertaken to 
address and categorize non-
responders . No clear if 
selection process likely to 
select individuals/schools 
that were representative  of 
the target/reference 
population under 
investigation. No adjustment 
for other potential 
confounders 
 







Sample of source Outcome Time point Estimate Potential limitations 


























Increased accessibility to 
prescription opioids was 
strongly associated with 
increased suicide attempt 
frequency (based on calls) 
(p< 0.0001), with a stronger 
correlation among females 
vs. males 
No information on 
reliability/validity of 
exposure and outcome 
measures. No adjustment for 
other potential confounders. 
Results for the analyses 
described in the methods 
were not presented  
(estimates of the association 
between exposure and 


















department of the 
Information Centre for 
Health and Social Care 
(England) and the 
Prescribing Services 





Mean quarterly change in 
co-proxamol suicide: -24 
(95% CI: -37, -12). 
Mean quarterly change in 
the overall suicide:     -22 
(95% CI: -89, 45) 
Reliability/validity of the 
outcome measure (suicides 
vs. unintentional overdose).  
 
  





Appendix Table 6: Confounders used in propensity score models 
 
Evidence Measure Operationalization 
Mood disorders 
Mood disorders including depression 
(1-3) and anxiety disorders (4, 5) have 
been associated with suicide 
ideation/behavior (1). Depression (6-8) 
anxiety (7-9), panic (6, 9), bipolar (6), 
and phobia (6, 9) have also been 
associated with substance use and 
abuse/dependence (10). 
We used measures of mood disorders 
experienced before age 18 measured at 
wave 1.  The following mood disorders 
were included: major depressive 
disorder, dysthymia, bipolar disorder, 
and anxiety disorders, i.e. panic 
disorder, social anxiety disorder, 
specific phobia, and generalized 
anxiety disorder. 
A measure for each mood disorder was 
generated and coded “1” if the person met 
criteria for the disorder and “0” otherwise. 
Personality disorders 
Personality disorders have been 
associated with depression, suicidal 
ideation and attempts (11) in the overall 
population but also among individuals 
using opioids or with opioid 
dependence problems (12). Borderline 
(13) and antisocial personality disorder 
are the two most frequently linked to 
suicide and suicidal ideation (12, 14). 
There is also evidence that life events 
can greatly increase risk of suicidal 
behavior in individuals with 
schizotypal, avoidant, borderline and 
obsessive-compulsive personality 
disorders (individuals at higher risk of 
suicidal behavior once experiencing 
these events) (15). 
There is also evidence of paranoid and 
borderline disorders being associated 
with increase suicide attempts risk in 
those with panic disorder (16). 
Personality disorders have also been 
associated with the use of different 
substances (7, 9-11). 
Personality disorders measured in wave 
1 included: conduct disorder with and 
without antisocial personality disorder, 
avoidant, dependent, obsessive-
compulsive, paranoid, schizoid, and 
histrionic personality disorder.  
The measure for meeting criteria for 
borderline personality disorder was 
obtained in wave 2. 
A variable for each personality disorder 
was generated and coded “1” if the person 
meet criteria for the disorder and “0” 
otherwise. Then a single combined 
measure for personality disorders was 
generated with the following categories: 1) 
not experiencing any personality disorder; 
2) experiencing one personality disorder; 
3) experiencing two personality disorders; 
and 4) experiencing three or more 
personality disorders. 
Low self-esteem 
Low self-esteem has ben associated 
with suicidal ideation and behavior (17-
21), and also with substance use and 
related problems. 
A measure of low self-esteem was 
obtained in wave 1. Participants were 
asked:  do you believe that you’re not 
as good, smart, or attractive as most 
Participants responding “yes” to this 
question were classified as having low 
self-esteem; otherwise, as not having low 
self-esteem. 





other people? This clarification was 
made before the question was asked: 
These following questions are about 
how you have felt or acted most of the 
time throughout. 
Substance use 
Polydrug use is associated with suicidal 
ideation and behavior (1-3, 14, 22). 
Substance abuse/dependence is also 
associated with use/abuse of other 
substances (23, 24). 
Variables for other substances, 
including marijuana, cocaine/crack, 
heroin, inhalants, hallucinogens, 
amphetamines, stimulants, tranquilizers 
and sedatives were generated to 
indicate whether a participant used a 
particular substance prior to the last 12 
months. 
For each substance a single variable was 
created and coded “1” if the person used 
the substance prior to the last 12 months, 
and “0” otherwise. Then a single combined 
measure for substance use was generated 
with the following categories: 1) no use of 
substances prior to the past 12 months; 2) 
having used one substance; 3) having used 
two or more substances 
Social deviance 
Conduct and antisocial personality 
disorder are associated with suicide and 
suicidal ideation/behavior (14, 25). 
Antisocial personality disorder has also 
been associated with the use of 
different substances (7, 9-11). 
In NESARC a list of 33 items assessing 
conduct disorder or antisocial 
personality disorder behaviors  
 (e.g. cut class, not go to class or go to 
school and leave without permission; 
stay out late at night even though 
parents told you to stay home; ever 
have time when bullied or pushed 
people around or tried to make them 
afraid of you) serve as measures of 
social deviance. 
We created two variables one measuring 
the number of symptoms before age 15 
years and another for symptoms after age 
15. Each variable was categorized as 
follows: 1) no social deviance experiences; 
2) experiencing one social deviance item; 
3) experiencing two; 4) experiencing three; 
5) experiencing four; and 6) experiencing 
five or more social deviance items. 






Childhood adverse events (e.g. 
maltreatment, parents’ substance abuse, 
parents’ psychiatric problems including 
antisocial behavior and depression, 
parents divorce/separation)(14, 26-29) 
have been previously associated with 
suicidal ideation/behavior and also with 
substance use and related problems (21, 
26, 27). 
Available measures of family history in 
NESARC that could be related to 
hardship during childhood/adolescence, 
include the following: lifetime history 
of: 1) depressive events among 
blood/natural parents; 2) drug abuse/ 
dependence in blood/natural parents; 3) 
drug abuse/ dependence in any full 
brothers/sisters; 4) behavior problems 
in blood/natural parents (e.g., being 
cruel to people or animals, fighting or 
destroying property, trouble keeping a 
job or paying bills, being impulsive); 
and 5) parents divorce/separation or 
death of at least one parent before the 
participant was 18 years old. 
We created dichotomous variables for each 
of item, coding it “1” if the person 
endorsed being exposed to it and “0” 
otherwise. 
History of suicide 
attempts among parents 
or other adults living in 
home before age 18 
years  
A family history of suicide and suicidal 
behavior has been associated with 
increased risk of suicide and suicidal 
behavior (30-32). 
 
NESARC wave 1 includes a measure of 
history of suicide attempts among 
parents or other adults living in home 
before the participant was 18 years old. 
We created a dichotomous variable coded 
“1” if the person endorsed living with a 
parent or family member who attempted 
suicide before the participant was 18 years 
old; we coded this variable “0” otherwise. 
History of end of 
marriage 
Divorce or death of spouse or partner is 
a stressful situation that can trigger 
depressive states and suicidal ideation 
(33, 34). 
NESARC includes 2 questions 
regarding how first marriage ended and 
the age when the person stopped living 
with first spouse/first spouse died. 
We created a variable coded as “1” if the 
person endorsed the first marriage had 
ended (divorced/separated/ widowed) and 
if the end of marriage had occurred prior to 
the past year prior to interview; or coded 
“0” if otherwise (including the option 
“never married” or “still married and 
living with 1st spouse”.  
Race/ethnic group 
Evidence suggest that in the U.S. the 
rate of suicides and the prevalence of 
suicide attempts are much greater in 
non-Hispanic white and American 
Indian/Native American populations 
than non-Hispanic black or Hispanic 
populations (35). Also, the prevalence 
of nonmedical use of prescription 
opioid and related overdose rate is 
greater in non-Hispanic white and 
American Indian/Native American 
NESARC wave 1 includes a race/ethnic 
measure with the following categories: 
Non-Hispanic (NH) whites; NH-
American Indian/AK Native; NH-
black; Hispanics; NH-Asian/native 
Hawaiian, Pacific islander. 
We used the race/ethnic variable as it was 
available in NESARC.  







The prevalence of suicide attempt is 
greater in females than males, although 
the rate of suicides is greater in males 
(29, 33, 37, 38). 
In NESARC the sex measure is 
categorized as male and female 
We used the sex variable as it was 
available in NESARC. 
Age 
The prevalence of suicides is greater 
among those ages 24 to 44 followed by 
those ages 75 and older (37). The 
prevalence of suicide attempts is 
greater among those ages 18-24 than 
other age groups (29, 38). 
In NESARC age is provided as a 
continuous measure.  
We used the age variable as it was 
available in NESARC. 
Socio-economic and 
health insurance status 
Low socio-economic status has been 
associated with higher risk of suicidal 
ideation and suicide attempts (29, 39, 
40). Health insurance coverage can 
influence access to treatment and to 
disease prevention programs can be a 
risk factor for substance use and 
suicidal ideation/behavior.  
NESARC wave 1 includes information 
on total family income, education and 
insurance coverage, which can be used 
as proxies of socio economic status. 
Two variables were used to asses socio-
economic status of participants: 1) Total 
family income was categorized as income 
lower than 20,000, between 20,000 and 
49,999, between 50,000 and 74,999, and 
75,000 or more; and 2) Education status, 
was categorized as a dichotomous variable: 
less than high school vs. highs school or 
more. 
Insurance coverage was coded “1” if 
participants were covered by insurance at 
wave 1 interview, “0” otherwise. An 
additional variable was used to indicate 
whether participants were covered by 1) 
Medicare, 2) Medicaid, 3) the VA or other 
military health care, or 4) obtained 
privately or through a current or former 





1. Darke S, Williamson A, Ross J, Teesson M. Attempted suicide among heroin users: 12-
month outcomes from the Australian Treatment Outcome Study (ATOS). Drug and Alcohol 
Dependence 2005;78(2):177-186. 
2. Darke S, Ross J, Marel C, Mills KL, Slade T, Burns L, et al. Patterns and correlates of 
attempted suicide amongst heroin users: 11-year follow-up of the Australian treatment 
outcome study cohort. Psychiatry Research 2015;227(2-3):166-170. 
3. Roy A. Characteristics of opiate dependent patients who attempt suicide. Journal of Clinical 
Psychiatry 2002;63(5):403-407. 
4. Sareen J, Cox BJ, Afifi TO, de Graaf R, Asmundson GJG, ten Have M, et al. Anxiety 
disorders and risk for suicidal ideation and suicide attempts - A population-based 
longitudinal study of adults. Archives of General Psychiatry 2005;62(11):1249-1257. 
5. Weissman MM, Klerman GL, Markowitz JS, Ouellette R. Suicidal Ideation and Suicide 
Attempts in Panic Disorder and Attacks. New England Journal of Medicine 
1989;321(18):1209-1214. 
6. Swendsen J, Conway KP, Degenhardt L, Glantz M, Jin R, Merikangas KR, et al. Mental 
disorders as risk factors for substance use, abuse and dependence: results from the 10-year 
follow-up of the National Comorbidity Survey. Addiction 2010;105(6):1117-1128. 
7. Compton WM, 3rd, Cottler LB, Jacobs JL, Ben-Abdallah A, Spitznagel EL. The role of 
psychiatric disorders in predicting drug dependence treatment outcomes. Am J Psychiatry 
2003;160(5):890-5. 
8. Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC. Lifetime co-
occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in 
the national comorbidity survey. Archives of General Psychiatry 1997;54(4):313-321. 
9. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of 
Mental-Disorders with Alcohol and Other Drug-Abuse - Results from the Epidemiologic 
Catchment-Area (Eca) Study. Jama-Journal of the American Medical Association 
1990;264(19):2511-2518. 
10. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, et al. Prevalence 
and co-occurrence of substance use disorders and independent mood and anxiety disorders - 
Results from the national epidemiologic survey on alcohol and related conditions. Archives 
of General Psychiatry 2004;61(8):807-816. 
11. Trull TJ, Jahng S, Tomko RL, Wood PK, Sher KJ. Revised NESARC personality disorder 
diagnoses: gender, prevalence, and comorbidity with substance dependence disorders. J Pers 
Disord 2010;24(4):412-26. 
12. Darke S, Ross J, Williamson A, Mills KL, Havard A, Teesson M. Borderline personality 
disorder and persistently elevated levels of risk in 36-month outcomes for the treatment of 
heroin dependence. Addiction 2007;102(7):1140-1146. 
  153
13. Black DW, Blum N, Pfohl B, Hale N. Suicidal behavior in borderline personality disorder: 
Prevalence, risk factors, prediction, and prevention. Journal of Personality Disorders 
2004;18(3):226-239. 
14. Beautrais AL, Joyce PR, Mulder RT. Risk factors for serious suicide attempts among youths 
aged 13 through 24 years. Journal of the American Academy of Child and Adolescent 
Psychiatry 1996;35(9):1174-1182. 
15. Yen S, Pagano ME, Shea MT, Grilo CM, Gunderson JG, Skodol AE, et al. Recent life 
events preceding suicide attempts in a personality disorder sample: Findings from the 
collaborative longitudinal personality disorders study. Journal of Consulting and Clinical 
Psychology 2005;73(1):99-105. 
16. Ozkan M, Altindag A. Comorbid personality disorders in subjects with panic disorder: do 
personality disorders increase clinical severity? Comprehensive Psychiatry 2005;46(1):20-
26. 
17. Overholser JC, Adams DM, Lehnert KL, Brinkman DC. Self-Esteem Deficits and Suicidal 
Tendencies among Adolescents. Journal of the American Academy of Child and Adolescent 
Psychiatry 1995;34(7):919-928. 
18. Vilhjalmsson R, Kristjansdottir G, Sveinbjarnardottir E. Factors associated with suicide 
ideation in adults. Social Psychiatry and Psychiatric Epidemiology 1998;33(3):97-103. 
19. Brent DA, Kalas R, Edelbrock C, Costello AJ, Dulcan MK, Conover N. Psychopathology 
and Its Relationship to Suicidal Ideation in Childhood and Adolescence. Journal of the 
American Academy of Child and Adolescent Psychiatry 1986;25(5):666-673. 
20. McGee R, Williams S, Nada-Raja S. Low self-esteem and hopelessness in childhood and 
suicidal ideation in early adulthood. J Abnorm Child Psychol 2001;29(4):281-91. 
21. Fergusson DM, Lynskey MT. Childhood circumstances, adolescent adjustment, and suicide 
attempts in a New Zealand birth cohort. J Am Acad Child Adolesc Psychiatry 
1995;34(5):612-22. 
22. Roy A. Risk Factors for Attempting Suicide in Heroin Addicts. Suicide and Life-
Threatening Behavior 2010;40(4):416-420. 
23. Degenhardt L, Dierker L, Chiu WT, Medina-Mora ME, Neumark Y, Sampson N, et al. 
Evaluating the drug use "gateway" theory using cross-national data: Consistency and 
associations of the order of initiation of drug use among participants in the WHO World 
Mental Health Surveys. Drug and Alcohol Dependence 2010;108(1-2):84-97. 
24. Degenhardt L, Hall W, Lynskey M. Alcohol, cannabis and tobacco use among Australians: 
a comparison of their associations with other drug use and use disorders, affective and 
anxiety disorders, and psychosis. Addiction 2001;96(11):1603-1614. 
25. Darke S, Ross J, Lynskey M. The relationship of conduct disorder to attempted suicide and 
drug use history among methadone maintenance patients. Drug Alcohol Rev 2003;22(1):21-
5. 
26. Rossow I, Lauritzen G. Shattered childhood: a key issue in suicidal behavior among drug 
addicts? Addiction 2001;96(2):227-240. 
  154
27. Dube SR, Anda RF, Felitti VJ, Chapman DP, Williamson DF, Giles WH. Childhood abuse, 
household dysfunction, and the risk of attempted suicide throughout the life span: findings 
from the Adverse Childhood Experiences Study. JAMA 2001;286(24):3089-96. 
28. Afifi TO, Boman J, Fleisher W, Sareen J. The relationship between child abuse, parental 
divorce, and lifetime mental disorders and suicidality in a nationally representative adult 
sample. Child Abuse & Neglect 2009;33(3):139-147. 
29. Borges G, Nock MK, Haro Abad JM, Hwang I, Sampson NA, Alonso J, et al. Twelve-
month prevalence of and risk factors for suicide attempts in the World Health Organization 
World Mental Health Surveys. J Clin Psychiatry 2010;71(12):1617-28. 
30. Qin P, Agerbo E, Mortensen PB. Suicide risk in relation to family history of completed 
suicide and psychiatric disorders: a nested case-control study based on longitudinal 
registers. Lancet 2002;360(9340):1126-1130. 
31. Cheng ATA. Mental-Illness and Suicide - a Case-Control Study in East Taiwan. Archives of 
General Psychiatry 1995;52(7):594-603. 
32. Murphy GE, Wetzel RD. Family History of Suicidal-Behavior among Suicide Attempters. 
Journal of Nervous and Mental Disease 1982;170(2):86-90. 
33. Weissman MM, Bland RC, Canino GJ, Greenwald S, Hwu HG, Joyce PR, et al. Prevalence 
of suicide ideation and suicide attempts in nine countries. Psychol Med 1999;29(1):9-17. 
34. Peters A, Liefbroer AC. Beyond marital status: Partner history and well-being in old age. 
Journal of Marriage and Family 1997;59(3):687-699. 
35. Centers for Disease Control and Prevention, National Center for Injury Prevention and 
Control. Wide-ranging ONline Data for Epidemiologic Research (WONDER). Available at: 
http://wonder.cdc.gov/ Accessed March 21, 2017. 
36. National Survey on Drug Use and Health (NSDUH-2002-2014) database. Substance Abuse 
& Mental Health Data Archive. Available at: 
https://www.datafiles.samhsa.gov/study/national-survey-drug-use-and-health-nsduh-2002-
2014-nid16959 Accessed September 21 2017. 
37. Curtin S, Warner M, Hedegaard H. Increase in suicide in the United States, 1999–2014. . 
Hyattsville, MD: National Center for Health Statistics; 2016. 
38. Baca-Garcia E, Perez-Rodriguez MM, Keyes KM, Oquendo MA, Hasin DS, Grant BF, et al. 
Suicidal ideation and suicide attempts in the United States: 1991-1992 and 2001-2002. Mol 
Psychiatry 2010;15(3):250-9. 
39. Dubow EF, Kausch DF, Blum MC, Reed J, Bush E. Correlates of Suicidal Ideation and 
Attempts in a Community Sample of Junior-High and High-School Students. Journal of 
Clinical Child Psychology 1989;18(2):158-166. 
40. Horwitz AG, Czyz EK, King CA. Predicting Future Suicide Attempts Among Adolescent 








Appendix Table 7: Association between exposure variables and confounders after adjustment for the log transformed 
propensity score 
 
RR Past-year prescription 
opioid use    
RR Past-year heavy/frequent 
use   
RR Past-year 
abuse/dependence 
Potential confounders RR p-value 95% CI   RR p-value 95% CI   RR p-value 95% CI 
Age at wave 1 interview (years); 
mean 
1.00 0.996 (0.99, 1.01)   1.00 0.985 (0.99, 1.01)   0.99 0.555 (0.98, 1.01) 
Sex                       
Female Ref       Ref       Ref     
Male 1.00 0.999 (0.80, 1.25)   1.04 0.851 (0.72, 1.49)   1.01 0.974 (0.65, 1.57) 
Race                       
Non-Hispanic white Ref       Ref       Ref     
Non-Hispanic black 1.00 0.998 (0.72, 1.39)   0.78 0.293 (0.49, 1.25)   1.03 0.941 (0.45, 2.34) 
American Indian/Alaska Native 1.00 0.999 (0.63, 1.58)   1.06 0.877 (0.50, 2.24)   0.92 0.843 (0.40, 2.13) 
Asian/Native Hawaiian/Pacific 
Islander 
1.00 1.000 (0.57, 1.76)   0.37 0.337 (0.05, 2.88)   1.17 0.810 (0.31, 4.44) 
Hispanic 1.00 0.999 (0.70, 1.42)   0.72 0.198 (0.43, 1.20)   1.05 0.895 (0.48, 2.31) 
History of 
divorce/separation/widowed 
1.00 1.000 (0.81, 1.23)   1.03 0.869 (0.74, 1.43)   0.89 0.623 (0.54, 1.45) 
Any other drug use                       
None Ref       Ref       Ref     
1 drug 1.00 0.989 (0.66, 1.51)   0.77 0.355 (0.44, 1.35)   0.72 0.404 (0.33, 1.58) 
2 or more drugs 1.00 0.985 (0.61, 1.63)   0.87 0.681 (0.43, 1.74)   0.68 0.34 (0.30, 1.52) 
Any mood disorder 0.98 0.703 (0.87, 1.10)   0.99 0.932 (0.84, 1.18)   1.04 0.744 (0.83, 1.29) 
Any personality disorder 1.01 0.924 (0.90, 1.12)   0.98 0.822 (0.83, 1.16)   0.98 0.869 (0.78, 1.24) 
Low self-esteem 1.00 0.999 (0.75, 1.33)   0.89 0.602 (0.57, 1.38)   1.18 0.601 (0.62, 2.24) 
Social deviance before 15 years 
(number items); mean 
0.98 0.586 (0.93, 1.04)   1.00 0.984 (0.90, 1.11)   1.05 0.538 (0.90, 1.23) 
Social deviance after 15 years 
(number items); mean 
1.01 0.768 (0.94, 1.09)   1.04 0.588 (0.89, 1.22)   0.97 0.769 (0.81, 1.17) 
History of depressive events among 
parents 
1.00 0.997 (0.81, 1.23)   1.22 0.322 (0.82, 1.81)   1.01 0.961 (0.62, 1.66) 
History of behavior problems among 
parents 
1.00 0.997 (0.79, 1.26)   1.01 0.968 (0.67, 1.52)   1.17 0.598 (0.65, 2.09) 
History of drug abuse/ dependence in 
blood/natural parents 






History of drug abuse/ dependence in 
any full brothers/sisters 
1.00 0.999 (0.80, 1.25)   0.92 0.682 (0.61, 1.38)   0.91 0.753 (0.52, 1.62) 
History of suicide attempts among 
parents (wave 2) 
1.00 0.999 (0.67, 1.49)   1.23 0.460 (0.70, 2.15)   1.65 0.342 (0.58, 4.70) 
Parents divorce/separation  1.00 0.999 (0.78, 1.28)   0.91 0.631 (0.63, 1.32)   0.89 0.654 (0.52, 1.52) 
Family income                       
<20,000 Ref       Ref       Ref     
20,000 and 49,999 1.00 1.000 (0.70, 1.43)   1.08 0.777 (0.63, 1.85)   1.04 0.943 (0.36, 2.99) 
50,000 and 74,999 1.00 0.998 (0.76, 1.31)   1.05 0.821 (0.67, 1.65)   0.82 0.603 (0.39, 1.73) 
 75,000 or more 1.00 0.998 (0.72, 1.39)   1.17 0.552 (0.70, 1.96)   0.85 0.709 (0.36, 2.00) 









Appendix Table 8: Models examining the effects of the rate of unintentional fatal prescription opioid overdoses (unimputed 
variable) on suicide rates 
  Estimate 95% CI   
Exposure 
lagged 1 year 95% CI   
Exposure 
lagged 2 years 95% CI 
Unadjusted 0.056 0.046, 0.065             
Adjusted by confounders 0.047 0.035, 0.060             
Adjusted by confounders at lag zero and 
lagged 1 year 0.043 0.031, 0.056       
Adjusted by confounders at lag zero and 
lagged 1 and 2 years 0.046 0.032, 0.060             
Exposure lagged 1 year* 0.046 0.032, 0.059   0.016 -0.013, 0.044       
Exposure lagged 2 years* 0.046 0.032, 0.060   0.017 -0.030, 0.065   -0.002 -0.049, 0.045 

















Model: log rate prescription opioid shipments on log suicide rate 
-2 Res Log Likelihood -1621.0 -1440.9 -1240.8 
AIC  -1619.0 -1438.9 -1238.8 
BIC  -1614.4 -1434.4 -1234.4 
Model: log rate of fatal prescription opioid overdoses on log suicide rate 
-2 Res Log Likelihood -1970.0 -1661.7 -1268.0 
AIC  -19568.0 -1659.7 -1266.0 








Appendix Figure 1: Checking the linearity assumption of the association between the volume of prescription opioid shipments 
and suicide rates (A. with untransformed variables; B. with log-transformed variables) 




Appendix Figure 2: Checking the linearity assumption of the association between the rate of unintentional fatal prescription 
opioid overdoses and suicide rates (A. with untransformed variables; B. with log-transformed variables) 










Appendix Figure 3: Predicted values vs. residuals: Model with logged transformed rate of 




Appendix Figure 4: Predicted values vs. residuals: Model with logged transformed rate of 
unintentional fatal prescription opioid overdoses and the rate of suicides adjusted by 





Appendix Figure 5: Q-Q plot: Model with logged transformed rate of prescription opioid 
shipments and the rate of suicides adjusted by current and lagged confounders 
 
 
Appendix Figure 6: Q-Q plot: Model with logged transformed rate of unintentional fatal 
prescription opioid overdoses and the rate of suicides adjusted by current and lagged 
confounders 
 
